[go: up one dir, main page]

WO1998039352A1 - Novel bicyclonucleoside and oligonucleotide analogues - Google Patents

Novel bicyclonucleoside and oligonucleotide analogues Download PDF

Info

Publication number
WO1998039352A1
WO1998039352A1 PCT/JP1998/000945 JP9800945W WO9839352A1 WO 1998039352 A1 WO1998039352 A1 WO 1998039352A1 JP 9800945 W JP9800945 W JP 9800945W WO 9839352 A1 WO9839352 A1 WO 9839352A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
analog
compound
mmol
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1998/000945
Other languages
English (en)
French (fr)
Inventor
Takeshi Imanishi
Satoshi Obika
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12942037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998039352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/380,638 priority Critical patent/US6268490B1/en
Priority to AT98905804T priority patent/ATE541576T2/de
Priority to AU61209/98A priority patent/AU720472B2/en
Priority to ES98905804T priority patent/ES2380354T5/es
Priority to CA002283509A priority patent/CA2283509C/en
Application filed by Individual filed Critical Individual
Priority to US13/533,781 priority patent/USRE44779E1/en
Priority to EP98905804.5A priority patent/EP1013661B2/en
Priority to DE98905804T priority patent/DE98905804T1/de
Priority to DK98905804.5T priority patent/DK1013661T4/en
Publication of WO1998039352A1 publication Critical patent/WO1998039352A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention relates to novel nucleoside and nucleotide analogs, and more particularly to nucleotide analogs suitable for antisense molecules.
  • Antisense oligonucleotides are one of the most promising fields in recent years as pharmaceuticals, as they specifically regulate the expression of unwanted genes.
  • the antisense method is based on the concept of controlling the flow of so-called centralola dogma using DNA ⁇ RNA ⁇ protein using an antisense oligonucleotide.
  • nucleic acid derivatives and analogs have been synthesized and studied. For example, phosphorothioate in which the oxygen atom on the phosphorus atom has been replaced by an ⁇ atom, methylphosphonate in which the methyl group has been replaced by a methyl group, and more recently, those in which the phosphorus atom has been replaced by a carbon atom, and also the structure of the sugar moiety Some have been synthesized, and others have been modified with modified nucleobases. In any case, derivatives and analogs that are sufficiently satisfactory in terms of stability in vivo, ease of synthesis, and sequence specificity (selective control of specific gene expression only) Is currently not available.
  • the inventors of the present invention designed a nucleic acid analog having a sugar moiety conformation immobilized thereon, which is considered to be useful in the antisense method, and designed a nucleoside analog having a unit structure thereof. The synthesis was performed, and it was confirmed that the oligonucleotide analogs prepared using this were extremely useful as antisense molecules.
  • FIG. 1 is a chart showing a time-dependent change in ultraviolet absorption (260 nm) when a natural oligonucleotide is decomposed with exonuclease.
  • FIG. 2 is a chart showing the change over time in the ultraviolet absorption (260 nm) when the oligonucleotide (X 2) of the present invention is decomposed with exonuclease.
  • nucleoside analog of the present invention can be represented by the following general formula (I)
  • B is pyrimidine or purine nucleobase or an analog thereof, and X and Y are the same or different and are hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, or an acyl group. Or a silyl group], or an amidite derivative thereof.
  • the alkyl group refers to a linear or branched alkyl group having 1 to 20 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, and a t-alkyl group. Butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and the like.
  • the alkenyl group refers to a linear or branched alkenyl group having 2 to 20 carbon atoms, and examples thereof include a vinyl group, an aryl group, a butenyl group, a pentenyl group, a geranyl group, and a farnesyl group. .
  • the alkynyl group refers to a linear or branched alkynyl group having 2 to 20 carbon atoms, and includes, for example, an ethynyl group, a propynyl group, a butynyl group and the like.
  • the cycloalkyl group refers to a cycloalkyl group having 3 to 8 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclohexyl group, and a cyclooctyl group.
  • Heterocyclic groups in which one or more arbitrary methylene on the ring of the cycloalkyl group is substituted with an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an alkyl group are also included, and examples include a tetrahydroviranyl group.
  • the aryl group means a monovalent substituent obtained by removing one hydrogen atom from an aromatic heterocyclic group or an aromatic hydrocarbon group, and preferably, by removing one hydrogen atom from an aromatic hydrocarbon group.
  • a monovalent substituent means, for example, a phenyl group, a tolyl group, a xylyl group, a biphenyl group, a naphthyl group, an anthryl group, a phananthryl group and the like.
  • the carbon atom on the ring of the aryl group may be substituted by one or more groups such as a halogen atom, a lower alkyl group, a hydroxyl group, an alkoxy group, an amino group, a nitro group and a trifluoromethyl group.
  • substituents include a halogen atom, a hydroxyl group, an amino group, an alkoxy group, an aryloxy group and the like.
  • An aralkyl group is a group in which an alkyl group is bonded to an aralkyl group, and the aralkyl group may be substituted.
  • An aralkyl group which may be substituted is a group in which an aralkyl group is bonded to an aralkyl group, wherein at least one hydrogen atom of an aryl group and an alkyl group is substituted with the following substituent. Means a good group.
  • substituent include an acyl group, an amino group, an aryl group, an alkyl group, a cycloalkyl group, an alkoxy group, a hydroxyl group, a nitro group, and a halogen atom.
  • the amino group may or may not be substituted.
  • the substituted amino group include an alkylamino group, an arylamino group, and an acylamino group.
  • alkoxy groups include methoxy, ethoxy, n-propoxy, i-pro Examples include a oxy group, an n-butoxy group, an i-butoxy group, an s-butoxy group, a t-butoxy group, a pentyloxy group, a hexyloxy group, and a phenoxy group.
  • Halogen atoms include fluorine, chlorine, bromine and iodine.
  • aralkyl group examples include, for example, a trityl group, a benzyl group, a phenethyl group, a tritylmethyl group, a diphenylmethyl group, a naphthylmethyl group, and a 4,4′-dimethoxytrityl (DMTr) group. Is the DMT r group.
  • acetyl group examples include an acetyl group, a formyl group, a propionyl group, a benzoyl group, and a benzyloxycarbonyl group.
  • silyl group examples include a trialkylsilyl group, and preferably a trimethylsilyl group, a triethylsilyl group, a triisopropylsilyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, and the like. Preferably it is a trimethylsilyl group.
  • the nucleotide analog of the present invention has the general formula (la)
  • ⁇ is a pyrimidine or purine nucleobase or an analog thereof
  • BB are the same or different and is a pyrimidine or purine nucleic acid base or their analogues
  • R represents hydrogen, hydroxyl, Ri halogen or alkoxy groups der
  • WW 2 are the same or different and are hydrogen, an alkyl group , An alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, a silyl group or a natural nucleoside via a phosphoric acid residue or a phosphoric diester bond, a synthetic nucleoside, or an oligo containing these nucleosides a nucleotide or Helsingborg nucleotide
  • n 1 or n 2 are the same or different, is an integer of 0-5 0
  • N 3 is an integer of 1 to 5 0, where, n When 1 and / or n 2 is 2 or more, B 1 and B may not be the same, and R may not be the same.
  • the pyrimidine or purine nucleobase is thymine, peracyl, cytosine, adenine, guanine and derivatives thereof.
  • nucleond analog and nucleotide analog of the present invention can be synthesized as follows ( (1) Synthesis of nucleoside analog) O— 98/39352
  • the second method is based on D-ribose [3] AGM Barrett et al., J. Org. Chem., 55, 3853 (1990); 4) GH Jones et al., Ibid., 44, 1309 (1979) )], Via compound 13. That is, compound 13 is converted into compound 16 in three steps, and the ring-closing reaction under basic conditions yields the target methylglycol. The sil compound 17 was obtained. Substitution of the OMe group at position 1 of this compound with various natural nucleobases or non-natural nucleobase analogs is possible by various methods already developed. For example, methods such as the following compounds 17 to 20 can be used.
  • a third method is to use diacetone D-glucose, which is obtained from D-glucose in one step and is commercially available, as a starting material.
  • Reference 5 Compound 31 is prepared according to RD Youssefyeh, JPH Verheyden and JG Moffatt., J. Org. Chem., 44, 1301-1309 (1979). Then, as shown in the following formula, compound 31 was stepwise protected with two kinds of primary hydroxyl groups with t-butyldiphenylsilyl group and P-toluenesulfonyl group, and acetylated to give compound 34.
  • Compound 8 is reacted with 2-cyanoethyl-N, N, ⁇ ', N * -tetraisopropylphosphoramidite to obtain an amide 21 and then combined with a natural nucleoside amidite to form an automatic DNA synthesizer. Is used to synthesize various oligonucleotide analogs.
  • the synthesized crude product is purified using Oligopak and reversed-phase chromatography columns, and the purity of the purified product is confirmed by HPLC analysis.
  • One or more monomer units of compound 8 can be present in the oligonucleotide analog. In addition, it may be present at two or more positions in the oligonucleotide analog in an isolated state via one or more natural nucleotides. According to the present invention, it is possible to synthesize an antisense molecule in which the nucleotide analog (nucleoside analog) of the present invention is introduced at a required position in a required number (length). The total length of the oligonucleotide analog is 2 to 50, preferably 10 to 30, nucleoside units.
  • oligonucleotide analogs are not easily degraded by various nucleases, and can exist in the living body for a long time after administration to the living body. For example, they form stable duplexes with messenger RNA to inhibit the biosynthesis of pathogenic proteins, or form triplexes with double-stranded DNA in the genome to form messenger RNAs. Inhibits transcription to It will also be able to control the growth of infected viruses. From these facts, the oligonucleotide analogs (antisense molecules) using the nucleoside analogs of the present invention can be used as pharmaceuticals for treating diseases by inhibiting the function of specific genes, such as antitumor agents and antiviral agents. Is expected to be useful.
  • the antisense molecule using the nucleotide (nucleotide) analog of the present invention may be formulated into a parenteral administration preparation by combining conventional auxiliaries such as a buffer and / or a stabilizer, or a ribosome preparation. Can be.
  • a common pharmaceutical carrier can be compounded to prepare an ointment, cream, solution, salve or the like.
  • Compound 3 White powder rap 119-120 ° C.
  • Methyl 5-0-(t-butyldiphenylsilyl) synthesis of 1-3-0,4-C-methylene-1 / 3-D-ribofuranoside (18)
  • Triethylamine (3.71 ml, 26.6 mraol) and t-butyl were added to a methylene chloride solution (50 ml) of compound 31 (2.50 g, 8.08 mmol) prepared according to the above reference 5) under a nitrogen stream and ice cooling.
  • Diphenylsilyl chloride (6.94 ml, 26.7 mmol) was added, and the mixture was stirred at room temperature for 10.5 hours. After adding a saturated aqueous solution of sodium bicarbonate to the reaction solution, the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated saline solution and dried over sodium sulfate.
  • triethylamine (395 ⁇ , 2.83 mmol) and p-toluenesulfonyl chloride (139.2) were added to a solution of 32 (250 mg, 0.456 mmol) in methylene chloride. mg, 0.730 mmol) and 4-dimethylaminopyridine (8.92 mg, 0.0730 mmol), and the mixture was stirred at room temperature for 15.5 hours. After adding a saturated aqueous solution of sodium bicarbonate to the reaction solution, the mixture was extracted with ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate.
  • acetic anhydride (6.0 ml, 63.6 mmol) and concentrated sulfuric acid (56 jul, 1.10 mol) were added to an acetic acid solution (56 ml) of 34 (3.70 g, 5.27 mmol), and the mixture was stirred at room temperature for 2 hours. did. After the reaction solution was poured into ice water (300 ml) and stirred for 30 minutes, saturated saline was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate.
  • tetrabutylammonium fluoride (1.0 M in THF, 379 ⁇ , 0.379 raol) was added to a solution of 37 (188.7 mg, 0.316 mmol) in tetrahydrofuran (1 ml), and the mixture was stirred at room temperature for 2.5 hours. did.
  • the reaction solution was evaporated under reduced pressure, and the crude product obtained was purified by silica gel column chromatography (AcOEt-hexane, 1: 1 ⁇ 1: 0) to give a white powder (38) (94.6 mg, 0.262 mg). Ol, 83%).
  • the oligomer was cleaved from the support by treatment with concentrated aqueous ammonia according to a conventional method, the cyanoethyl group on the phosphorus atom was removed, and the protecting groups of adenine, guanine and cytosine were removed.
  • the resulting 5 '— 0— DMT r-oligonucleotide analog was purified on reverse phase column chromatography (Millipore, Oligo-Pak TM SP) by removing the DMT r group with 5 ml of trifluoroacetic acid.
  • the target oligonucleotide analog was obtained.
  • the various oligonucleotide analogs synthesized in Example 2 were used as antisense strands, and the melting temperature (Tm value) of annealed natural strands of DNA or RNA was measured to determine the melting temperature (Tm value) of the present invention.
  • Tm value melting temperature
  • the final concentrations were NaC 110 Om.
  • a nitrogen stream was passed through the cell chamber of the spectrophotometer (Shimadzu UV-2100PC) to prevent dew condensation, the sample solution was gradually cooled to 5 ° C, and kept at 5 ° C for another 20 minutes before measuring. It has started.
  • the sample temperature was increased by 0.2 ° C per minute to 90 ° C, and ultraviolet absorption at 260 nm was measured at 0.1 ° C intervals.
  • the cell was used with a lid, and the measurement was performed with one drop of mineral oil added to the surface of the sample solution.
  • oligomers in which one or two units (X) of the nucleoside analog (general formula (la)) of the present invention were introduced into a natural DNA chain, hybridized with a complementary DNA oligomer. 2 to 7 degrees (approximately 2 times per modified residue) as compared to the natural chain as assessed by Tm value, and as high as 11 degrees for all T substituted with X (X6) did.
  • the increase in the Tm value of the oligomer introduced with one or two oligomers was 410 to 10 degrees (4 to 6 degrees per modified residue) compared to the natural chain.
  • a buffer solution of snake venom phosphodiesterase (0.003 U / ml, 400 1) was mixed with the buffer solution of the oligonucleotide kept at C (10 M, 400 H). The mixed solution was placed in a quartz cell (800 il) maintained at 37 ° C, and the increase in ultraviolet absorption (260 nm) due to the decomposition of the oligonucleotide was measured over time using SHIMADZU UV-2100PC.
  • the buffer composition used was 0.1 mM Tris-HCl (pH 8.6), 0.1 mM NaCl, and 14 mM MgCl 2, and was sufficiently degassed before measurement.
  • FIG. 1 naturally chain
  • FIG. 2 X 2
  • the UV absorption value of the natural chain became constant at about 30 minutes after the start of the oxygen reaction, and became constant at about 90 minutes for X2.
  • this analog provides an oligonucleotide analog antisense molecule that is not easily hydrolyzed by an enzyme in a living body, has high binding ability to a sense strand, and is easy to synthesize.
  • Sequence type nucleotide, nucleotide analog
  • Sequence type nucleotide, nucleotide analog Number of strands: single strand
  • Sequence type nucleotide, nucleotide analog Number of strands: single strand
  • Sequence type nucleotide, nucleotide analog Number of strands: single strand
  • Sequence type nucleotide, nucleotide analog
  • Sequence type nucleotide, nucleotide analog
  • Sequence type nucleotide, nucleotide analog
  • Sequence type nucleotide, nucleotide analog Number of strands: single strand

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

明 細 書 新規ビシクロヌクレオシド及びォリゴヌクレオチド類縁体
[技術分野]
本発明は新規なヌクレオシド類縁体とヌクレオチド類縁体に関し、 更に詳細に はアンチセンス分子に適したヌクレオチド類縁体に関するものである。
[背景技術]
1 9 7 8年にアンチセンス分子がィンフルェンザウィルスの感染を阻害したと の報告が初めて成された。 以後、 ガン遺伝子発現や A I D S感染を阻害したとの 報告もなされている。 アンチセンスオリゴヌクレオチドが望ましくない遺伝子の 発現を特異的に制御することから、 医薬品として近年、 最も期待されている分野 の一つである。
アンチセンス法とは、 D N A→R N A→タンパク質という、 いわゆるセントラ ノレドグマの一連の流れをアンチセンスオリゴヌクレオチドを用いて制御しようと いう概念に基づいている。
しかしながら、 天然型オリゴヌクレオチドをアンチセンス分子としてこの方法に 適用した場合、 生体内の各種ヌクレア一ゼにより分解を受けたり、 細胞膜透過性 が高くないなどの問題が生じた。 そのため、 様々な核酸誘導体や類縁体が数多く 合成され、 研究が重ねられてきた。 例えば、 リン原子上の酸素原子をィォゥ原子 に置換したホスホロチォエート、 メチル基に置換したメチルホスホネート、 また 最近になっては、 リン原子も炭素原子で置換したもの、 さらには糖部の構造を変 換したもの、 核酸塩基を修飾したものなども合成されている。 しカヽし、 いずれの 場合も、 生体内での安定性、 合成の容易さ、 配列特異性 （特定の遺伝子発現のみ を選択的に制御する） などの点で十分に満足のいく誘導体や類縁体が得られてい ないのが現状である。
生体内でヌクレアーゼによる分解を受けにく く、 高い親和力で標的のメ ッセン ジャー R N Aに結合し、 その特異性に優れ、 よって特定の遺伝子の発現を効率よ く制御することのできるアンチセンス用の分子の創製が望まれている。
[発明の開示] 本発明の発明者らは、 アンチセンス法において有用と考えられる、 核酸におけ る糖部のコンホメーションの固定化を施したした核酸類縁体を設計し、 その単位 構造となるヌクレオシド類縁体の合成を行い、 これを用いて調製したオリゴヌク レオチド類縁体にアンチセンス分子として極めて有用であることを確認した。
[図面の簡単な説明]
第 1図は、 天然型のオリゴヌクレオチドをェキソヌクレアーゼで分解した時の 紫外部吸収 （2 6 0 n m) の経時変化を示すチャートである。
第 2図は、 本発明のオリゴヌクレオチド （X 2 ) をェキソヌクレアーゼで分解 した時の紫外部吸収 （2 6 0 n m) の経時的変化を示すチヤ一トである。
以下に本発明の詳細を説明する。
本発明のヌクレオシド類縁体の構造は下記の一般式 （ I ) で表すことができる
Figure imgf000004_0001
[式中、 Bはピリ ミジンもしくはプリン核酸塩基又はそれらの類縁体であり、 X及び Yは同一もしくは異なり、 水素、 アルキル基、 アルケニル基、 アルキニル 基、 シクロアルキル基、 ァラルキル基、 ァリール基、 ァシル基、 又はシリル基で ある] で表わされるヌクレオシド類縁体もしくはそれらのアミダイ ト誘導体であ
O o
アルキル基とは炭素数 1一 2 0の直鎖または分枝鎖状のアルキル基を示し、 例 えば、 メチル基、 ェチル基、 n—プロピル基、 i—プロピル基、 n—ブチル基、 t—ブチル基、 ペンチル基、 へキシル基、 ヘプチル基、 ォクチル基、 ノニル基、 デシル基等があげられる。 アルケニル基とは、 炭素数 2— 2 0の直鎖または分枝鎖状のアルケニル基を示 し、 例えば、 ビニル基、 ァリル基、 ブテニル基、 ペンテニル基、 ゲラニル基、 ファ ルネシル基等があげられる。
アルキニル基とは、 炭素数 2— 2 0の直鎖または分枝鎖状のアルキニル基を示 し、 例えば、 ェチニル基、 プロピニル基、 プチニル基等があげられる。
シクロアルキル基とは、 炭素数 3— 8のシクロアルキル基を示し、 例えば、 シ クロプロピル基、 シクロブチル基、 シクロペンチル基、 シクロへキシル基、 シク 口へプチル基、 シクロォクチル基等があげられる。 シクロアルキル基の環上の 1 つ以上の任意のメチレンが酸素原子や硫黄原子あるいはアルキル基で置換された 窒素原子に置換された複素環基も含まれ、 例えばテトラヒ ドロビラニル基などが あげられる。
ァリール基とは、 芳香族複素環基又は芳香族炭化水素基、 から水素原子 1個を 除いた 1価の置換基を意味し、 好ましくは、 芳香族炭化水素基から水素原子 1個 を除いた 1価の置換基を意味し、 例えば、 フエニル基、 トリル基、 キシリル基、 ビフヱニル基、 ナフチル基、 アントリル基、 フヱナントリル基等である。 また、 ァリール基の環上の炭素原子はハロゲン原子、 低級アルキル基、 水酸基、 アルコ キシ基、 アミノ基、 ニトロ基、 トリフルォロメチル基等の 1種以上の基によって 置換されていてもよい。 置換基としてはハロゲン原子、 水酸基、 アミノ基、 アル コキシ基、 ァリールォキシ基等があげられる。
ァラルキル基とは、 ァリール基にアルキル基が結合した基で、 ァラルキル基は 置換されていてもよい。 置換されていてもよいァラルキル基とはァリール基にァ ルキル基が結合した基で、 ァリ一ル基及びアルキル基の任意の 1つ以上の水素原 子が以下の置換基で置換されていてもよい基を意味する。 ここで置換基として は、 ァシル基、 アミノ基、 ァリール基、 アルキル基、 シクロアルキル基、 アルコ キシ基、 水酸基、 ニトロ基、 ハロゲン原子等がある。
ァミノ基は置換されていてもいなくてもよいが、 置換されているァミノ基の例 としてはアルキルアミノ基、 ァリールアミノ基、 ァシルァミノ基等がある。 アル コキシ基の例としては、 メ トキシ基、 エトキン基、 n—プロポキシ基、 i—プロ ポキシ基、 n—ブトキシ基、 i一ブトキン基、 s—ブトキシ基、 t一ブトキシ基、 ペンチルォキシ基、 へキシルォキシ基、 フヱノキシ基等がある。 ハロゲン原子と してはフッ素、 塩素、 臭素、 ヨウ素がある。
ァラルキル基の好ましい例としては、 例えばトリチル基、 ベンジル基、 フエネ チル基、 トリチルメチル基、 ジフヱニルメチル基、 ナフチルメチル基、 4 , 4 '一 ジメ トキシトリチル （D MT r ) 基等があるが、 特に好ましいのは D M T r基で ある。
ァシル基としては、 ァセチル基、 ホルミル基、 プロピオニル基、 ベンゾィル基、 ベンジルォキシカルボニル基等があげられる。 シリル基の例としては、 卜リアル キルシリル基があげられるが、 好ましくは、 トリメチルシリル基、 トリェチルシ リル基、 トリイソプロビルシリル基、 t—ブチルジメチルシリル基、 t—ブチル ジフエニルシリル基等があげられ、 更に好ましくはトリメチルシリル基である。 また、 本発明のヌクレオチド類縁体は、 一般式 （ l a )
Figure imgf000006_0001
[式中、 Βはピリ ミジンもしくはプリン核酸塩基又はそれらの類縁体である] で 表される構造を 1または 2以上有するオリゴヌクレオチドまたはポリヌクレオチ ド類縁体、 または、 一般式 （Π)
Figure imgf000007_0001
II
[式中、 B Bは同一または異なり、 ピリ ミジンもしくはプリン核酸塩基又は それらの類縁体であり、 Rは水素、 水酸基、 ハロゲン、 またはアルコキシ基であ り、 W W2は同一または異なり、 水素、 アルキル基、 アルケニル基、 アルキニ ル基、 シクロアルキル基、 ァラルキル基、 ァリール基、 ァシル基、 シリル基また はリン酸残基もしくはリン酸ジエステル結合を介した天然型ヌクレオシド、 合成 ヌクレオシドまたはこれらヌクレオンドを含むォリゴヌクレオチドもしくはボリ ヌクレオチドであり、 n 1または n 2は同一または異なり、 0〜 5 0の整数である
(ただし、 n 1または n 2が同時にゼロになることはない。 また、 n 2の全てが同 時にゼロになることはない。 ） 、 n 3は 1〜5 0の整数である、 ただし、 n 1およ び または n 2が 2以上の場合には B 1と Bは同一でなくてもよく、 Rも同一でな くてもよい] で表されるオリゴヌクレオチドもしくはポリヌクレオチド類縁体で あ 。
本発明における、 ピリ ミジンもしくはプリン核酸塩基とは、 チミン、 ゥラシル、 シ トシン、 アデニン、 グァニン及びそれらの誘導体である。
本発明のヌクレオンド類縁体及びヌクレオチド類縁体は次のように合成できる ( ( 1 ) ヌクレオシド類縁体の合成 O— 98/39352
Figure imgf000008_0001
Figure imgf000008_0002
roヽ y
Figure imgf000008_0003
a
ゥリジンから文献 [1) J. A. Secrist et al. , J. Am. Chem. So ， 101, 155 4 (1979); 2) G. H. Jones et al. , J. Org. Chem. , 44, 1309 (1979)] に従い 合成した化合物 1をトシルクロリ ド （Ts C 1 ) で 2個ある第一級アルコールの 一方のみをトシル化して化合物 2に導き、 酸加水分解して卜リオール体 3とした c 化合物 3はベンズアルデヒ ドと酸触媒下で縮合反応を行いベンジリデン化合物 4 として、 このものを四塩化チタン （T i C 14) 存在下にナトリゥムシァノボ口 ヒ ドリ ド （Na BH3CN) で還元すると化合物 5が得られた。 本化合物をテ卜 ラヒ ドロフラン （THF) 中でナトリウムへキサメチルジシラジド （N a HMD S) と反応させたところ、 ビシクロ化合物 6 (化合物 I ： Β-ゥラシル （U) , χ = Η, Υ =ベンジル） が得られた。 化合物 6をパラジウム炭素触媒下で接触 還元すると、 ジオール化合物 7 (化合物 （ I ) ； B = U, X = Y = H) が得られ、 更に、 4、 4' ージメ 卜キシ卜リチルク口リ ド （DMT r C 1 ) 処理すると卜リ チル体 8 (化合物 I ； B = U. X = DMT r, Y = H) が得られた。 化合物 6、 7及び 8は様々な化合物 Iの原料として利用することができる。
ゥリジン以外の天然 ·非天然を問わず様々な核酸塩基を有する化合物 （ I ) は 3通りの方法で合成することができる。
その一つは、 化合物 8からの変換である。 すなわち、 化合物 8をァセチル化し て化合物 9とした後、 1、 2、 4一トリァゾールと反応して化合物 10に導き、 加水分解すると化合物 11 (化合物 （I ) : B =シ トシン （C) . X = DMT r, Y = H) が得られた。 オリゴヌクレオチド合成の原料となる化合物 12 (化合物 ( I) ； B-ベンゾイルントシン （CBz)， X = DMT r, Y = H) は化合物 1 1のベンゾィル化で容易に得られる。
Figure imgf000009_0001
第二の方法は D—リボースから文献 [3) A. G. M. Barrett et al. , J. Org. Ch em. , 55, 3853(1990); 4) G. H. Jones et al. , ibid. , 44, 1309 (1979)] に従つ て容易に得られる化合物 13を経由する方法である。 すなわち、 化合物 13を 3 工程で化合物 16に導き、 塩基性条件下に閉環反応すると、 目的のメチルグリコ シル化合物 1 7が得られた。 本化合物の 1位 O M e基を天然の様々な核酸塩基や 非天然の核酸塩基類縁体に置換するには、 既に開発された種々の方法により可能 である。 例えば、 下式化合物 1 7から化合物 2 0のような方法が使用できる。
Figure imgf000011_0001
Me 2)
Figure imgf000011_0002
Figure imgf000011_0003
20 Wひ ·98/39352 さらに、 第三の方法としては、 D-グルコースから 1工程で得られ、 しかも市 販品であるジアセトン D-グルコースを出発原料とする方法である。 文献 5) R. D. Youssefyeh, J. P. H. Verheyden and J. G. Moffatt. , J. Org. Chem. , 44, 1301-1309 (1979) に従って化合物 31を調製する。 次いで、 化合物 31を下記 の式に示した通り、 2種の 1級水酸基を t-ブチルジフエニルシリル基、 P-トル エンスルホニル基で段階的に保護し、 ァセチル化処理して化合物 34に導いた。
Figure imgf000012_0001
Figure imgf000012_0002
Figure imgf000012_0003
化合物 34にトリメチルシリル化して活性化したチミン （2TMS · T) 、 ベ ンゾィルアデニン （2TMS . ABz) 、 イソプチリルグァニン （3TMS * GiBu) を別々に縮合させ、 下記の式に示すように、 化合物 5、 10、 14をそれぞれ高 収率で得た。 ついで、 これら縮合体は脱ァセチル化 （化合物 36、 41、 45) 、 5員環形成 （化合物 37、 42、 46) 、 脱シリル化 （化合物 38、 43、 47) 、 更に脱べンジル化して目的の化合物 39へと誘導した。
Figure imgf000013_0001
Figure imgf000013_0002
Figure imgf000013_0003
38: B= 39a: B=T 43: B=A Bz 39b: B=ABz 47: B=G iBu 39c: B=G旧 u ( 2 ) オリゴヌクレオチド類縁体の合成
化合物 8に 2—シァノエェチルー N, N, Ν' , N* ーテトライソプロピルホ スホロアミダイ トを作用させ、 ァミダイ 卜体 2 1を得、 このものと天然ヌクレオ シドアミダイ ト体とを組み合わせて、 D N A自動合成機を用いて種々のオリゴヌ クレオチド類縁体を合成する。 合成した粗生成物はオリゴパック、 逆相クロマト カラムを用いて精製し、 精製物の純度を H P L Cで分析することにより確認する
天 «ヌクレオシド
アミダイト オリゴヌクレオテド
Figure imgf000014_0001
CN
21
化合物 8のモノマーュニッ トは、 オリゴヌクレオチド類縁体の中に 1つ以上存 在させることができる。 また、 オリゴヌクレオチド類縁体の中の 2ケ所以上の位 置に、 1または 2以上の天然ヌクレオチドを介して隔離された状態で存在させて も良い。 本発明に依れば、 本発明のヌクレオチド類縁体 （ヌクレオシド類縁体） を必要な位置に必要な数 （長さ） で導入したアンチセンス分子を合成することが できる。 オリゴヌクレオチド類縁体全体の長さとしてヌクレオシド単位が 2〜5 0、 好ましくは 1 0〜3 0個である。
このようなオリゴヌクレオチド類縁体 （アンチセンス分子） は、 各種ヌクレア5 ーゼに対して分解されにく く、 生体への投与後、 長時間生体内に存在することが できる。 そして、 例えば、 メ ッセンジャー R N Aと安定な二重鎖を形成して病因 となるタンパク質の生合成を阻害したり、 ゲノム中の二重鎖 D N Aとの間で三重 鎖を形成して、 メ ッセンジャー R N Aへの転写を阻害する。 また、 感染したウイ ルスの増殖を抑えることも可能となる。 これらのことから、 本発明のヌクレオシド類縁体を用いたオリゴヌクレオチド 類縁体 （アンチセンス分子） は、 抗腫瘍剤、 抗ウィルス剤をはじめとした、 特定 遺伝子の働きを阻害して疾病を治療する医薬品としての有用性が期待される。 本発明のヌクレオチド （ヌクレオチド） 類縁体を用いたアンチセンス分子は、 例 えば、 緩衝剤および/または安定剤等の慣用の助剤を配合して非経口投与製剤と したり、 リボソーム製剤とすることができる。 また、 局所用の製剤としては、 慣 用の医薬用担体を配合して軟膏、 クリーム、 液剤、 または膏薬等に調剤できる。 ' 本発明のヌクレオシド類縁体ならびにヌクレオチド類縁体の合成を実施例およ び製造例により、 さらに詳しく説明する。 実施例では、 塩基としてゥラシルを主 として使用しているが、 他のプリン核酸塩基も同様に使用できる。
[実施例 1] ヌクレオシド類縁体の合成
(1) 2'. 3' -0-シクロへキシリデン -4'- (P-トルエンスルホニルォキシ
メチル） ゥリジン（2)の合成
窒素気流下、 文献既知化合物 1 ( 956 mg, 2.70 匪 ol ) の無水ピリジン溶液 ( 13.5 ml ) に室温で p -トルエンスルホニルクロリ ド （771 mg, 4.05 raraol)を 加え、 60 でで 5時間撹拌した。
反応溶液に飽和重曹水を加えた後、 ベンゼンで 3回抽出した。 有機層を飽和食 塩水で 1回洗浄後、 無水 MgS04 にて乾燥した。 溶媒を減圧留去し、 ベンゼンで 3回共沸し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （CHC13: MeOH = 15:1) により精製後、 ベンゼン一へキサンにて再沈澱し、 白色粉末とし て化合物 2 (808 mg, 1.59 ramol, 59%) を得た。
化合物 2 : 白色粉末 rap 104-106 °C (ベンゼン一へキサン）. IR (KBr): 33 26. 2929. 2850, 1628. 1577, 1544, 1437, 1311, 1244 era—1. !H-NMR (d6-acet one): δ 1.45-1.67 (瓶 m), 2.45 (3H, s), 3.71 (2H, ABq, J = 12 Hz), 4. 20 (2H, ABq, J = 11 Hz), 4.92 (1H， d, J' = 6 Hz), 5.05, 5.06 (1H, dd， J = 4, 6 Hz), 5.60 (1H, d, J = 7 Hz), 5.75 (1H, d, J = 4 Hz), 7.48 (2H, d, J = 8 Hz), 7.77 (1H, d, J = 8 Hz), 7.81 (2H, d, J = 8 Hz), 10.10 (1H, s, ). 13C-NMR (de-acetone): δ 21.5, 24.1, 24.5, 25.5, 34.8, 36.9, 63.5, 69.7, 82.5, 84.7, 87.8, 92.9, 102.9, 115.4， 128.8， 130.8, 133.9, 1 42.7, 145.9, 151.3, 163.5. ass(EI): m/z 481(M+- H20).
Anal. Calcd for C23H28N209S- 1/3 H20: C， 53.69; H, 5.61; N, 5.44; S, 6. 22. Found: C, 53.99 ;H, 5.48 :N, 5.42 :S, 6.10.
(2) 4'—(p-トルエンスルホニルォキシメチル）ゥリジン（3)の合成
化合物 2 (107 mg( 0.21 随 ol)を TFA— H2O (98:2, 1 ml) 中室温で 10 分 間撹拌した。 反応溶液を減圧留去し、 EtOHを加えて 3回共沸した。 得られた粗成 繽体をシリカゲルカラムクロマ卜グラフィ一（CHCl3:MeOH = 10:1)により精製し、 化合物 3(85. O mg, 0.20 随 ol, 94%)を得た。
化合物 3 : 白色粉末 rap 119-120 °C. IR v (KBr): 3227, 3060, 2932, 2837, 1709, 1508, 1464, 1252, 978, 835, 763. 556 era—1. ^-NMR (d6 - acetone) : 5 2.31 (3H, s), 2.84 (3H, s), 3.71 (2H, s), 4.13, 4.20 (2H, ABq, J = 11 Hz), 4.28, 4.31 (1H, dd, J' = 9, 6 Hz), 4.36 (1H, d, J' = 6 Hz), 5.54 (1 H, d, J' = 8 Hz), 5.75 (1H, d, J = 7 Hz), 7.32 (2H, d, J = 8 Hz), 7.67 (2H, d, J = 8 Hz), 7.70 (1H, d, J' = 8 Hz), 10.14 (1H, s). 13C-NMR (de- acetone)： δ 21.5, 63.7, 70.8, 72.7, 74.6, 86.8, 88.8, 103.1, 128.8, 130. 7. 133.9, 141.7, 145.8, 151.8, 163.9. Mass (EI): m/z 256 (M+- OTs) . (3) 2', 3'- O-ベンジリデン一 4' _(p-トルエンスルホニルォキシメチル） ゥリジン （4) の合成
窒素気流下、 化合物 3 (400 mg, 0.93 圆 ol) にべンズアルデヒ ド （2.4 ml, excess), 塩化亜鉛 （670 mg, 5.0 mmol)を加え室温にて 5時間撹拌した。 反応を 飽和重曹水により止め、 クロ口ホルムで抽出し、 飽和重曹水、 水、 飽和食塩水で 洗浄した。 有機層を無水硫酸ナトリウムで乾燥し、 溶媒留去後シリカゲルカラム クロマトグラフィー（CHC13 ： eOH = 40： 1) により精製し、 化合物 4 (380 rag, 0.74 ramol, 80¾ を得た。
化合物 4: 白色粉末. mp 99-102 。C (CH2C12-へキサン）. [«]□ 23- 26.7 ° (c = 1.0, CHC13). IR v (KBr)： 3059, 1691, 1460, 1362, 1269, 1218, 1177 cm-1. !H-NMR (CDC13) δ： 2.41 (3H, s), 3.25 (1H, br), 3.79 (2H, ra), 4.19 (2H, s), 5.09 (1H, d, J = 7 Hz), 5.28 (1H, dd, J = 3, 7 Hz), 5.60 (1H, d , J = 4 Hz), 5.73 (1H， d , J = 8 Hz), 5.94 (1H, s), 7.24 (1H, d, J = 8 H z), 7.38 (2H, d, J = 9 Hz), 7.42 (5H, br), 7.69 (2H, d, J = 9 Hz), 9.11 (1H, br). 13C-NMR ( CDC13): δ 21.6, 63.5, 68.3, 77.2. 82.8, 84.2, 87.7, 94.9, 102.6, 107.5, 126.5, 127.9, 128.5, 129.7, 132.2, 135.0, 143.0, 14 5.0, 150.4, 163.5.
Anal. Calcd for C24H24N209S'l/3 H20: C, 55.17; H, 4.76; N, 5.36; S， 6. 14. Found: 55.19 ;H, 4.66; N， 5.29; S， 5.98.
(4) 3'一 0—ベンジル一 4'—(p -トルエンスルホニルォキシメチル）
ゥリジン （5) の合成
窒素気流下、 化合物 4 (150 mg, 0.29 mraol)のァセトニトリル溶液 （3 ml)に シァノ水素化ホウ素ナトリウム （92 mg, 1.5 mmol)を室温にて加えた。 その後、 四塩化チタン （0.16 ml, 1.5 mmol)を氷冷下で滴下し室温にて 15 時間撹拌した。 反応液をクロ口ホルムに希釈して飽和重曹水、 水、 飽和食塩水で洗浄したのち有 機層を無水硫酸ナトリゥムで乾燥し、 溶媒留去後シリ力ゲル力ラムクロマトグラ フィー（CHC13 ： MeOH = 25:1)により精製し、 化合物 5 (112 mg, 0.22 mmol. 75¾) を得た。
化合物 5 : 無色結晶. mp 195-197°C (AcOEt-へキサン）. [a]o 23 -14.6° (c = 1.0, CHC13). I v (KBr)： 3033, 2885, 2820, 1726, 1470, 1361, 1274, 1175, 1119 cm-1. !H-NMR (CDC13) δ 2.40 (3H, s)， 3.59-3.77 (3H, m), 4. 10, 4.24 (2H, AB, J = 11 Hz), 4.32 (1H, d, J = 6 Hz), 4.56 (2H, m), 4.69 (1H, d, J = 11 Hz), 5.52 (1H, d , J = 6 Hz), 5.67 (1H, d . J = 8 Hz). 7.24 -7.29 (7H, m), 7.48 (1H, d, J = 8 Hz), 7.70 (2H, d, J = 9 Hz), 9.91 (1H, s). 13C-霞 (CDC13): δ 21.6, 63.2, 69.2, 73.6, 74.6, 78.1, 86.6, 92.9, 102.5. 127.9, 128.2, 128.3, 128.6. 129.9, 132.3, 136.9, 142.4, 145.2, 1 50.7, 163.8.
Anal. Calcd for C24H26N209S ： C, 55.59; H, 5.05; N, 5.40; S, 6.18.
Found: C, 55.41;H, 5.02; N, 5.32; S, 6.15. (5) 3'— 0—ベンジル一 2'—0, 4'— C—メチレンゥリ ジン （6) の合成 窒素気流下、 化合物 5 (80 mg, 0.16 mraol)の無水 T H F溶液 （1.5 ml) に室 温で NaHMDS (3.2 raraol) の無水ベンゼン懸濁液 （0.7 ml) を加え、 室温で 20 時 間撹拌した。 反応溶液に飽和重曹水を加え、 CHC13 にて抽出した。 有機層を飽和 食塩水で洗浄した後、 無水硫酸ナトリウムにて乾燥した。 溶媒を減圧留去し、 得 られた粗成績体をシリカゲルカラムクロマトグラフィー （CHC13 ： MeOH = 10:1) にて精製後、 MeOHにて再結晶し、 化合物 6 (41 mg, 0.10 raraol, 61%) を得た。 化合物 6 : 無色結晶. rap 217-219 °C (MeOH). [a]D 23+108.4 。 (c = 0.3, M eOH). IR v (KBr)： 3059, 2951, 1688, 1459, 1271. 1053 cm—1. 'H-N R (de - D MS0) δ： 3.75, 3.85 (2H, AB, J = 8 Hz), 3.77 (2H, d, J = 5 Hz), 3.92 (1H, s)， 4.44 (1H, s), 4.60 (2H, s), 5.39 (1H, t , J = 5 Hz), 5.48 (1H, s), 7. 31 (5H, ra)， 7.72 (1H, d, J = 8 Hz), 11.37 (1H, s). 13C-NMR (d6-DMS0): δ 56.0, 71.1, 71.6, 75.8, 76.5, 86.5, 88.3, 100.9, 127.4, 127.6, 128.2, 1 37.9, 139.0, 150.0, 163.3. Mass(EI): m/z 346 (M+, 1.1).
Anal. Calcd. for C17H18N206 ： C, 58.96; H, 5.24; N, 8.09.
Found: C, 58.67; H, 5.23; N, 8.05.
(6) 2'— O, 4'— C—メチレンゥリジン （7) の合成
化合物 6 (25 rag, 0.072 匪 ol)のメタノール溶液 (2.5 ml)に 10% Pd-C (25 mg) を加え、 水素気流下、 常圧にて 15 時間撹拌した。 反応液を濾過し、 溶媒留去後、 シリカゲルカラムクロマトグラフィ一 （CHC13： MeOH = 10:1 then 5:1) にて精 製し、 7 (18.3 rag, quant.)を得た。
化合物 7 : 無色結晶. mp 239-243 °C (MeOH). [a]o 23+92.2 ° (c = 0.3, Me OH). IR v (KBr)： 3331, 3091, 3059, 2961, 1689, 1463, 1272. 1049 cm"1. !H-NM (CD30D) δ： 3.76, 3.96 (2H, AB, J = 8 Hz), 3.90 (2H, s), 4.04 (1H, s), 4.28 (1H, s), 5.55 (1H, s), 5.69 (1H, d, J = 8 Hz), 7.88 (1H, d. J = 8 Hz).
Anal. Calcd. for d。1^ 2N206 ： C, 46.88; H, 4.72; N, 10.93.
Found: C, 46.74; H. 4.70; N, 10.84. (7) 5'—0—（4, 4' _ジメ トキシトリチル）一 2'— 0, 4'— C—メチレン ゥリジン （8) の合成
化合物 7 (140 mg, 0.53 ramol) に無水ピリジンを加えて 3回共沸した後、 無 水ピリジン溶液 （1.5 ml) とし、 窒素気流下、 室温で 4 , 4 '—ジメ トキシトリチ ルクロリ ド （210 rag, 0.63 隱 ol)、 DMAP (6.5 mg, 0.053 隱 ol)を加え室温 で 5時間撹拌した。 反応溶液に飽和重曹水を加えた後、 CH2C12 で抽出した。 有 機層を水、 飽和食塩水で洗浄後、 無水硫酸ナトリウムにて乾燥した。 溶媒を減圧 留去し、 得られた粗成績体をシリ力ゲル力ラムクロマトグラフィ一（CHC13 ： MeOH = 40:1)により精製し、 化合物 8 (230 mg, 0.34 mmol, 66¾)を得た。
化合物 8 : 白色粉末. mp 117-120 °C (CHC13). [«]D 23+17.2 ° (c = 1.0, CHCU). IR v (KBr): 3393， 3101, 2885, 1689, 1464, 1272， 1047 cm-1.1H-N MR (CDCI3) δ 2.59 (1H, br), 3.56 (2H. q, J = 7. 11 Hz), 3.87 (1H, d， J = 7 Hz), 4.26 (1H, s), 4.47 (1H, s), 5.60 (1H, d, J = 9 Hz), 5.63 (1H, s), 5.84 (4H, d, J = 9 Hz), 7.22-7.45 (9H, ra), 7.93 (1H, d, J = 9 Hz). [実施例 2] ヌクレオシド類縁体の合成
(1) メチル =5— 0— ( t—ブチルジフヱニルシリル） 一4—ヒ ドロキシ
メチル一 2, 3— 0—イソプロピリデン一 /3— D—リボフラノシド (14) の合成
窒素気流下、 文献既知化合物 13 (2.0()8,8.54匪01)の無水じ^12じ 12溶液（40 ml)に氷冷下で Et3N(2.62ral, 18.8mmol)、 tーブチルジフエニルシリノレクロリ ド（4. 88ml， 18.8mmol)を加え、 室温で 13時間撹拌した。 反応溶液に飽和重曹水を加え た後、 AcOEtで 3回抽出した。 有機層を飽和食塩水で 1回洗浄後、 無水 Na2S04に て乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマト グラフィ一 （へキサン： AcOEt=5:l)により精製し、 無色油状物質 14 (2.82g, 5.9 8mmol， 70%)を得た。
[α]ο17-16.2° (c=0.52,CHCl3) IRレ （KBr) :3510, 3061, 2938, 2852, 1465, 110 3cm—
^-NMR (CDC 13) δ ： 1.09(9H,s), 1.28(3H, s), 1.49(3H，s), 3.22(3H, s), 3.67, 3.76(2H, AB, J=llHz), 3.88, 3.93(2H, AB, J=llHz), 4.49(1H, d, J=6Hz), 4.57C1H, d, J=6Hz), 4.93(1H, s), 7.38-7.43C6H, m). 7.67(4H, d， J=7Hz).
13C— NMR (CDC ") 5 c : 19. % 24.4, 25.9, 26.9, 55.0, 62.9, 64.8, 82.2, 85.9, 88.7, 108.6, 112.6, 127.8, 129.9, 133.0, 135.7.
Anal. Calcd for C26H3606Si · 1/4 H20： C, 65.45; H， 7.71. Found :C, 65.43; H, 7.59.
(2) メチル =5—0— ( t—ブチルジフヱニルシリル） 一2, 3—0—
ィソプロピリデン一 4— (p— トルエンスルホニルォキシメチル） —^—リボフラノシド （15) の合成
窒素気流下、 化合物（2.13g,4.51mmol)の無水 CH2C12溶液 （15ml)に室温で Et3N (3.92g, 28.0匪 ol)、p—トルエンスルホニルクロリ ド（1.34g, 7.22ramol)、 4ージメ チルァミノピリジン（90mg, 0.72mmol)を加え、 室温で 17時間撹拌した。 反応溶 液に飽和重曹水を加えた後、 AcOEtで 3回抽出した。 有機層を飽和食塩水で 1回 洗浄後、 無水 Na2S04にて乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリ 力ゲルカラムクロマトグラフィ一 （へキサン： AcOEt=10:l)により精製し、 無色 油状物質 15 (2.76g, 4.42隱 ol, 98%)を得た。
[α]ο17-3.82° (c=0.56,CHCl3) IR （KBr) :2934, 2852, 1369, 1104cm-1.
1H— NMR (CDC ") δ ： 1.02(9H,s), 1.20(3H, s), 1.32(3H, s), 2.4K3H, s), 3.09(3H, s), 3.51,3.77(2H. AB, J=10Hz)( 4.34(1H, d, J=6Hz), 4.25, 4.39(2H, AB, J=9Hz), 4.47(1H, d, J=6Hz), 4.77(1H, s), 7.28, 7.8K4H, AB, J=9Hz), 7.39-7. 44(6H,ra), 7.62-7.65(4H, m), 7.8K2H, d, J=9Hz).
13C 匪 R (CDC ") (5 c ： 19.2, 21.6, 24.5, 25.8, 26.8, 54.9, 62.7, 68.8, 81.9, 85.6, 87.5, 108.7. 112.8, 127.7, 127.8, 128.2, 129.6, 129.9, 132.9, 135.6, 144.4.
Anal. Calcd for C33H4208SSi:C, 63.23; H, 6.75;S， 5.11. Found :C, 62.99; H.6.5 3; S, 5.13.
(3) メチル =5— 0— ( t—ブチルジフヱニルシリル） 一 4一 （p— トルエン スルホニルォキシメチル） 一 3— D—リボフラノシド （16) の合成 化合物 15 (645rag, 1.03ramol)の THF- H20[llml, 8:3(v/v)]溶液に室温でトリフロ 口酢酸（14ml)を加え、 室温で 20分撹拌した。 溶媒を減圧留去し、 得られた粗成 績体をシリカゲルカラムクロマ卜グラフィー （hexane:AcOEt=5:l)により精製し、 無色油状物質 16 (464mg, 0.79ramol, 77%)を得た。
[ ] D1 7 - 35.8° (c=1.90,CHCl3) IRレ （KBr) :3499， 3051, 2931. 2840, 1594, 146 8, 1362, 1109cm-1.
'H-N R (CDC 13) δ 1.02(9Η( s), 2.42(3Η, s), 3.16(3Η, s), 3.54. 3.70(2Η, ΑΒ, J=10Hz), 3.97(1Η, d, J=5Hz), 4.18(1Η, d, J=5Hz), 4.26, 4.39(2H, AB, J=10Hz), 4.73C1H, s), 7.30(2H, d, J=8Hz)( 7.36-7.44(6H, m), 7.59-7.66(4H, m), 7.78(2H, d, J=8Hz).
13C-NMR(CDC 13)5c : 19.2, 21.6, 26.7. 55.2, 66.5, 69.6, 74.0, 75.2, 76.5, 84.8, 107.5, 127.7, 128.0, 129.8， 132.6, 132.7. 132.8, 135.5, 135.6, 144.9.
Anal. Calcd for C30H38SSi08'l/4 H20:C, 60.94; H, 6.56. Found :C, 60.94; H, 6.4 3.
(4) メチル =5—0— ( t—ブチルジフエニルシリル） 一2— 0, 4 -C- メチレン一 yS— D—リボフラノシド （17) 及び
メチル =5— 0— （ t—プチルジフエニルシリル） 一3— 0, 4 -C- メチレン一 /3— D—リボフラノシド （18) の合成
窒素気流下、 化合物 16 (194mg,0.33隱 ol)の無水 THF溶液 （4ral)に室温で NaHMDS(3.30匪 ol)の benzene懸濁液 (1.6ml)を加え、 室温で 1時間撹拌した。 反 応溶液に飽和重曹水を加えた後、 反応溶媒を留去し、 AcOEtで 3回抽出した。 有 機層を飽和食塩水で 1回洗浄後、 無水 Na2S04にて乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマ卜グラフィ ー （へキサン： Ac0Et=5: 1)により精製し、 無色油状物質 17 (48mg,0.116mmol,35¾ 及び無色油状物質 1 8 (59mg, 0.142raraol, 43¾)を得た。
化合物 17 :IRリ（KBr):3438, 3064, 1103, 1036cm—
1H— NMR (CDC 13) δ ： 1.08(9H,s), 2.04(lH,br s), 3.39(3H, s), 3.65, 3.98(2H, AB, J=8Hz), 3.95, 4.02(2H, AB, J=12Hz), 4.02(lH,s), 4.30(1H, s), 4.79 (lH,s)， 7.38-7.46(6H, m), 7.65-7.69(4H, m).
13C-NMR (CDC 1 3) (5 : 19.2, 26.7, 55.0, 60.7. 71.2, 73.1, 79.9, 85.5, 104.3, 127.8, 129.9. 130.0, 132.9, 135.6, 135.7.
Anal. Calcd for C23Il3005Si'l/4 H20:C.65.68; H, 7.34. Found :C, 65.98; H, 7.23. 化合物 1 8 :IRレ （KBr):3456, 3058, 2938, 2852, 1467, 1108cm-1.
^-NMR (CDC 1 3) δ ： 1.10(9H. s), 3.26C3H, s), 3.71(2H,s), 4.02(1H, d, J=6Hz), 4.35, 4.95(2H, d, J=7Hz), 5. Ol(lH.s), 5.1K1H, d, J=6Hz), 7.38-7.4 4(6H, m), 7.66(4H, d, J=7Hz).
13C-NMR (CDC 1 3) 。 ： 19.3, 26.8, 55.4, 63.7, 75.1, 77.9, 84.5, 86.3， 111.9, 127.8, 128.0, 129.9, 132.9, 133.0, 135.6, 135.8. 135.9. Anal. Calcd for C23H3005Si.l/4 H20:C, 65.91; H, 7.34. Found :C.66.07; H, 7.14. (5) メチル = 3—O—ァセチルー 5—O— ( t—ブチルジフヱ二ルシリ
ル） 一 2— 0, 4— C—メチレン一^一 D—リボフラノシド （ 1 9 ) の合成
窒素気流下、 化合物 1 7 (704mg, 1.70議 ol)の無水ピリジン溶液 （10ml)に室温 で無水酢酸（0.38ml, 4.08關 ol)、 4ージメチルァミノピリジン（21mg, 0.170園 ol)を 加え、 室温で 3時間撹拌した。 反応溶液に飽和重曹水を加えた後、 AcOEtで 3回 抽出した。 有機層を飽和食塩水で 1回洗浄後、 無水 Na2S04にて乾燥した。 溶媒を 減圧留去し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （へキサ ン ： Ac0Et=7:l)により精製し、 無色油状物質 19 (665mg, 1.46隱 ol,86¾)を得た。
[ ] D17— 34.3° (c=0.93, CHC13) IRレ （KBr):3438, 3064, 2934, 1749, 1468, 110 3, 1036cm一1.
'H-NMR (CD C ") δ ： 0.99(9H,s), 1.97C3H, s), 3.34(3H, s), 3.69.3.8 6(2H, AB, J=8Hz), 3.86(2H, s), 4.17(1H, s), 4.77C1H, s), 5.06(1H, s), 7.28-7.3 9(6H, ra), 7.58-7.63(4H, m).
13C— NMR (CDC 1 3) (5 : 19.3, 20.9, 26.7, 55.0, 60.3, 72.0, 73.6, 78.3, 85.3, 104.4, 127.7. 129.8, 133.0, 135.6, 169.8. Anal. Calcd for C25H3206Si- 1/4 H20:C, 65.12; H, 7.10. Found :C, 65.27;H, 7.00. (6) 5'— 0— (t—プチルジフヱニルシリル） 一2' -0, 4' — C—メチ レン一 5—メチルゥリジン （20) の合成
窒素気流下、 化合物 19 (109.2g.0.239mraol)の無水 CH3CN溶液 （2ml)に室 温で 0, 0'—ビストリメチルシリルチミン（154mg， 0.598mmol)を加えた後、 氷冷 下で卜リメチルシリルトリフルォロメタンスルホネ一卜（0.82ml, 8.74匪 ol)の 1, 1ージクロロェタン（0.31ral)溶液を加え、 室温で 18時間撹拌した。 反応溶液を CH2C 12で希釈し、 飽和重曹水を加えた後、 AcOEtで 3回抽出した。 有機層を 飽和食塩水で 1回洗浄後、 無水 Na2S04にて乾燥した。 溶媒を減圧留去し、 得られ た粗成績体をシリカゲルカラムクロマトグラフィ一 （へキサン： Ac0Et=3:l)によ り精製し、 無色油状物質 20 (87.7mg, 0.173隨 ol' 70¾)を得た。
IRレ （KBr):3048, 2935, 2852. 1749, 1466, 1369, 1234, 1108, 1040cm-1.
1H— NMR (CDC 13) δ 1.06(9H, s), 1.94(3H. s), 2.98(1H, br s), 3.63. 4.00(2H, AB, J=10Hz), 3.72(1H, d, J=7Hz), 3.82-3.84(2H, m), 4.30(1H, s), 5.25 (lH,s), 7.40-7.46(6H, m), 7.60(4H, d, J=6Hz), 7.66(1H. s), 9.68(lH,br s).
[実施例 3] ヌクレオシド類縁体の合成 （別法）
(1) 3— 0—ベンジルー 5— 0— t一ブチルジフヱニルシリル一 4— (ヒ ドロ キシメチル） 一 1, 2— 0—イソプロピリデン一 一 D—エリス口ベント フラノース （32) の合成
窒素気流下、 氷冷下で前記文献 5) に従って調整した化合物 31(2.50 g, 8.0 8 mmol) の塩化メチレン溶液 （50 ml) に、 卜リェチルァミ ン （3.71 ml, 26.6 m raol)、 t-ブチルジフヱニルシリルクロリ ド （6.94 ml, 26.7 mmol) を加え、 室温 で 10.5 時間撹拌した。 反応溶液に飽和重曹水を加えた後、 酢酸ェチルで抽出し た。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムで乾燥した。 溶媒を減圧留去 し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （AcOEt-へキサン， 1:4 → 1:3) により精製し、 白色固体 （32) (2.97 g, 5.41 mmol, 67 ¾) を 得た。
mp. 98 - 99 °C (へキサン） . [a] D 20 + 54.8 ° (c = 1.12. アセトン）. IR レ max (Or) ： 3553, 2936. 1463, 1379, 1107 cm 1. 'H-N R (CDC13) δ： 1.13 (9Η, s), 1.50 (3H, s), 1.78 (3H, s)， 2.56 (1H, t, J = 7 Hz), 3.82, 3.92 (2H, AB, J = 11 Hz), 3.94 (2H, t, J = 6 Hz), 4.57 (1H, d. J = 5 Hz), 4. 64, 4.95 (2H, AB, J = 12 Hz), 4.83 (III, dd, J = 4, 5 Hz), 5.95 (1H， d, J = 4 Hz), 7.44-7.55 (11H, m), 7.72-7.78 (4H, ra). 13C-讓 (CDC13) < 19. 2, 26.2, 26.5, 26.8, 63.2, 65.4, 72.5, 77.9, 79.1, 87.4, 104.4, 113.7. 1 27.6, 127.7, 128.0, 128.5, 129.5, 129.7, 132.9, 133.1, 134.7, 135.5, 137. 2.
Anal. Calcd for C32H4006Si ： C, 70.04; H, 7.38. Found ： C, 70.19; H, 7.3 5.
(2) 3—0—ベンジル一 5—O— ( t _プチルジフエ二ルンリル） 一4— (p — トルエンスルホニルォキシメチル） 一 1, 2— <¾— D—エリス口ベント フラノース （33) の合成
窒素気流下、 氷冷下で 32(250 mg, 0.456 mmol) の塩化メチレン溶液に、 ト リエチルアミ ン （395 ρΛ, 2.83 mmol), p-トルエンスルホニルクロリ ド （139.2 mg, 0.730 mmol) 及び 4 -ジメチルアミノピリジン （8.92 mg, 0.0730 mmol) を 加え、 室温で 15.5 時間撹拌した。 反応溶液に飽和重曹水を加えた後、 酢酸ェチ ルで抽出した。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムにて乾燥した。 溶 媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （Ac OEt-へキサン， 1:6) により精製し、 淡黄色油状物質 （33) (310.6 mg, 0.442 mmol, 97 ¾) を得た。
[ ] D20 + 16.0 ° (c = 0.44, アセトン）. IR max (KBr) ： 2935, 1595, 146
2, 1363. 1174. 1106 cm"1. ^-NMR (CDC13) δ： 1.08 (9Η, s), 1.40 (3H, s), 1.46 (3H, s). 2.48 (3H, s), 3.68, 3.83 (2H, AB, J = 11 Hz) ， 4.45 (2H, dd, J = 4. 5 Hz), 4.64, 4.81 (2H, AB, J = 12 Hz), 4.68 (1H, dd, J = 4, 5 Hz), 5.81 (1H, d, J = 4 Hz), 7.32 (2H, d, J = 8 Hz). 7.42-7.72 (15H， m), 7.82, (2H, d， J = 8 Hz), 7.66 (4H, m), 7.72 (2H, d, J = 8 Hz). 13C-讀 (CDC13) 5c: 19.1, 21.5, 26.1, 26.4. 26.7, 64. , 70.0, 72.5. 78.1, 78.9, 85.4, 104.2, 113.6, 127.3, 127.7, 127.9, 128.0, 128.4. 129.6. 129.7. 12 9.8, 132.7, 132.8, 135.5, 137.2, 144.4. MS (EI) m/z ： 646 ( +-t-Bu). Hi gh-HS (EI) ： Calcd for C35H3708SSi (M+-t-Bu) ： 645.1978. Found ： 645.19
69.
(3) 1, 2—ジ一 O—ァセチル一 3—0—ベンジルー 5—0— t—ブチルジ フエニルシリル一4_ (p—トルエンスルホニルォキシメチル） — α— および一 ;9— D—リボフラノース （34) の合成
窒素気流下、 34 (3.70 g, 5.27 mmol) の酢酸溶液 （56 ml) に無水酢酸 （6. 0 ml, 63.6 mmol) 及び濃硫酸 （56 jul, 1.10 mol) を加え、 室温で 2 時間撹 拌した。 反応溶液を氷水 （300 ml) にあけて 30 分間撹拌した後、 飽和食塩水を 加え、 酢酸ェチルで抽出した後、 有機層を硫酸マグネシウムにて乾燥した。 溶媒 を留去して得られた粗成績体をシリカゲルカラムクロマトグラフィー （AcOEt-へ キサン， 2:1) により精製し、 黄色油状物質 （34) (3.36 g, 4.53 匪 ol, 86 ¾) を α ： ;3 = 1:4 の混合物として得た。
IR レ max (KBr) ： 2934, 2863, 1751. 1365, 1217, 1106 cm"1. 'H-NMR (CDC13) [/3体] δ： 1.02 (9H( s), 1.77 (3H, s), 1.98 (3H, s), 2.39 (3H, s), 3.61, 3.76 (2H, AB, J = 11 Hz), 4.21-4.58 (5H, m), 5.26 (1H, d, J = 5 Hz). 5. 94 (1H, s), 7.15-7.59 (13H, in), 7.58-7.66 (4H, ra), 7.72 (2H, d, J = 8 Hz) . [ 体] d: 1.02 (9H, s), 1.98 (3H, s), 2.36 (3H, s), 3.48. 3.58 (2H, AB, J = 11 Hz), 4.21-4.58 (5H, m)， 5.12 (1H, dd, J = 5, 6 Hz), 6.33 (1H, d, J = 5 Hz), 7.15-7.59 (13H, m), 7.58-7.66 (4H, m), 7.72 (2H. d, J = 8 Hz) • 13C -腿 (CDC13) ( c : 14.2, 19.3, 20.5, 20.8, 21.6, 26.7, 26.8, 60.3, 6 4.8, 69.1, 73.6, 74.1, 78.6, 85.3, 97.4, 127.4, 127.6, 127.7, 127.8, 127. 9, 128.0, 128.2, 128.3, 128.4, 129.5, 129.6, 1289.8. 129.9, 132.4, 132.8, 132.9, 135.4, 135.5, 135.6. 136.9, 144.5, 168.7， 169.4. High-MS(FAB) ： Calcd for 。！ 0SSiNa (M++Na) ： 769.2479, Found ： 769.2484.
(4) 2' —0—ァセチル一 3' —0—ベンジル一 5' — 0— t—ブチルジフエ ニルシリルー 4' — P— トルエンスルホニルォキシメチル一 5—メチルゥ リジン （35) の合成
窒素気流下、 氷冷下で 34(L88g, 2.52 mraol) の 1, 2-ジクロロエタン溶液 (26 ml) に 2TMS.T (1.04 g, 4.03議 ol) 及びトリメチルシリルトリフルォロメ タンスルホナート （730 β\, 4.03 ramol) を加え、 室温で 17 時間撹拌した。 反 応溶液に飽和重曹水を加え、 セライ 卜濾過した後、 母液をクロ口ホルムで抽出し た。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムにて乾燥した。 溶媒を減圧留 去して得られた粗成績体をシリカゲルカラムクロマトグラフィー （AcOEt-へキサ ン， 2:3) により精製し、 白色粉末 （35) (2.00 g, 2.44 mmol, 97 ) を得た。 mp. 70 - 71.5 °C. C«] D24 + 4.58 ° (c = 1.25, アセトン）. IR レ max (KBr) ： 3059, 2934, 1694, 1465， 1368, 704 cm-1. -匿 (CDC13) δ 1.18 (9Η, s) , 1.63 (3H, d, J = 1 Hz), 2.10 (3H, s) , 2.42 (3H, s) , 3.73, 3.86 (2H, AB, J = 11 Hz), 4.12, 4.20 (2H, AB, J = 11 Hz), 4.44, 4.57 (2H, AB, J = 11 Hz) , 4.45 (1H, d, J = 6 Hz), 5.38 (1H, t, J = 6 Hz), 6.02 (1H, d, J = 6 Hz), 7.21-7.60 (13H， m), 7.62-7.69 (7H, m), 8.91 (1H, br s). 13C -賺 (CDCI3) δ 11.9, 19.3. 20.6, 21.6, 27.0, 65.3, 68.6, 74.1. 74.8, 77.2, 77.3, 86.0, 86.4, 111.6, 127.9, 128.0, 128.2, 128.5, 129.7, 130.1. 130. 2, 131.8, 132.3, 132.5, 135.3, 135.5, 135.6. 136.8, 144.9, 150.2, 163.4, 170.2. MS (FAB) m/z ： 813 (M++H).
Anal. Calcd for C43H48 2O10SSi-2H20: C, 60.83; H, 6.17; N, 3.30. Found ： C, 60.55; H, 5.78; N, 3.22.
(5) 3' —0—ベンジルー 5' —O— t—ブチルジフヱニルシリル一 4' - p —トルエンスルホニルォキシメチル一 5—メチルゥリジン （36) の合成 氷冷下、 35 (250 mg, 0.308 mmol) のメチルアルコール溶液 （4 ml) に炭酸 カリウム （12.75 rag, 0.0923 mmol) 及び水 （0.5 ml) を加え、 室温で 22 時間 撹拌した。 氷冷下、 反応溶液に酢酸を加えて中和した後、 溶媒を減圧留去した。 残渣に水を加えた後、 酢酸ェチルで抽出した。 有機層を飽和食塩水で洗浄した後、 硫酸ナトリウムで乾燥した。 溶媒を減圧留去した後、 得られた粗成績体をシリカ ゲルカラムクロマトグラフィー （AcOEt-へキサン， 3:2) により精製し、 白色粉 末 （36) (216.7 rag, 0.283 mmol, 92 ¾) を得た。
rap. 74 ― 77 °C. [ ] D 23 + 5.15 ° (c = 1.23, CHC13). IR レ max (KBr) ： 30 48, 2934, 1695, 1363, 1181, 1108. 977, 819, 704 cm- 1. 1H-NMR (CDC13) d: 1.05 (9H, s), 1.65 (3H, d, J = 1 Hz), 2.39 (3H， s), 3.04 (1H, br d, J = 9 Hz), 3.72 (2H, s), 4.17 (2H, s), 4.18 (1H, d, J = 5 Hz), 4.24-4.32 (1H, m), 4.54, 4.62 (2H, AB, J = 11 Hz), 5.62 (1H, d, J = 6 Hz), 7.19-7.69 (20H, ra), 8.46 (1H, br s). 13C-NMR (CDC13) δ 12.1, 19.4. 26.9, 58.8. 7 2.0, 72.2. 75.8, 76.7, 87.4, 88.8, 110.4, 127.7, 12.79, 128.1, 128.2, 12 8.5, 128.7, 129.8, 130.0, 130.1, 132.2, 134.3, 135.3, 135.5, 136.8, 149. 8, 163.9. MS (FAB) m/z ： 771 (M++H).
Anal. Calcd for C41H46N209SSi: C, 63.41; H, 6.16; N, 3.51; S, 3.95.
Found ： C, 63.87; H, 6.01; N, 3.63; S, 4.16.
(6) 3' —O—ベンジルー 5' —O— tーブチルジフエニルシリル一 2' — 0, 4' —C—メチレン一 5—メチルゥリ ジン （37) の合成
窒素気流下、 氷冷下で 36 (1.86 g, 2.42 mraol) のテトラヒ ドロフラン溶液 (30 ml) にナトリウムビス （卜リメチルシリル） アミ ド （1.0 M in THF, 8.47 m 1, 8.47 mmol) を加え、 室温で 1 時間撹拌した。 反応溶液に飽和重曹水 （14 ml) を加えた後、 溶媒を減圧留去した。 残渣に水を加え、 クロ口ホルムで抽出した。 有機層を飽和食塩水で洗浄した後、 硫酸ナトリウムにて乾燥した。 溶媒を減圧留 去し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （AcOEt-へキサ ン， 2:3) により精製し、 白色粉末 （37) (1.42 g, 2.37 mmol, 98 ¾) を得た。 mp. 70.5- 72 °C. [ ] D 22 + 52.47 ° (c = 1.025， ァセトン）. IR リ max (KBr) ： 2936, 1694, 1465, 1275, 1106, 1055, 809. 704 cm-1. ^- HR (CDC13) δ : 1.21 (9H, s). 1.76 (3H, s), 3.88， 4.07 (2H, AB, J = 8 Hz), 4.07, 4.15 (2H, AB, J = 11 Hz), 4.16 (1H, s), 4.66, 4.80 (2H, AB, J = 11 Hz), 4.76 (1H, s), 7.34-7.79 (16H, ra), 10.0 (1H, br s). MS (FAB) m/z ： 599 (M++H). Anal. Calcd for C34H38N20eSi'2H20: C, 64.33; H, 6.03; N, 4.41. Found ： C, 64.58; H, 6.15; N, 4.28.
(7) 3' —0—ベンジル一 2' -0, 4' —C—メチレン一 5—メチルゥリジ ン （38) の合成
窒素気流下、 37 (188.7 mg, 0.316mmol) のテトラヒ ドロフラン溶液 （1 ml) に、 テトラプチルアンモニゥムフルオリ ド （1.0 M in THF, 379 βΐ, 0.379 ra ol) を加え、 室温で 2.5 時間撹拌した。 反応溶液を減圧留去して得られた粗成 績体をシリカゲルカラムクロマトグラフィー （AcOEt-へキサン， 1:1→1:0) によ り精製し、 白色粉末 （38) (94.6 mg, 0.262隨 ol, 83 %) を得た。
IR max (KBr) ： 3424, 3183, 3063, 2950, 1691, 1463, 1273, 1057, 734cm-1. •H-NMR (CDC13) δ： 1.90 (3Η, d, J = 1 Hz), 3.83, 4.05 (2H. AB, J = 8 Hz) ， 3.93, 4.02 (2H， AB, J = 12 Hz), 3.94 (1H, s)， 4.53 (1H, s), 4.56, 4.58 (2H, AB, J = 12 Hz), 5.65 (1H, s), 7.32 (5H, s), 7.44 (1H, d， J = 1 Hz). High - MS (EI) ：
Calcd for C18H20N06 (M+) ： 360.1321, Found ： 360.1312. (8) 2'— 0. 4' —C—メチレン一 5—メチレンゥリジン （39 a) の合成 化合物 38 (86.5 mg, 0.240 mraol) のメチルアルコール溶液 （4 ml) に 20 % Pd(0H)2-C (86.5 mg) を加え、 水素気流下常圧にて 14.5 時間撹拌した。 反応溶 液を濾過した後、 溶媒を減圧留去して無色結晶 （39) (62.5 mg, 0.230 mmol, 96 ¾) を得た。
nip. 194- 195 °C. [a] D 20 + 53.7 ° (c =1.02, EtOH). IR レ max (KBr) ： 332 3, 3163, 3027, 2889, 2826, 1689, 1471. 1276, 1057 cm— 1. »H-NMR (CD30D) δ： 1.89 (3H, q, J = 1 Hz), 3.74, 3.95 (2H, AB, J = 8 Hz), 3.90 (1H, s),
4.07 (1H, s), 4.26 (1H, s), 5.53 (1H, s) , 7.74 (1H, d, J = 1 Hz). 13C - 隱 (CD30D) dc: 12.6, 57.6, 70.3, 72.4, 80.8, 88.3， 90.4, 110.7, 136.8,
151.8, 166.5.
[実施例 4 ]
(1) 2' — O—ァセチルー 3' —O—ベンジル一 5' — O— t—ブチルジフエ ニルシリル一 4' — p— トルエンスルホニルォキンメチル一Νβ —べンゾ ィルアデノシン （40) の合成
文献 6) (H. Vorbrggen, K. Krolikiewicz and B. Bennua, Chem. , Ber. , 114, 1234-1255 (1981)) に従って調整した 2TMS-ABz (128.7 rag. 0.336 mmol) に窒 素気流下、 室温で 34 (250 mg, 0.336 mmol) の 1, 2-ジクロロエタン溶液 （5.0 ml) 及び卜リメチルシリルトリフルォロメタンスルホナー ト （6.7〃 1, 0.0336 mmol) を加え、 26 時間加熱還流した。 反応溶液に飽和重曹水を加えた後、 塩化 メチレンで 3 回抽出した。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムにて 乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマトグ ラフィー （CHC13- MeOH. 30:1) により精製し、 白色粉末 （40) (234.5 mg, 0. 253 mmol, 75 ¾) を得た。
mp. 77-78 。C (AcOEt / へキサン）. [な] D 24 _ 13.2 ° (c = 1.00. CHC13). IR umax (KBr) ： 3058, 2934, 1749, 1703. 1606, 1105 cnr1. 'H-NM (CDC13) 6 : 0.99 (9H, s). 2.04 (3H, s), 2.38 (3H, s), 3.74, 3.85 (2Π, AB, J = 1 1 Hz), 4.31, 4.43 (2H, AB, J = 11 Hz), 4.52. 4.58 (2H, AB, J = 11 Hz) , 4.81 (1H, d, J = 6 Hz), 5.94 (10, d, J = 6 Hz), 6.04 (1H, d, J = 5 Hz), 7.18 一 7.61 (20H, m), 7.69 (2H, d, J = 8 Hz), 7.99 (1H, s), 8.01 (2H. d, J = 7 Hz), 8.56 (1H, s), 8.99 (1H, br s). 13C-隱 (CDC13) <5c: 19.1, 20. 5， 21.5, 26.7, 64.1, 68.4, 74.0, 74.6. 77.9, 86.57, 86.64, 123.4, 127.7, 127.8, 127.9, 128.1, 128.5, 128.8， 129.6, 129.9, 132.0. 132.3, 132.6, 1 32.7, 133.5, 135.4, 135.5, 136.8, 142.0, 144.7, 149.6, 151.2, 152.6, 164. 5, 169.8. MS (FAB) m/z ： 926 (M++H) .
(2) 3' —O—べンジルー 5' — O— t—ブチルジフヱニルシリル一 4' - p —トルエンスルホニルォキシメチル一Νβ —ベンゾィルアデノシン （41) の合成
化合物 40(167.9 mg, 0.182 mmol) のメチルアルコール溶液 （3.0 ml) に室 温で炭酸カリウム （15.0 mg, 0.109 mmol) を加えた後、 室温で 15 分撹拌した。 反応溶液に濃塩酸を加えて溶液を中和した後、 塩化メチレンで 3 回抽出した。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムにて乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （CHCl3-MeOH, 30:1) により精製し、 白色粉末 （41) (140.5 mg, 0.160 mmol, 88 ¾) を得た。
mp. 82- 83 °C (AcOEt—へキサン）. [a] D 25 — 6.02 。 （c = 0.96, CHC13). IB リ max (KBr) ： 3306, 3066. 2935. 2859, 1701. 1611 cm 1. ^- HR (CDC13) δ : 0.98 (9H, s), 2.37 (3H, s), 3.76 (2H, s), 4.39, 4.45 (1H, AB, J = 11 Hz), 4.54 (1H, d, J = 6 Hz), 4.67, 4.76 (2H， AB, J = 11 Hz), 4.85 (1H, dd, J = 5, 6 Hz), 5.79 (1H, d, J = 5 Hz), 7.20 - 7.58 (21H, m), 7.73 (2H, d， J = 8 Hz), 7.80 (1H, s)， 7.96 (2H, d, J = 8 Hz), 8.49 (1H, s), 9.18
(1H, br s). 13C-NME (CDC13) 5c: 19.1, 21.6. 26.8. 64.4. 68.9, 74.1, 74.
6， 79.2, 86.8, 89.8. 123.1, 127.7, 127.8, 128.0, 128.2. 128.4. 128.6. 12 8.8, 129.7, 130.0, 132.1, 132.5, 132.6, 132.8, 133.4, 135.4. 135.5, 136.
8, 142.1, 144.8, 149.4, 152.3, 164.5.
(3) 3' —O—ベンジル一 5' —O— t—ブチルジフエニルシリル一 2' — 0， 4' — C—メチレン一 Νβ —ベンジルアデノシン （42) の合成 窒素気流下、 41(210.5 mg, 0.238 mmol) のテトラヒ ドロフラン溶液 （8· 0 m 1) に室温でナトリウムビス （トリメチルシリル） ァミ ド （1.0 M in THF, 0.58 ml, 0.572 mmol) を加えた後、 室温で 3 時間撹拌した。 反応溶液に飽和重曹水 を加えた後、 塩化メチレンで 3 回抽出した。 有機層を飽和食塩水で洗浄後、 硫 酸ナトリウムにて乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲル カラムクロマトグラフィー （CHC13- MeOH, 30:1) により精製し、 白色粉末 （42) (169.5 rag, 0.238 mmol, quant. ) を得た。
mp. 80- 81 °C. IR レ max (KBr) ： 3259, 3064, 2932, 2858. 1703, 1607 cm"1. Ή-NMR (CDC13) δ ： 1.07 (9H, s), 3.95, 4.10 (2H, AB, J = 8 Hz), 4.02 (2 H， d， J = 8 Hz), 4.56, 4.64 (2H, AB, J = 12 Hz), 4.26 (1H， s) , 4.86 (1H, s), 6.14 (1H, s), 7.26 ― 7.70 (18H, m), 8.04 (2H, d, J = 7 Hz), 8.22 (1 H, s), 8.78 (1H, s), 9.18 (1H, br s). 13C-NMR (CDC13) (5c: 19.2, 26.5, 2 6.8, 29.7, 59.2, 72.4, 72.6. 76.5, 76.8, 86.7, 88.6, 123.4, 127.7, 127.8. 127.9, 128.1, 128.4, 128.8, 129.5, 130.0， 132.4, 132.5, 132.8. 133.5, 1 34.8, 135.2, 135.5, 135.6, 136.8. 140.4, 152.7.
(4) 3' —O—ベンジル一 2' -O, 4' — C—メチレン一 N6 —ベンゾィル アデノシン （43) の合成
化合物 42 (173.6 mg, 0.244 mmol) のテトラヒ ドロフラン溶液 （7.0 ml) に 室温でテトラプチルアンモニゥムフルオリ ド （1.0 M in THF, 1.0 ml, 1.0 mmol) を加え、 室温で 25 分撹拌した。 反応溶液を減圧留去して得られた粗成績体を シリカゲルカラムクロマトグラフィー （CHC13- MeOH, 15:1) により精製し、 白色 粉末 （43) (115.4 mg, 0.244 mmol, quant. ) を得た。
mp. 154 一 155 °C (Et20). IR レ max (KBr) ： 3339, 2944, 1701, 1611 cm—1. 1 H-NMR (CDCI3) δ： 3.91, 4.13 (2H, AB, J = 8 Hz), 3.93, 4.01 (2H, AB, J = 12 Hz), 4.38 (1H, s), 4.64 (1H, s), 4.85 (1H, s), 6.08 (1H, s), 7.29 (1 H, s), 7.51 (2H, d, J = 8 Hz), 7.58 (1H, d, J = 7 Hz), 8.05 (2H, d, J = 7 Hz), 8.14 (1H, s), 8.75 (1H， s), 9.50 (1H, br s). 13C-NMR (CDC13) δ c: 57.1, 2.4, 77.0, 77.1, 86.9, 88.6, 122.9, 127.6, 128.0, 128.1, 128.4. 128.7, 132.8, 133.5, 136.9. 140.5, 149.8, 150.5, 152.8, 165.0.
[実施例 5]
(1) 2' —0—ァセチル一 3' — 0—ベンジル一 5' — 0— t—ブチルジフエ ニルシリル一 4' — p— トルエンスルホニルォキシメチル一 N2 —イソブ チリルグアノシン （44) の合成
前記の文献 6) に従って調整した 3TMS* Gi Bu (146.8 rag, 0.336 mmol) に窒 素気流下、 室温で 4 (250 mg, 0.336 mraol) の 1, 2-ジクロロェタン溶液 （5.0 ml) 及びトリメチルシリルトリフルォロメタンスルホナート （6.7 βΐ, 0.0336 mmol) を加え、 15 時間加熱還流した。 反応溶液に飽和重曹水を加えた後、 塩化 メチレンで 3 回抽出した。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムにて 乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマトグ ラフィー （CHCl3-MeOH, 30:1) により精製し、 白色粉末 （44) (213.6 mg, 0.2 35 mmol, 70 ¾) を得た。
mp. 96一 97 °C (AcOEt—へキサン）. [a] D 24 -11.09 。 (c = 0.97, CHC13). I R ymax (KBr) ： 3152. 3065, 2934, 1746, 1681, 1606 cm— Ή-NMR (CDC13) d: 0.96 (9H, s), 1.10 (3H, d, J = 9 Hz), 1.13 (3H, d, J = 9 Hz), 1.98 (3H, s), 2.36 (3H, s), 2.48 (1H, m), 3.65, 3.72 (2H, AB, J = 11 Hz), 4.2 3, 4.43 (2H, AB, J = 11 Hz), 4.47 (2H, s), 4.63 (1H, d, J = 6 Hz), 5.74 (1H, t, J = 6 Hz), 5.96 (1H, d, J = 6 Hz), 7.14 ― 7.68 (20H, m), 9.15 (1 H, s)， 12.20 (1H, s). 13C-NMR (CDC13) (5c: 19.1, 19.3, 19.4. 20.8， 21.9, 27.0, 27.2, 36.5, 64.5, 68.9, 74.4, 74.9. 76.7, 86.1, 86.7, 122.0. 127. 6, 127.7, 127.9, 128.1, 128.3, 128.4, 128.8, 130.1, 130.4, 132.3, 132.7, 132.9, 135.7, 135.8, 137.3. 137.8, 145.2, 147.8, 148.5, 156.2, 170.2， 1 78.8.
(2) 3' — O—ベンジルー 5' —O— t—プチルジフエニルシリル一 4' - p ― トルエンスルホニルォキシメチル一 N2 —ィソブチリルグアノシン (45) の合成
化合物 44 (137.0 mg, 0.151 mmol) のメチルアルコール溶液 （3.0 ml) に室 温で炭酸カリウム （15.8 mg, 0.113 ramol) を加えた後、 室温で 45 分撹拌した。 反応溶液に濃塩酸を加えて溶液を中和した後、 塩化メチレンで 3 回抽出した。 有機層を飽和食塩水で洗浄後、 硫酸ナトリウムにて乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマトグラフィー （CHC13- MeOH, 30:1) により精製し、 白色粉末 45 (83.4 mg, 0.097 mmol, 64 %) を得た。
mp. 102 一 103 。C (AcOEt—へキサン）. [a] D 25 - 2.00 ° (c = 0.40, CHC13). IR レ max (KBr) ： 3166, 2932, 1684, 1607 cm— 1. !H-NMR (CDC13) δ： 0.90 (9H, s), 1.09 (3H, d, J = 7 Hz), 1.13 (3H, d, J = 7 Hz). 2.30 (1H, m), 2. 37 (3H, s), 3.71, 3.76 (2H, AB, J = 11 Hz), 4.32, 4.48 (2H, AB, J = 11 H z), 4.35 (1H, d， J = 6 Hz), 4.63, 4.90 (2H, AB, J = 12 Hz), 4.96 (1H, t， J = 6 Hz), 5.67 (1H, d, J = 7 Hz), 7.17 ― 7.71 (20H, m), 8.82 (1H, s)， 12.05 (1H, br s).13C-N R (CDC13) <5c: 18.7, 19.0, 21.6, 26.5, 36.2. 63.5, 69.1, 73.7, 74.3, 78.8. 86.2, 89.5, 127.7, 127.8, 128.0, 128.1, 128.5, 129.7, 130.0, 132.0, 132.6, 132.7, 135.3. 135.4, 137.4, 138.2, 144.8, 14 6.9, 155.5, 178.5.
(3) 3' —0—ベンジルー 5' — 0— t—ブチルジフエニルシリル一 2' — 0, 4' — C—メチレン一 N2 —イソプチリルグアノシン （46) の合成 窒素気流下、 45 (92.1 mg, 0.102 mmol) のテトラヒドロフラン溶液 （3.0 m 1) に室温でナトリウムビス （トリメチルシリル） ァミ ド （1.0 M in THF, 0.31 ml, 0.315 mmol) を加えた後、 室温で 3 時間撹拌した。 反応溶液に飽和重曹水 を加えた後、 塩化メチレンで 3 回抽出した。 有機層を飽和食塩水で洗浄後、 硫 酸ナトリウムにて乾燥した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲル カラムクロマトグラフィー （CHC13- MeOH, 25:1) により精製し、 白色粉末 （46) (31.4 mg, 0.160 mmol, 44 %) を得た。
mp. 99 - 100 °C. IR max (KBr) ： 3162, 3068, 2932, 1683, 1610 cm"1. Ή- 隱 (CDC13) δ： 1.06 (9Η, s), 1.25 (3H, d, J = 7 Hz), 1.27 (3H, d, J = 7 Hz), 2.64 (1H, m), 3.83, 4.01 (2H, AB, J = 8 Hz). 3.97 (2H， d, J = 7 H z), 4.18 (1H， s)， 4.51 (1H, s), 4.54 (2H, d, J = 2 Hz), 5.77 (1H, s), 7. 17-7.42 (5H, πθ, 7.64 - 7.72 (雇, m), 7.84 (1H, s). 9.03 (1H, s), 12.08 (1H, br s). 13C-NMR (CDC13) <5c: 18.9, 19.0. 19.1, 26.5, 26.7. 36.4, 59. 1. 72.4, 72.5, 76.8, 77.5, 86.3, 88.3, 121.7, 127.6. 127.7， 127.8, 127.9, 128.1. 128.4, 129.6, 130.0, 132.36, 132.42, 134.8, 135.45, 135.54, 135.
8, 136.8. 146.8, 147.7, 155.4, 178.6.
(4) 3' —0—ベンジル 1—2' -0, 4' — C—メチレン一 N2 —イソプチ
リルグアノシン （47) の合成
化合物 46 (41.3 nig, 0.060 mmol) のテトラヒ ドロフラン溶液 （3.0 ml) に 室温でテトラプチルアンモニゥムフルオリ ド （1.0 M in THF, 0.90 ml, 0.90 mm ol) を加えた後、 室温で 1 時間撹拌した。 反応溶液を減圧留去して得られた粗 成績体をシリカゲルカラムクロマトグラフィー （AcOH- EtOH, 20:1) により精製 し、 白色粉末 （47) (27.1 mg, 0.060 mmol, quant. ) を得た。
mp. 228 - 229 °C (Et20). [a] D25 + 32.90 。 （c = 0.875. CHC13). IR max (KBr) ： 3162, 2934, 1683, 1608 cm"1. Ή-NMR (CDC") δ： 1.24 (3H. d, J = 7 Hz), 1.26 (3H, d, J = 7 Hz), 2.76 (1H， m), 3.83, 4.03 (2H, AB, J = 8 Hz), 3.92. 4.02 (2H, AB, J = 13 Hz), 4.33 (1H, s), 4.55 (1H, s), 4.62 (2H, s), 5.80 (1H, s). 7.25 (5H. s), 7.91 (1H, s), 9.85 (1H, s), 12.05 (1H, s). 13C-薩 (CDC13) (5c: 19.19, 19.25, 36.4, 57.4, 72.5, 77.0, 77.5. 86.5, 88.8, 121.0, 127.8, 128.1, 128.2. 128.3, 128.4, 128.6, 137.1, 137. 5, 147.5, 148.2, 155.7, 179.9.
[実施例 6] オリゴヌクレオチド類縁体の合成
天; »ヌクレオシド
アミダイト
«■«オリゴヌクレオチド ¾ΒΛ*
Figure imgf000034_0001
21
Figure imgf000035_0001
(1) 3'—0— [2—シァノエ卜キシ （ジイソプロピルァミノ） ホスフイノ]— 5'— 0— (4, 4'—ジメ トキシトリチル）一 2'— 0, 4'—メタノ
ゥリジン （21) の合成
化合物 8 (200 mg, 0.31 mmol)、 ジイソプロピルアンモニゥム テトラゾリ ド （39.6 mg, 0.23 mmol)を無水 CH3CN で 3回共沸した後、 無水 CH3CN - 無水 THF溶液 （3:1, 4 ml)とし、 窒素気流下 2—シァノエチル N, N, N' , N'—テトラ イソプロピル ホスホロジアミダイ ト （0.12 ml, 0.37 ramol)を加え、 室温で 90 分間撹拌した。 溶媒を減圧留去し、 得られた粗成績体をシリカゲルカラムクロマ トグラフィー （AcOEt：へキサン： Et3N = 75:25:1) により精製後、 AcOEt-へキ サンにて再沈澱し、 アミダイ 卜体 21 (181 mg. 0.25 mmol, 81¾) を得た。
mp71- 74。C (AcOEt-へキサン）. 31P-隱 (CDC13): δ 149.6, 149.5, 149.4, 149.3. 149.2.
(2) オリゴヌクレオチド類縁体の一般合成 ォリゴマーの合成は Pharmacia社 製 DN A合成装置 Gene Assembler Plusにより 0.2 ； amolスケールで行った。 溶 媒、 試薬、 ホスホロアミダイ トの濃度は天然 DNA合成の場合と同じである。 3' -水酸基が CPG支持体に結合した 5'-0— DMTr-チミジン （0.2 zmol) の DMT r 基をトリクロロ酢酸によって脱保護し、 その 5'-水酸基に天然 DNA合成用の 4 種の核酸塩基からなるアミダイ トおよび化合物 21を用いて縮合反応を繰り返し 行い、 それぞれの配列のオリゴヌクレオチド類縁体を合成した。 合成サイクルは 下記の通りである。
合成サイクル （0.2 ^mol scale)
1) detritylation 1% CC13C00H in CH2C1CH2C1( 6 sec
2) coupling 0.1 phosphoramidite (25 equiv. ), 0.5 M lH-tetrazole (500 equiv. ) in MeCN, 2 min
3) capping 3% 4-(dimethylaraino)pyridine, 10¾ Ac20,
in MeCN, 18 sec
4) oxidation 0.01 M I2 in 2, 4, 6-collidine/H20/MeCN(l:5:ll),
6 sec
合成後は、 常法に従って、 濃アンモニア水処理によりオリゴマーを支持体から 切り出すとともに、 リン原子上の保護基シァノエチル基をはずし、 さらにはアデ ニン、 グァニン、 シトシンの保護基をはずした。
得られた 5' — 0— DMT r化されたオリゴヌクレオチド類縁体は、 逆相カラ ムクロマト （Millipore, Oligo-Pak™ SP) 上でトリフルォロ酢酸 5 m 1により DMT r基をはずし、 引き続き精製を行い、 目的のオリゴヌクレオチド類縁体を 得た。
本一般合成法に従って、 以下のォリゴヌクレオチド類縁体を合成した。
(2) 5' - GCGXTTTTTGCT - 3' (XT5)
収量 0.06 mol (30¾ yield)
(3) 5 GCGTTXTTTGCT - 3' (T 2 XT3)
収量 0.05 〃mol (25¾ yield)
(4) 5 GCGTTTXTTGCT- 3' (T3 XT2)
収量 0.03 1 (15% yield)
(5) 5' 一 GCGTTTTTXGCT - 3' (T 5 X)
収量 0.06 fiml (30% yield)
(6) 5' GCGXXTTTTGCT - 3' (X2T4)
収量 0.06 βαοΐ (30¾ yield)
(7) 5' GCGTTXXTTGCT- 3' (T 2 X 2T 2)
収量 0.05 raol (25% yield)
(8) 5' GCGTTTTXXGCT - 3' (T4 X 2)
収量 0.06 〃mol (30¾ yield)
(9) 5' GCGXXXXXXGCT- 3' (X 6) 収量 0.06 raol (30¾ yield)
(10) 5' - GTTTTTTTTTXXC - 3' (X 2) 収量 0.07 ϊϋοΐ (35¾ yield)
[実験例 1] 融解温度 （Tm) の測定
実施例 2で合成した種々のオリゴヌクレオチド類縁体をアンチセンス鎖とし、 天然の DN Aあるいは RN Aからなるセンス鎖とをァニーリング処理したものの 融解温度 （Tm値） を測定することにより、 本発明のオリゴヌクレオチド類縁体 の相補 DN Aおよび RN Aに対するハイプリッ ド形成能を調べた。
終濃度をそれぞれ、 N a C 1 10 Om . リン酸ナトリウム緩衝液 （ p H 7. 2) 1 OmM、 アンチセンス鎖 4〃M、 センス鎖 4 /Mとしたサンプル溶液 （5 Ο Ο βΙ) を沸騰水中に浴し、 10時間をかけてゆっく り室温まで冷却した。 分 光光度計 （島津 UV-2100PC) のセル室内に結露防止のために窒素気流を通し、 サ ンプル溶液を 5°Cまで徐々に冷却し、 さらに 20分間 5°Cに保った後、 測定を開 始した。 サンプル温度は 90°Cまで毎分 0.2°Cずつ上昇させ、 0. 1°C間隔で 2 60 nmにおける紫外線吸収を測定した。 なお、 温度上昇とともにサンプル濃度 が変化するのを防ぐため、 セルは蓋付きのものを用い、 サンプル溶液表面に鉱油 を 1滴添加して測定した。
結果は、 下記の表に示した。 アンチセンスオリゴヌクレオチド類縁体の相補 DNA及び RNAに対する 融解温度 （Tm値） アンチセンス分子 相補 DNAa>との Tm 相補 RNAb>との Tm
(△Tm/raod. ) (△Tm/mod. )
5' -GCGTTTTTTGCT-3' (天然） 47°C 45°C
5' -GCGXTTTTTGCT-3* (XT5) 50°C (+3°C) 49°C (+4°C)
5' -GCGTTXTTTGCT-3' (T2XT3) 49°C (+2°C) 49°C (+4°C)
5' - GCGTTTXTTGCT- 3' (T3XT2) 49°C (+2°C) 50°C (+5°C)
5' -GCGTTTTTXGCT-3* (T5X) 52°C (+4°C) 51°C (+6°C)
5' -GCGXXTTTTGCT-3* (X2T4) 51。C (+2°C) 53°C (+4°C)
5' -GCGTTXXTTGCT-3' (T2X2T2) 49°C (+1°C) 53°C (+4。C) 5' -GCGTTTTXXGCT-3' (T4X2) 54°C (+3.5°C) 55°C (+5°C)
5' -GCGXXXXXXGCT-3* (X6) 58°C (+1.8°C) 71°C (+4.3°C) a): 3' -CGCAAAAAACGA-5' . b): 3' -r(CGCAAAAAACGA).
表から明らかなように、 天然 DNA鎖中に本発明のヌクレオシド類縁体 （一般式 ( l a) ) のュニッ 卜 （X) が 1個あるいは 2個導入したオリゴマーでは、 相補 DNAオリゴマーとのハイプリ ド形成能が、 Tm値で評価して天然鎖よりも 2— 7度 (1修飾残基当たり 2度程度） 上昇し、 Tをすベて Xで置換した （X6) におい ては 1 1度も上昇した。 一方、 相補 RMに対するハイプリッ ド形成能を評価した ところ、 1個あるいは 2個導入したオリゴマ一では天然鎖よりも 4一 10度 （1 修飾残基当たり 4度から 6度） の Tm値の上昇が認められ、 しかも （X6) にお いては相補 RNAに対するハイブリツ ド形成能が更に強まり、 Tm値が 25度以上 (1修飾残基当たり 4度） も上昇が認められた。 このように、 天然鎖よりも Tm 値がかくも上昇する類縁体の例がなく、 また DNAよりも RNAに対する親和性が高 いことは、 本発明のビシクロオリゴヌクレオシド類縁体を構成単位としたオリゴ ヌクレオチド類縁体がァンチセンス分子として極めて高い性能と医薬品素材とし ての有用性を有していることを意味していると言える。
[実験例 2] ヌクレアーゼ酵素耐性の測定
15分間 3了。 Cに保ったオリゴヌクレオチドのバッファ一溶液（10〃M, 400 H) に蛇毒ホスホジエステラーゼのバッファー溶液 （0.003U/ml, 400 1)を混合した。 混合溶液を 37°Cに保った石英セル（800 il)に入れ、 オリゴヌクレオチドの分解 による紫外部吸収（260nm)の増加を SHIMADZU UV- 2100PCを用いて経時的に測定し た。 用いたバッファーの組成は Tris- HCl(pH8.6)0. lM、NaCl 0. lM、MgCl214mMであ り測定前に十分に脱気した。
半減期（t1/2)の測定
測定開始時（t=0)及び紫外部吸収が認められなくなった点の UV吸収の平均値 を示す時間を半減期 （t1/2)とした。
ォリゴヌクレオチド配列 t1/2 (秒） 5' -GTTTTTTTTTTTC-3' (天然型） 260
5' - GTTTTTTTTT- XX- C- 3' ( X 2 ) 850
また、 紫外部吸収の経時変化を示すチャートを図 1 (天然鎖） 及び図 2 ( X 2 ) に示した。 天然鎖は酸素反応開始後、 約 3 0分で紫外部吸収値が一定となり、 X 2では約 9 0分で一定となつた。
[産業上の利用可能性]
この類縁体の使用により、 生体内で酵素の加水分解を受けにく く、 センス鎖との 結合能が高く、 しかも合成が容易であるオリゴヌクレオチド類縁体アンチセンス 分子が提供される。
[配列表]
出願人の氏名 ：今西武
発明の名称：新規ビシクロヌクレオシド及びォリゴヌクレオチド類縁体 整理番号：
出願番号：
出願日 ：平成 10年 3月 曰
優先権番号：特願平 9一 53409号
優先日 ：平成 9年 3月 7曰
配列の数： 10 配列番号： 1
配列の長さ ： 12
配列の型： ヌクレオチド
鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' 一 GCGTTTTTTGCT - 3' 配列番号： 2
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体
鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' 一 GCGXTTTTTGCT - 3' 配列番号： 3
配列の長さ ： 12 配列の型： ヌクレオチド、 ヌクレオチド類縁体 鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' -GCGTTXTTTGCT-3' 配列番号： 4
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体 鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' -GCGTTTXTTGCT-3' 配列番号： 5
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体 鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' 一 GCGTTTTTXGCT - 3' 配列番号： 6
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体 鎖の数： 1本鎖
トポロジー：直鎖状
配列： W098/39352 PC雷 98/00945
5' 一 GCGXXTTTTGCT - 3' 配列番号： 7
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体
鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' - GCGTTXXTTGCT - 3' 配列番号： 8
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体
鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' 一 GCGTTTTXXGCT - 3' 配列番号： 9
配列の長さ ： 12
配列の型： ヌクレオチド、 ヌクレオチド類縁体
鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' -GCGXXXXXXGCT-3' 配列番号： 10
配列の長さ ： 13 配列の型： ヌクレオチド、 ヌクレオチド類縁体 鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' -GTTTTTTTTTTTC-3' 配列番号： 11
配列の長さ ： 13
配列の型： ヌクレオチド、 ヌクレオチド類縁体 鎖の数： 1本鎖
トポロジー：直鎖状
配列：
5' -GTTTTTTTTXXTC-3'

Claims

請求の範囲 一般式 （ I )
Figure imgf000045_0001
[式中、 Bはピリ ミジンもしくはプリン核酸塩基又はそれらの類縁体であり、 X及び Yは同一もしくは異なり、 水素、 アルキル基、 アルケニル基、 アルキニル 基、 シクロアルキル基、 ァラルキル基、 ァリール基、 ァシル基、 又はシリル基] で表わされるヌクレオシド類縁体もしくはそのァミダイ ト誘導体。
2. X、 Yがともに水素である請求項 1記載のヌクレオシド類縁体。
3. が 4, 4' -ジメ トキシトリチル （DMT r ) で、 Yが 2—シァノエトキシ (ジイソプロピルアミノ） ホスフイノ基 （アミダイ ト基） である請求項 1記載の モノヌクレオシドアミダイ ト誘導体。
4. 一般式 （ I a )
Figure imgf000045_0002
( Ι ) [式中、 Bはピリ ミジンもしくはプリン核酸塩基又はそれらの類縁体である] で 表される構造を 1または 2以上有するオリゴヌクレオチドまたはポリヌクレオチ ド類縁体。
5. —般式 （II)
Figure imgf000046_0001
( II )
[式中、 B '、 Bは同一または異なり、 ピリ ミジンもしくはプリン核酸塩基又は それらの類縁体であり、 Rは水素、 水酸基、 ハロゲン、 またはアルコキシ基であ り、 、 W2は同一または異なり、 水素、 アルキル基、 アルケニル基、 アルキニ ル基、 シクロアルキル基、 ァラルキル基、 ァリール基、 ァシル基、 シリル基また はリン酸残基もしくはリン酸ジエステル結合を介した天然型ヌクレオシド、 及び その類縁体またはこれらヌクレオシドを含むオリゴヌクレオチドもしくはポリヌ クレオチドであり、 n 1または n 2は同一または異なり、 0から 5 0の整数である (ただし、 n lまたは n 2が同時にゼロになることはない。 また n 2のすべてがゼ 口になることはない。 ） 、 n 3は 1〜5 0の整数である、 ただし、 n 1および Zま たは n 2が 2以上の場合には B 1と Bは同一でなくてもよく、 Rも同一でなくても よい] で表されるオリゴヌクレオチドもしくはポリヌクレオチド類縁体。
PCT/JP1998/000945 1997-03-07 1998-03-09 Novel bicyclonucleoside and oligonucleotide analogues Ceased WO1998039352A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK98905804.5T DK1013661T4 (en) 1997-03-07 1998-03-09 2'-O, 4'-C-methylene bicyclonucleosides
AT98905804T ATE541576T2 (de) 1997-03-07 1998-03-09 2'-o,4'-c-methylen bicyclonukleoside
AU61209/98A AU720472B2 (en) 1997-03-07 1998-03-09 Novel bicyclonucleoside and oligonucleotide analogue
ES98905804T ES2380354T5 (es) 1997-03-07 1998-03-09 2'-O,4'-C-metilen biciclonucleósidos
CA002283509A CA2283509C (en) 1997-03-07 1998-03-09 Novel bicyclonucleoside and oligonucleotide analogue
US09/380,638 US6268490B1 (en) 1997-03-07 1998-03-09 Bicyclonucleoside and oligonucleotide analogues
US13/533,781 USRE44779E1 (en) 1997-03-07 1998-03-09 Bicyclonucleoside and oligonucleotide analogues
EP98905804.5A EP1013661B2 (en) 1997-03-07 1998-03-09 2'-O,4'-C-methylene bicyclonucleosides
DE98905804T DE98905804T1 (de) 1997-03-07 1998-03-09 Bicyclonukleosid- und oligonukleotid-analoga

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/53409 1997-03-07
JP5340997 1997-03-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/380,638 A-371-Of-International US6268490B1 (en) 1997-03-07 1998-03-09 Bicyclonucleoside and oligonucleotide analogues
US90456701A Continuation 1997-03-07 2001-07-16

Publications (1)

Publication Number Publication Date
WO1998039352A1 true WO1998039352A1 (en) 1998-09-11

Family

ID=12942037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/000945 Ceased WO1998039352A1 (en) 1997-03-07 1998-03-09 Novel bicyclonucleoside and oligonucleotide analogues

Country Status (11)

Country Link
US (1) US6268490B1 (ja)
EP (3) EP2295441B1 (ja)
JP (1) JP3756313B2 (ja)
AT (1) ATE541576T2 (ja)
AU (1) AU720472B2 (ja)
CA (1) CA2283509C (ja)
DE (1) DE98905804T1 (ja)
DK (3) DK1013661T4 (ja)
ES (3) ES2380354T5 (ja)
PT (2) PT2295441E (ja)
WO (1) WO1998039352A1 (ja)

Cited By (608)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047599A1 (en) * 1999-02-12 2000-08-17 Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
WO2000056748A1 (en) * 1999-03-18 2000-09-28 Exiqon A/S Xylo-lna analogues
WO2000066604A3 (en) * 1999-05-04 2001-01-11 Exiqon As L-ribo-lna analogues
WO2001007455A1 (en) * 1999-07-22 2001-02-01 Sankyo Company, Limited Novel bicyclonucleoside analogues
US6303315B1 (en) 1999-03-18 2001-10-16 Exiqon A/S One step sample preparation and detection of nucleic acids in complex biological samples
US6316198B1 (en) 1999-03-18 2001-11-13 Exiqon A/S Detection of mutations in genes by specific LNA primers
WO2002018388A1 (fr) * 2000-08-29 2002-03-07 Takeshi Imanishi Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues
WO2001048190A3 (en) * 1999-12-23 2002-05-10 Exiqon As Therapeutic uses of lna-modified oligonucleotides
WO2003033696A1 (en) * 2001-10-18 2003-04-24 Sankyo Company, Limited Vegf antisense compound
RU2211223C2 (ru) * 1998-05-26 2003-08-27 Ай-Си-Эн Фармасьютикалз, Инк. Новые нуклеозиды, имеющие бициклическую сахарную группировку, и содержащие их олигонуклеотиды
US6639059B1 (en) 1999-03-24 2003-10-28 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6670461B1 (en) 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US6734291B2 (en) 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
WO2004078922A2 (en) 2003-02-28 2004-09-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6822088B2 (en) 2001-07-17 2004-11-23 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides on solid support
RU2243231C2 (ru) * 1997-09-12 2004-12-27 Эксикон А/С Бициклические аналоги нуклеозидов, нуклеотидов и олигонуклеотидов
WO2005019418A2 (en) 2003-08-18 2005-03-03 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 2 expression
WO2005049630A2 (en) 2003-11-17 2005-06-02 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7005265B1 (en) 2002-06-20 2006-02-28 Wenhong Fan Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
US7229767B2 (en) 2001-03-27 2007-06-12 University Of Delaware Genomics applications for modified OLIGO nucleotides
WO2007106690A2 (en) 2006-03-15 2007-09-20 Siemens Healthcare Diagnostics Inc. Degenerate nucleobase analogs
US7358068B2 (en) 2002-09-13 2008-04-15 Replicor, Inc. Antiviral oligonucleotides
EP1959012A2 (en) 2004-12-29 2008-08-20 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7504495B2 (en) 2003-11-20 2009-03-17 Exiqon A/S Quencher compositions comprising anthraquinone moieties
WO2009045469A2 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
WO2009044392A2 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
EP2050763A2 (en) 2005-03-10 2009-04-22 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
WO2009093384A1 (ja) * 2008-01-24 2009-07-30 National Institute Of Advanced Industrial Science And Technology ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
WO2010024231A1 (ja) * 2008-08-26 2010-03-04 株式会社日立ハイテクノロジーズ 高発現遺伝子由来のcDNAクローンの含有率を低減させたcDNAライブラリーの作製方法
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
WO2010027831A1 (en) 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
US7687617B2 (en) 2002-11-18 2010-03-30 Santaris Pharma A/S Oligonucleotides with alternating segments of locked and non-locked nucleotides
US7695902B2 (en) 1996-06-06 2010-04-13 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
EP2174945A1 (en) 2001-08-01 2010-04-14 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2010042281A2 (en) 2008-08-25 2010-04-15 Excaliard Pharmaceuticals Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2179996A1 (en) 2000-11-28 2010-04-28 Applera Corporation Sulfonated diarylrhodamine dyes
EP2196544A1 (en) 2001-11-21 2010-06-16 Applied Biosystems, LLC Kit for ligation detection assays using codeable labels
US7745122B2 (en) 2005-07-15 2010-06-29 Applied Biosystems, Llc Analyzing messenger RNA and micro RNA in the same reaction mixture
WO2010074562A1 (en) 2008-12-22 2010-07-01 Keygene N.V. Use of double stranded rna to increase the efficiency of targeted gene alteration in plant protoplasts
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
EP2208796A2 (en) 2005-01-06 2010-07-21 Applied Biosystems, LLC Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
EP2218727A1 (en) 2003-06-02 2010-08-18 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
EP2221376A2 (en) 2001-06-21 2010-08-25 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US7807372B2 (en) 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
EP2241572A2 (en) 2003-06-03 2010-10-20 Eli Lilly And Company Modulation of survivin expression
WO2010120420A1 (en) 2009-04-15 2010-10-21 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
US7829275B2 (en) 2001-07-20 2010-11-09 North Carolina State University Light addressable electrochemical detection of duplex structures
WO2010135384A2 (en) 2009-05-21 2010-11-25 Siemens Healthcare Diagnostics Inc. Universal tags with non-natural nucleobases
EP2256200A2 (en) 2003-09-18 2010-12-01 ISIS Pharmaceuticals, Inc. Modulation of eIF4E expression
EP2256213A1 (en) 2000-06-06 2010-12-01 Applied Biosystems, LLC Asynchronous primed PCR
EP2270230A2 (en) 2001-10-09 2011-01-05 ISIS Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A2 (en) 2001-10-09 2011-01-05 ISIS Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2272857A1 (en) 2003-04-28 2011-01-12 ISIS Pharmaceuticals, Inc. Modulation of glucagon receptor expression
EP2272958A1 (en) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
EP2272985A1 (en) 2001-08-07 2011-01-12 ISIS Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (A) expression
EP2280019A1 (en) 2001-07-25 2011-02-02 ISIS Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP2281869A2 (en) 2003-03-21 2011-02-09 ISIS Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 1 expression
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011047307A1 (en) 2009-10-15 2011-04-21 Ibis Biosciences, Inc. Multiple displacement amplification
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011052436A1 (ja) 2009-10-29 2011-05-05 国立大学法人大阪大学 架橋型人工ヌクレオシドおよびヌクレオチド
WO2011053994A1 (en) 2009-11-02 2011-05-05 Alnylam Pharmaceuticals, Inc. Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
WO2011056215A1 (en) 2009-11-03 2011-05-12 Landers James P Versatile, visible method for detecting polymeric analytes
WO2011056687A2 (en) 2009-10-27 2011-05-12 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2011063403A1 (en) 2009-11-23 2011-05-26 Swift Biosciences, Inc. Devices to extend single stranded target molecules
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2332955A2 (en) 2001-07-30 2011-06-15 ISIS Pharmaceuticals, Inc. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
EP2333115A1 (en) 2005-12-22 2011-06-15 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
EP2336318A1 (en) 2002-11-13 2011-06-22 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2336319A1 (en) 2002-11-13 2011-06-22 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2338991A2 (en) 2005-08-29 2011-06-29 Regulus Therapeutics, Inc Methods for use in modulating MIR-122a
WO2011085056A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
EP2360277A1 (en) 2006-05-03 2011-08-24 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
EP2363503A1 (en) 2002-11-23 2011-09-07 ISIS Pharmaceuticals, Inc. Modulation of HIF1A and HIF2A expression
EP2363481A1 (en) 2006-05-05 2011-09-07 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
EP2363480A2 (en) 2004-01-20 2011-09-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
US8017338B2 (en) 2007-11-20 2011-09-13 Life Technologies Corporation Reversible di-nucleotide terminator sequencing
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
WO2011133695A2 (en) 2010-04-20 2011-10-27 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
WO2011134474A1 (en) 2010-04-30 2011-11-03 Exiqon A/S In situ hybridization method and buffer
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP2388318A1 (en) 2001-12-10 2011-11-23 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156278A1 (en) 2010-06-07 2011-12-15 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8084437B2 (en) 2006-11-27 2011-12-27 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2405024A1 (en) 2005-07-15 2012-01-11 Life Technologies Corporation Hot start reverse transcription by primer design
WO2012005572A1 (en) 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2410054A1 (en) 2006-10-18 2012-01-25 Isis Pharmaceuticals, Inc. Antisense compounds
EP2412724A1 (en) 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2441449A1 (en) 2003-04-16 2012-04-18 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein C-III expression
EP2444482A1 (en) 2003-11-03 2012-04-25 Isis Pharmaceuticals, Inc. Modulation of SGLT2 expression
EP2447274A2 (en) 2008-10-24 2012-05-02 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2012061778A2 (en) 2010-11-05 2012-05-10 Genalyte, Inc. Optical analyte detection systems and methods of use
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP2458011A1 (en) 2005-10-03 2012-05-30 Life Technologies Corporation Compositions, methods, and kits for amplifying nucleic acids
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
WO2012074386A1 (en) 2010-12-02 2012-06-07 Keygene N.V. Targeted alteration of dna with oligonucleotides
WO2012074385A1 (en) 2010-12-02 2012-06-07 Keygene N.V. Targeted alteration of dna
EP2468865A1 (en) 2004-02-06 2012-06-27 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of stat3 expression
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
WO2012096523A2 (en) 2011-01-11 2012-07-19 Seegene, Inc. Detection of target nucleic acid sequences by pto cleavage and extension assay
EP2484781A2 (en) 2006-08-01 2012-08-08 Applied Biosystems, LLC Detection of analytes and nucleic acids
WO2012106508A1 (en) 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
WO2012106509A1 (en) 2011-02-02 2012-08-09 The Trustees Of Princeton University Sirtuin modulators as virus production modulators
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012118911A1 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2012118910A2 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
EP2505648A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PTP1B
WO2012134195A2 (en) 2011-03-29 2012-10-04 Seegene, Inc. Detection of target nucleic acid sequence by pto cleavage and extension-dependent cleavage
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US8293684B2 (en) 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
WO2012149339A2 (en) 2011-04-29 2012-11-01 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2012149495A1 (en) 2011-04-27 2012-11-01 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein ciii (apociii) expression
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2012150835A2 (en) 2011-05-04 2012-11-08 Seegene, Inc. Detection of target nucleic acid sequences by po cleavage and hybridization
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
EP2530157A2 (en) 2003-07-31 2012-12-05 Regulus Therapeutics, Inc Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2012170957A2 (en) 2011-06-08 2012-12-13 Nitto Denko Corporation Retinoid-liposomes for enhancing modulation of hsp47 expression
WO2012174476A2 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013003808A1 (en) 2011-06-29 2013-01-03 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2013040499A1 (en) 2011-09-14 2013-03-21 Northwestern University Nanoconjugates able to cross the blood-brain barrier
WO2013043817A1 (en) 2011-09-20 2013-03-28 Isis Phamaceuticals, Inc. Antisense modulation of gcgr expression
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
WO2013067076A2 (en) 2011-11-03 2013-05-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2013070786A1 (en) 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
WO2013090457A2 (en) 2011-12-12 2013-06-20 Oncoimmunin Inc. In vivo delivery of oligonucleotides
WO2013096837A1 (en) 2011-12-22 2013-06-27 Isis Pharmaceuticals, Inc. Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
WO2013095132A1 (en) 2011-12-22 2013-06-27 Interna Technologies B.V. Mirna for treating head and neck cancer
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
WO2013133561A1 (en) 2012-03-05 2013-09-12 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay
WO2013138536A1 (en) 2012-03-13 2013-09-19 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
WO2013138251A1 (en) 2012-03-12 2013-09-19 The Board Of Trustes Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2013177468A2 (en) 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
WO2013177248A2 (en) 2012-05-22 2013-11-28 Isis Pharmaceuticals, Inc. Modulation of enhancer rna mediated gene expression
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2014004572A2 (en) 2012-06-25 2014-01-03 Isis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
WO2014018930A1 (en) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
WO2014028739A1 (en) 2012-08-15 2014-02-20 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
EP2700720A2 (en) 2004-03-15 2014-02-26 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNASE H
WO2014039916A1 (en) 2012-09-06 2014-03-13 The University Of Chicago Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
US8680254B2 (en) 2009-01-14 2014-03-25 Philadelphia Health & Education Corporation Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
WO2014046212A1 (ja) 2012-09-21 2014-03-27 国立大学法人大阪大学 グアニジン架橋を有する人工ヌクレオシドおよびオリゴヌクレオチド
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014059238A2 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals Inc Modulation of androgen receptor expression
WO2014062686A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for modulating c9orf72 expression
US8710209B2 (en) 2009-12-09 2014-04-29 Nitto Denko Corporation Modulation of HSP47 expression
WO2014070868A1 (en) 2012-10-31 2014-05-08 Isis Pharmaceuticals Inc Cancer treatment
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
WO2014076195A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Oligonucleotide conjugates
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
WO2014118267A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
WO2014126229A1 (ja) 2013-02-18 2014-08-21 塩野義製薬株式会社 含窒素複素環構造を有するヌクレオシド及びヌクレオチド
EP2770065A1 (en) 2013-02-25 2014-08-27 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence
WO2014134144A1 (en) 2013-02-28 2014-09-04 The General Hospital Corporation Mirna profiling compositions and methods of use
WO2014134179A1 (en) 2013-02-28 2014-09-04 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014142575A1 (en) 2013-03-13 2014-09-18 Seegene, Inc. Quantification of target nucleic acid using melting peak analysis
WO2014152673A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
WO2014152659A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US8889350B2 (en) 2010-03-26 2014-11-18 Swift Biosciences, Inc. Methods and compositions for isolating polynucleotides
WO2014197938A1 (en) 2013-06-13 2014-12-18 Antisense Therapeutics Ltd Combination therapy
WO2014205449A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
WO2015002971A2 (en) 2013-07-02 2015-01-08 Isis Pharmaceuticals, Inc. Modulators of growth hormone receptor
EP2826863A1 (en) 2007-05-30 2015-01-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2015008985A1 (en) 2013-07-15 2015-01-22 Seegene, Inc. Detection of target nucleic acid sequence by pto cleavage and extension-dependent immobilized oligonucleotide hybridization
WO2015010135A2 (en) 2013-07-19 2015-01-22 Isis Pharmaceuticals, Inc. Compositions for modulating tau expression
WO2015021457A2 (en) 2013-08-09 2015-02-12 Isis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
WO2015031679A2 (en) 2013-08-28 2015-03-05 Isis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
US8999634B2 (en) 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
US8999947B2 (en) 2005-06-14 2015-04-07 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2015057998A1 (en) 2013-10-16 2015-04-23 The University Of British Columbia Device for formulating particles at small volumes
WO2015057008A2 (en) 2013-10-18 2015-04-23 Seegene, Inc. Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2015100394A1 (en) 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US9096895B2 (en) 2009-02-02 2015-08-04 Exiqon A/S Method for quantification of small RNA species
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015126502A2 (en) 2013-12-03 2015-08-27 Northwestern University Liposomal particles, methods of making same and uses thereof
WO2015125783A1 (ja) * 2014-02-18 2015-08-27 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
EP2913402A1 (en) 2010-07-16 2015-09-02 Tocagen Inc. Retrovirus detection
US9139827B2 (en) 2008-11-24 2015-09-22 Northwestern University Polyvalent RNA-nanoparticle compositions
WO2015143246A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
WO2015153800A2 (en) 2014-04-01 2015-10-08 Isis Pharmaceuticals, Inc. Compositions for modulating sod-1 expression
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
US9205102B2 (en) 2013-12-06 2015-12-08 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
WO2015190922A1 (en) 2014-06-10 2015-12-17 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease
WO2016006697A1 (ja) * 2014-07-10 2016-01-14 賢二 中野 アンチセンス抗悪性腫瘍剤
DE202013012241U1 (de) 2012-05-25 2016-01-18 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
WO2016017422A1 (ja) * 2014-07-31 2016-02-04 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
EP2982753A1 (en) 2008-04-18 2016-02-10 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2016027263A2 (en) 2014-08-21 2016-02-25 Omrix Biopharmaceuticals Ltd. Stabilized thrombin
WO2016027168A2 (en) 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016034611A1 (en) 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
US9290816B2 (en) 2010-06-07 2016-03-22 Firefly Bioworks Inc. Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
WO2016054032A1 (en) 2014-09-29 2016-04-07 The Jackson Laboratory High efficiency, high throughput generation of genetically modified mammals by electroporation
US9310361B2 (en) 2006-10-05 2016-04-12 Massachusetts Institute Of Technology Multifunctional encoded particles for high-throughput analysis
US9315811B2 (en) 2011-06-10 2016-04-19 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
WO2016075584A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Combination long acting compositions and methods for hepatitis c
WO2016075583A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intelle Ctual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3031920A1 (en) 2010-07-19 2016-06-15 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (dmpk) expression
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
US9376690B2 (en) 2009-10-30 2016-06-28 Northwestern University Templated nanoconjugates
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
US9416360B2 (en) 2010-11-05 2016-08-16 MiRagen Therapeutics, Inc. Base modified oligonucleotides
WO2016138353A1 (en) 2015-02-26 2016-09-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of p23h rhodopsin
WO2016141236A1 (en) 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
WO2016161429A1 (en) 2015-04-03 2016-10-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating tmprss6 expression
US9464106B2 (en) 2002-10-21 2016-10-11 Exiqon A/S Oligonucleotides useful for detecting and analyzing nucleic acids of interest
WO2016164602A1 (en) 2015-04-08 2016-10-13 The University Of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
WO2016168592A2 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
US9523094B2 (en) 2012-10-11 2016-12-20 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
WO2017015109A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
WO2017018360A1 (ja) * 2015-07-24 2017-02-02 日産化学工業株式会社 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
WO2017023861A1 (en) 2015-08-03 2017-02-09 The Regents Of The University Of California Compositions and methods for modulating abhd2 activity
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US9580743B2 (en) 2005-09-09 2017-02-28 Life Technologies Corporation SSB-polymerase fusion proteins
WO2017032726A1 (en) 2015-08-24 2017-03-02 Roche Innovation Center Copenhagen A/S Lna-g process
US9593374B2 (en) 2005-08-17 2017-03-14 Lianidou Evriklia Composition and method for determination of CK19 expression
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2017047816A1 (ja) * 2015-09-18 2017-03-23 田辺三菱製薬株式会社 架橋型核酸ＧｕＮＡ、その製造方法および中間体化合物
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
WO2017064546A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
WO2017075421A1 (en) 2015-10-29 2017-05-04 Temple University-Of The Commonwealth System Of Higher Education Modification of 3' terminal ends of nucleic acids by dna polymerase theta
US9644207B2 (en) 2013-03-14 2017-05-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
WO2017079442A1 (en) 2015-11-04 2017-05-11 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
US9650421B2 (en) 2011-09-02 2017-05-16 Northwestern University Self-assembled nanostructures
WO2017098468A1 (en) 2015-12-09 2017-06-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2017109679A1 (en) 2015-12-21 2017-06-29 Novartis Ag Compositions and methods for decreasing tau expression
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9701708B2 (en) 2013-01-31 2017-07-11 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
WO2017124086A1 (en) 2016-01-15 2017-07-20 The Jackson Laboratory Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
EP3208347A1 (en) 2010-02-08 2017-08-23 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
WO2017147483A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed single molecule rna visualization with a two-probe proximity ligation system
WO2017157899A1 (en) 2016-03-14 2017-09-21 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
US9846126B2 (en) 2008-10-27 2017-12-19 Genalyte, Inc. Biosensors based on optical probing and sensing
WO2017216390A1 (en) 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
WO2017218573A1 (en) 2016-06-16 2017-12-21 The Regents Of The University Of California Methods and compositions for detecting a target rna
WO2018002105A1 (en) 2016-07-01 2018-01-04 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
EP3276004A2 (en) 2009-06-08 2018-01-31 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
WO2018026282A1 (en) 2016-08-05 2018-02-08 Erasmus University Medical Center Rotterdam (Erasmus Mc) Antisense oligomeric compound for pompe disease
WO2018026284A1 (en) 2016-08-05 2018-02-08 Erasmus University Medical Center Rotterdam (Erasmus Mc) Natural cryptic exon removal by pairs of antisense oligonucleotides
US9890427B2 (en) 2007-02-09 2018-02-13 Northwestern University Particles for detecting intracellular targets
WO2018044239A1 (en) 2016-09-01 2018-03-08 Agency For Science, Technology And Research Method of treating cancer by antisense oligonucleotides targeting prdm15
US9914922B2 (en) 2012-04-20 2018-03-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
US9932581B2 (en) 2013-05-01 2018-04-03 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein C-III expression
EP3312189A1 (en) 2011-04-21 2018-04-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
WO2018080393A1 (en) 2016-10-28 2018-05-03 Agency For Science, Technology And Research Antisense oligonucleotides
EP3321361A1 (en) 2010-02-08 2018-05-16 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
WO2018087200A1 (en) 2016-11-11 2018-05-17 Roche Innovation Center Copenhagen A/S Therapeutic oligonucleotides capture and detection
US9983206B2 (en) 2013-03-15 2018-05-29 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
US9994855B2 (en) 2014-05-01 2018-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2018130581A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rela expression
WO2018130584A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
WO2018130582A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rel expression
WO2018130583A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
WO2018130585A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
EP3354750A1 (en) 2012-07-18 2018-08-01 Siemens Healthcare Diagnostics Inc. Kit of normalizing biological samples
WO2018143475A1 (ja) 2017-02-06 2018-08-09 日産化学工業株式会社 一本鎖オリゴヌクレオチド
EP3375877A1 (en) 2013-11-18 2018-09-19 Crispr Therapeutics AG Crispr-cas system materials and methods
WO2018181428A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
US10098958B2 (en) 2009-01-08 2018-10-16 Northwestern University Delivery of oligonucleotide functionalized nanoparticles
EP3400947A1 (en) 2013-02-14 2018-11-14 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
WO2018220034A1 (en) 2017-06-01 2018-12-06 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
WO2019022196A1 (ja) 2017-07-26 2019-01-31 日産化学株式会社 一本鎖オリゴヌクレオチド
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
WO2019030313A2 (en) 2017-08-11 2019-02-14 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019038228A1 (en) 2017-08-22 2019-02-28 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2019045532A2 (en) 2017-08-31 2019-03-07 Seegene, Inc. EVALUATION OF COMPONENT PERFORMANCE USING A PAIR OF DIMER FORMER PRIMERS
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
WO2019066461A2 (en) 2017-09-29 2019-04-04 Seegene, Inc. DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY CLEAVAGE ANALYSIS AND EXTENSION OF PTO
EP3466960A2 (en) 2011-04-01 2019-04-10 Ionis Pharmaceuticals, Inc. Modulation of signal transducer and activator of transcription 3 (stat3) expression
WO2019073018A1 (en) 2017-10-13 2019-04-18 Roche Innovation Center Copenhagen A/S METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
WO2019076842A1 (en) 2017-10-16 2019-04-25 F. Hoffmann-La Roche Ag NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 MRNA FOR THE TREATMENT OF HEPATITIS B INFECTION
US10273474B2 (en) 2012-03-30 2019-04-30 Washington University Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2019086603A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
US10294477B2 (en) 2014-05-01 2019-05-21 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating PKK expression
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
WO2019115416A2 (en) 2017-12-11 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating fndc3b expression
WO2019116346A1 (en) 2017-12-15 2019-06-20 Novartis Ag Polya tail length analysis of rna by mass spectrometry
WO2019118935A1 (en) 2017-12-14 2019-06-20 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and their use in genome editing and other applications
WO2019115417A2 (en) 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
WO2019122277A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
WO2019122282A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019121838A1 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Companion diagnostic for htra1 rna antagonists
WO2019122279A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
US10351853B2 (en) 2014-10-14 2019-07-16 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019137974A1 (en) 2018-01-12 2019-07-18 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating gsk3b expression
WO2019137883A1 (en) 2018-01-10 2019-07-18 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating pias4 expression
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019138057A1 (en) 2018-01-12 2019-07-18 Roche Innovation Center Copenhagen A/S Alpha-synuclein antisense oligonucleotides and uses thereof
WO2019141723A1 (en) 2018-01-18 2019-07-25 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
WO2019141656A1 (en) 2018-01-17 2019-07-25 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating erc1 expression
US10365224B2 (en) 2007-12-06 2019-07-30 Genalyte, Inc. Label-free optical sensors
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019154979A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Oligonucleotides for modulating tmem106b expression
WO2019155094A1 (en) 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
WO2019165067A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
US10407680B2 (en) 2016-09-29 2019-09-10 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing Tau expression
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
WO2019182037A1 (ja) 2018-03-20 2019-09-26 国立大学法人東京工業大学 毒性が低減されたアンチセンスオリゴヌクレオチド
WO2019183150A1 (en) 2018-03-19 2019-09-26 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and uses thereof
WO2019193165A1 (en) 2018-04-05 2019-10-10 F. Hoffmann-La Roche Ag Use of fubp1 inhibitors for treating hepatitis b virus infection
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2019215066A1 (en) 2018-05-07 2019-11-14 Roche Innovation Center Copenhagen A/S Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
WO2019217459A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2019215175A1 (en) 2018-05-08 2019-11-14 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating myh7 expression
WO2019219723A1 (en) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treatment of microrna related diseases
WO2019224172A1 (en) 2018-05-25 2019-11-28 Roche Innovation Center Copenhagen A/S Novel process for making allofuranose from glucofuranose
US10494633B2 (en) 2015-11-12 2019-12-03 Roche Innovation Center Copenhagen A/S Oligonucleotides for inducing paternal UBE3A expression
WO2019233922A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
WO2019243391A1 (en) 2018-06-21 2019-12-26 F. Hoffmann-La Roche Ag Hybridizing all-lna oligonucleotides
WO2019246262A2 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
WO2019246450A1 (en) 2018-06-20 2019-12-26 Yale University Rig-i agonists and treatments using same
WO2019246112A1 (en) 2018-06-18 2019-12-26 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
WO2020007702A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
WO2020007700A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting spi1
WO2020007826A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mbtps1
WO2020007772A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
WO2020007892A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
WO2020007889A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting stat1
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
WO2020011745A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
WO2020011743A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mafb
WO2020011744A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020011653A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011902A1 (en) 2018-07-13 2020-01-16 F. Hoffmann-La Roche Ag Oligonucleotides for modulating rtel1 expression
EP3603677A1 (en) 2013-09-13 2020-02-05 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
WO2020025563A1 (en) 2018-07-31 2020-02-06 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
WO2020025527A1 (en) 2018-07-31 2020-02-06 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
US10557137B2 (en) 2015-11-06 2020-02-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
EP3608406A1 (en) 2014-05-01 2020-02-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
WO2020038971A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting vcan
WO2020038973A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting sptlc1
WO2020041456A1 (en) 2018-08-22 2020-02-27 The Regents Of The University Of California Variant type v crispr/cas effector polypeptides and methods of use thereof
WO2020038976A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting usp8
WO2020038968A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
WO2020043750A1 (en) 2018-08-28 2020-03-05 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
WO2020056341A2 (en) 2018-09-14 2020-03-19 Northwestern University Programming protein polymerization with dna
WO2020068398A2 (en) 2018-09-07 2020-04-02 The General Hospital Corporation Compositions and methods for immune checkpoint inhibition
WO2020069055A1 (en) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2020086701A1 (en) 2018-10-24 2020-04-30 Codiak Biosciences, Inc. Methods to improve potency of electroporation
WO2020089260A1 (en) 2018-11-01 2020-05-07 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting tia1
WO2020099533A1 (en) 2018-11-16 2020-05-22 F. Hoffmann-La Roche Ag Streptavidin-coated solid phases with a member of a binding pair
WO2020104492A1 (en) 2018-11-22 2020-05-28 Roche Innovation Center Copenhagen A/S Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
WO2020109344A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020118259A1 (en) 2018-12-06 2020-06-11 Northwestern University Protein crystal engineering through dna hybridization interactions
WO2020123663A1 (en) 2018-12-11 2020-06-18 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
WO2020136125A2 (en) 2018-12-21 2020-07-02 Boehringer Ingelheim International Gmbh Antisense oligonucleotides targeting card9
WO2020152303A1 (en) 2019-01-25 2020-07-30 F. Hoffmann-La Roche Ag Lipid vesicle for oral drug delivery
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
WO2020167822A2 (en) 2019-02-13 2020-08-20 University Of Rochester Gene networks that mediate remyelination of the human brain
WO2020169695A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Phosphonoacetate gapmer oligonucleotides
WO2020169696A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Novel phosphoramidites
WO2020173845A1 (en) 2019-02-26 2020-09-03 Roche Innovation Center Copenhagen A/S Oligonucleotide formulation method
WO2020178258A1 (en) 2019-03-05 2020-09-10 F. Hoffmann-La Roche Ag Intracellular targeting of molecules
WO2020186059A2 (en) 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020191377A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
WO2020206115A2 (en) 2019-04-03 2020-10-08 Bristol-Myers Squibb Company Angptl2 antisense oligonucleotides and uses thereof
WO2020203880A1 (ja) 2019-03-29 2020-10-08 田辺三菱製薬株式会社 Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物
WO2020201339A1 (en) 2019-04-04 2020-10-08 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
WO2020212301A1 (en) 2019-04-16 2020-10-22 Roche Innovation Center Copenhagen A/S Novel process for preparing nucleotide p(v) monomers
WO2020221705A1 (en) 2019-04-30 2020-11-05 Roche Innovation Center Copenhagen A/S Novel process for preparing rhenium chelated mag3 oligonucleotides
WO2020236600A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2020243644A1 (en) 2019-05-31 2020-12-03 Streck, Inc. Detection of antibiotic resistance genes
WO2020245377A1 (en) 2019-06-07 2020-12-10 F. Hoffmann-La Roche Ag Hybridizing all-lna oligonucleotides
WO2020245233A1 (en) 2019-06-06 2020-12-10 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
WO2021011936A2 (en) 2019-07-18 2021-01-21 University Of Rochester Cell-type selective immunoprotection of cells
WO2021020412A1 (ja) 2019-07-30 2021-02-04 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
US10912792B2 (en) 2015-10-08 2021-02-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
WO2021030781A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
WO2021030780A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
WO2021030777A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle linked to molecules and uses thereof
WO2021030768A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with stat3-antisense oligonucleotides
WO2021030776A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2021030773A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
EP3797860A1 (en) 2016-01-06 2021-03-31 The University of British Columbia Bifurcating mixers and methods of their use and manufacture
WO2021062058A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021075538A1 (ja) 2019-10-18 2021-04-22 第一三共株式会社 二環性ホスホロアミダイトの製造方法
WO2021092371A2 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021108647A1 (en) 2019-11-27 2021-06-03 Crispr Therapeutics Ag Methods of synthesizing rna molecules
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
WO2021119275A1 (en) 2019-12-11 2021-06-17 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
WO2021122921A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of cops3 inhibitors for treating hepatitis b virus infection
WO2021122869A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of scamp3 inhibitors for treating hepatitis b virus infection
WO2021123086A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for inhibiting scn9a expression
WO2021122910A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sbds inhibitors for treating hepatitis b virus infection
WO2021122993A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of saraf inhibitors for treating hepatitis b virus infection
WO2021123074A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Methods of sequencing by synthesis using a consecutive labeling scheme
WO2021122735A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sept9 inhibitors for treating hepatitis b virus infection
WO2021130270A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2021130266A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
EP3844303A1 (en) 2018-08-27 2021-07-07 The Regents of The University of California Reporter nucleic acids for type v crispr-mediated detection
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
WO2021158810A1 (en) 2020-02-05 2021-08-12 Bristol-Myers Squibb Company Oligonucleotides for splice modulation of camk2d
WO2021170697A1 (en) 2020-02-28 2021-09-02 F. Hoffmann-La Roche Ag Oligonucleotides for modulating cd73 exon 7 splicing
US11111535B2 (en) 2003-06-20 2021-09-07 Qiagen Gmbh Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
EP3877517A1 (en) 2018-11-09 2021-09-15 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021198883A1 (en) 2020-03-31 2021-10-07 Janssen Biopharma, Inc. Synthesis of oligonucleotides and related compounds
US11174470B2 (en) 2019-01-04 2021-11-16 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
WO2021231210A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2021230286A1 (ja) 2020-05-12 2021-11-18 田辺三菱製薬株式会社 Ａｔａｘｉｎ ３発現を調節するための化合物、方法及び医薬組成物
WO2021231211A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2021229036A1 (en) 2020-05-13 2021-11-18 F. Hoffmann-La Roche Ag Oligonucleotide agonists targeting progranulin
WO2021231204A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
WO2021233551A1 (en) 2020-05-22 2021-11-25 F.Hoffmann-La Roche Ag Oligonucleotides for splice modulation of card9
WO2021249993A1 (en) 2020-06-09 2021-12-16 Roche Innovation Center Copenhagen A/S Guanosine analogues for use in therapeutic polynucleotides
WO2021260197A1 (en) 2020-06-26 2021-12-30 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for modulating fubp1 expression
WO2022011214A1 (en) 2020-07-10 2022-01-13 Alnylam Pharmaceuticals, Inc. Circular sirnas
WO2022008935A1 (en) 2020-07-10 2022-01-13 Horizon Discovery Limited Method for producing genetically modified cells
DE212020000516U1 (de) 2019-03-07 2022-01-17 The Regents of the University of California CRISPR-CAS-Effektorpolypeptide
WO2022018155A1 (en) 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Lna oligonucleotides for splice modulation of stmn2
WO2022018187A1 (en) 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Oligonucleotides targeting rna binding protein sites
WO2022038211A2 (en) 2020-08-21 2022-02-24 F. Hoffmann-La Roche Ag Use of a1cf inhibitors for treating hepatitis b virus infection
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US11261446B2 (en) 2019-03-29 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating UBE3A-ATS
US11273442B1 (en) 2018-08-01 2022-03-15 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
WO2022107025A1 (en) 2020-11-18 2022-05-27 Lemba Bv Umlilo antisense transcription inhibitors
WO2022117747A2 (en) 2020-12-03 2022-06-09 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
WO2022117745A1 (en) 2020-12-03 2022-06-09 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
WO2022122613A1 (en) 2020-12-08 2022-06-16 F. Hoffmann-La Roche Ag Novel synthesis of phosphorodithioate oligonucleotides
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2022129320A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Antisense oligonucleotides for targeting progranulin
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
WO2022147214A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
WO2022167456A1 (en) 2021-02-02 2022-08-11 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for inhibiting rtel1 expression
WO2022178149A2 (en) 2021-02-17 2022-08-25 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
WO2022178180A1 (en) 2021-02-17 2022-08-25 Codiak Biosciences, Inc. Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
EP4056703A1 (en) 2015-03-03 2022-09-14 Ionis Pharmaceuticals, Inc. Methods for modulating mecp2 expression
WO2022192038A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
US11447521B2 (en) 2020-11-18 2022-09-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
US11453891B2 (en) 2017-05-10 2022-09-27 The Regents Of The University Of California Directed editing of cellular RNA via nuclear delivery of CRISPR/CAS9
WO2022213118A1 (en) 2021-03-31 2022-10-06 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
WO2022212884A1 (en) 2021-04-01 2022-10-06 Codiak Biosciences, Inc. Extracellular vesicle compositions
WO2022241408A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
WO2022240760A2 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
WO2022240721A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
WO2022256597A1 (en) 2021-06-04 2022-12-08 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
WO2022261292A1 (en) 2021-06-10 2022-12-15 Intellia Therapeutics, Inc. Modified guide rnas comprising an internal linker for gene editing
WO2022258753A1 (en) 2021-06-11 2022-12-15 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
WO2022258555A1 (en) 2021-06-08 2022-12-15 F. Hoffmann-La Roche Ag Oligonucleotide progranulin agonists
US11530409B2 (en) 2016-01-26 2022-12-20 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2022271818A1 (en) 2021-06-23 2022-12-29 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
WO2023003922A1 (en) 2021-07-21 2023-01-26 Alnylam Pharmaceuticals, Inc. Metabolic disorder-associated target gene irna compositions and methods of use thereof
WO2023021046A1 (en) 2021-08-16 2023-02-23 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023034817A1 (en) 2021-09-01 2023-03-09 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
WO2023043280A1 (ko) 2021-09-17 2023-03-23 주식회사 씨젠 합성 비자연 염기를 포함하는 태그 올리고뉴클레오타이드를 이용한 타겟 핵산 서열의 검출
WO2023052317A1 (en) 2021-09-29 2023-04-06 F. Hoffmann-La Roche Ag Rna editing
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
US11634711B2 (en) 2012-05-17 2023-04-25 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2023078883A1 (en) 2021-11-03 2023-05-11 F. Hoffmann-La Roche Ag Oligonucleotides for modulating apolipoprotein e4 expression
WO2023083906A2 (en) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
US11667903B2 (en) 2015-11-23 2023-06-06 The Regents Of The University Of California Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9
WO2023104693A1 (en) 2021-12-07 2023-06-15 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting actl6b
WO2023111336A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Oligonucleotide gba agonists
WO2023111210A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Combination of oligonucleotides for modulating rtel1 and fubp1
WO2023122762A1 (en) 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023117738A1 (en) 2021-12-20 2023-06-29 F. Hoffmann-La Roche Ag Threose nucleic acid antisense oligonucleotides and methods thereof
US11690920B2 (en) 2017-07-13 2023-07-04 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
US11708614B2 (en) 2016-06-15 2023-07-25 Streck Llc Assays and methods for determining microbial resistance
WO2023141507A1 (en) 2022-01-20 2023-07-27 Genentech, Inc. Antisense oligonucleotides for modulating tmem106b expression
WO2023150553A1 (en) 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
US11732261B2 (en) 2011-08-11 2023-08-22 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2023156652A1 (en) 2022-02-21 2023-08-24 F. Hoffmann-La Roche Ag Antisense oligonucleotide
WO2023217890A1 (en) 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2023222858A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Improved oligonucleotides targeting rna binding protein sites
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023240277A2 (en) 2022-06-10 2023-12-14 Camp4 Therapeutics Corporation Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
WO2023242324A1 (en) 2022-06-17 2023-12-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for targeting progranulin
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
EP4332221A1 (en) 2022-08-29 2024-03-06 Roche Innovation Center Copenhagen A/S Threose nucleic acid antisense oligonucleotides and methods thereof
WO2024052403A1 (en) 2022-09-06 2024-03-14 F. Hoffmann-La Roche Ag Double-stranded rna molecule for administration to the eye
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2024073042A1 (en) 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
US11957788B2 (en) 2014-06-04 2024-04-16 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2024098061A2 (en) 2022-11-04 2024-05-10 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2024101446A1 (ja) 2022-11-10 2024-05-16 ルクサナバイオテク株式会社 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法
WO2024104914A1 (en) 2022-11-14 2024-05-23 BioNTech SE Rna capping efficiency assay
WO2024119145A1 (en) 2022-12-01 2024-06-06 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2024126654A1 (en) 2022-12-14 2024-06-20 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting actl6b
WO2024161314A1 (en) 2023-01-31 2024-08-08 Seqirus Inc. Capping assay
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024175707A1 (en) 2023-02-22 2024-08-29 Helmholtz-Zentrum für Infektionsforschung GmbH A synthetic oligonucleotide for treating nidovirales infections
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2024216155A1 (en) 2023-04-12 2024-10-17 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery of double-stranded rna agents
WO2024227047A2 (en) 2023-04-28 2024-10-31 Beam Therapeutics Inc. Modified guide rna
WO2024227765A2 (en) 2023-05-04 2024-11-07 F. Hoffmann-La Roche Ag Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2024231285A1 (en) 2023-05-05 2024-11-14 BioNTech SE Method of analysing contaminants in rna products by ion-pair chromatography
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024243062A1 (en) 2023-05-19 2024-11-28 Streck Llc Detection of antibiotic resistance genes
WO2024256674A1 (en) 2023-06-14 2024-12-19 Sanofi Methods of simultaneously identifying or quantifying capping and tailing modifications of messenger rna
WO2024256707A1 (en) 2023-06-16 2024-12-19 F. Hoffmann-La Roche Ag Double stranded oligonucleotide for modulating jak1 expression
US12176067B2 (en) 2012-12-20 2024-12-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP4481401A2 (en) 2015-02-24 2024-12-25 The University of British Columbia Continuous flow microfluidic system and method
WO2025005265A1 (ja) * 2023-06-30 2025-01-02 日産化学株式会社 毒性が低減されたアンチセンスオリゴヌクレオチド
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
WO2025038902A2 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2025038901A1 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
US12258620B2 (en) 2018-09-25 2025-03-25 Co-Diagnostics, Inc. Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
WO2025061842A1 (en) 2023-09-19 2025-03-27 Charité - Universitätsmedizin Berlin Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci)
WO2025064660A2 (en) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
US12263227B2 (en) 2018-11-28 2025-04-01 Crispr Therapeutics Ag Optimized mRNA encoding CAS9 for use in LNPs
WO2025072246A1 (en) 2023-09-26 2025-04-03 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 50 in duchenne muscular dystrophy
WO2025074331A1 (en) 2023-10-04 2025-04-10 Lemba Bv Compounds for inhibiting amanzi
WO2025074330A1 (en) 2023-10-04 2025-04-10 Lemba Bv Compounds for inhibition of il-1beta expression
WO2025101994A2 (en) 2023-11-10 2025-05-15 Intellia Therapeutics, Inc. Compositions, methods, and systems for genomic editing
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
WO2025132962A2 (en) 2023-12-21 2025-06-26 F. Hoffmann-La Roche Ag Antisense oligonucleotide
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
WO2025252669A1 (en) 2024-06-03 2025-12-11 Evotec International Gmbh Modified oligonucleotides for reducing atxn3 expression
WO2025255388A1 (en) 2024-06-05 2025-12-11 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2026006390A2 (en) 2024-06-26 2026-01-02 Intellia Therapeutics, Inc. Modified guide rnas for genome editing

Families Citing this family (585)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119184B2 (en) * 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JP3756313B2 (ja) † 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
IL135000A0 (en) * 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
JP4148662B2 (ja) * 2000-08-10 2008-09-10 第一三共株式会社 ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
US6436640B1 (en) * 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
WO2002006297A1 (en) * 2000-07-19 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Novel antisense oligonucleotide derivatives against wilms's tumor gene
JP2002322192A (ja) * 2000-08-10 2002-11-08 Sankyo Co Ltd ２’−ｏ，４’−ｃ−架橋ヌクレオシドトリリン酸体
DK1334109T3 (da) * 2000-10-04 2006-10-09 Santaris Pharma As Forbedret syntese af purin-blokerede nukleinsyre-analoger
EP1251183A3 (en) * 2001-04-18 2003-12-10 Exiqon A/S Improved helper probes for detection of a target sequence by a capture oligonucleotide
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
EP1437408A4 (en) * 2001-09-17 2006-08-23 Takeshi Imanishi NOVEL ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST HEPATITIS C VIRUS
US7468244B2 (en) * 2001-09-27 2008-12-23 University Of Delaware Polymorphism detection and separation
EP1448766A2 (en) * 2001-09-27 2004-08-25 University Of Delaware Coisogenic eukaryotic cell collections
WO2003040395A2 (en) * 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
US20030198980A1 (en) * 2001-12-21 2003-10-23 Applera Corporation Heteroconfigurational polynucleotides and methods of use
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
AU2003211953A1 (en) * 2002-02-13 2003-09-04 Takeshi Imanishi Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
US20030198960A1 (en) * 2002-04-01 2003-10-23 Wenhong Fan Signal amplifying targeted reporters for biological and chemical sensor applications
US7211382B2 (en) * 2002-04-09 2007-05-01 Orchid Cellmark Inc. Primer extension using modified nucleotides
US20040033602A1 (en) * 2002-06-12 2004-02-19 Ambion, Inc. Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040175722A1 (en) * 2002-10-07 2004-09-09 Kmiec Eric B. Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration
JP5132025B2 (ja) * 2002-11-19 2013-01-30 第一三共株式会社 新規２’，５’−オリゴアデニル酸類縁体
TWI347948B (en) * 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions
EP2292793B1 (en) 2003-05-19 2013-12-04 Gen-Probe Incorporated Compositions, methods and kits for determining the presence of Trichomonas Vaginalis in a test sample
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005045033A1 (ja) 2003-11-07 2005-05-19 Sankyo Company, Limited 遺伝子多型の検出方法
US7972783B2 (en) * 2003-11-24 2011-07-05 Branhaven LLC Method and markers for determining the genotype of horned/polled cattle
CA2980050C (en) 2004-08-27 2018-01-23 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US7713697B2 (en) * 2004-08-27 2010-05-11 Gen-Probe Incorporated Methods and kits for amplifying DNA
EP1647600A3 (en) 2004-09-17 2006-06-28 Affymetrix, Inc. (A US Entity) Methods for identifying biological samples by addition of nucleic acid bar-code tags
US20060073511A1 (en) 2004-10-05 2006-04-06 Affymetrix, Inc. Methods for amplifying and analyzing nucleic acids
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
US20060166238A1 (en) * 2004-12-22 2006-07-27 Ramsing Niels B Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
CA2596496A1 (en) 2005-02-01 2006-08-10 Agencourt Bioscience Corp. Reagents, methods, and libraries for bead-based sequencing
EP2236628A3 (en) 2005-02-01 2010-10-13 AB Advanced Genetic Analysis Corporation Reagents, methods and libraries for bead-based sequencing
US20070065840A1 (en) * 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
JP4741328B2 (ja) * 2005-09-08 2011-08-03 クラリオン株式会社 ナビゲーション装置
WO2007062442A2 (en) 2005-11-30 2007-06-07 St. Anna Kinderkrebsforschung Detection of fungi
US20090324587A1 (en) 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US20100286044A1 (en) * 2005-12-29 2010-11-11 Exiqon A/S Detection of tissue origin of cancer
EP3210633B1 (en) 2006-01-26 2019-06-19 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
EP2332951A3 (en) * 2006-01-27 2014-08-13 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
CN101495654A (zh) * 2006-04-19 2009-07-29 阿普里拉股份有限公司 无凝胶珠基测序的试剂、方法和文库
CA2651453C (en) * 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US20090023221A1 (en) * 2006-05-19 2009-01-22 Exigon A/S Oligonucleotide probes useful for detection and analysis of microrna precursors
PL2017356T3 (pl) 2006-06-06 2012-03-30 Gen Probe Inc Znakowane oligonukleotydy i ich zastosowanie w sposobach amplifikacji kwasu nukleinowego
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
WO2008011473A2 (en) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
AU2007310982A1 (en) * 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
US8183359B2 (en) * 2007-03-01 2012-05-22 Gen-Probe Incorporated Kits for amplifying DNA
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
EP2126081A2 (en) * 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
US20100055782A1 (en) * 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
EP2121923A1 (en) * 2007-03-02 2009-11-25 MDRNA, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US20100041140A1 (en) * 2007-03-02 2010-02-18 Mdrna, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
WO2008109357A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
CA2679387A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
US20100047909A1 (en) * 2007-03-02 2010-02-25 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
WO2008106803A1 (en) * 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
EP2134736A4 (en) * 2007-03-15 2013-05-29 Jyoti Chattopadhyaya FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
EP1978111B1 (en) 2007-04-02 2013-03-27 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of Pseudomonas aeruginosa
FR2915208A1 (fr) 2007-04-20 2008-10-24 Millipore Corp Composition comprenant l'association d'edta et de pei pour augmenter la permeabilite des parois des microorganismes et utilisations de ladite composition
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US20100261175A1 (en) * 2007-06-15 2010-10-14 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2692579C (en) * 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
JP5723154B2 (ja) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型
CN101910415B (zh) * 2007-11-07 2015-02-25 不列颠哥伦比亚大学 微流体装置及其使用方法
US20090171078A1 (en) * 2007-11-20 2009-07-02 Applied Biosystems Inc. Method of sequencing nucleic acids using elaborated nucleotide phosphorotiolate compounds
US8546556B2 (en) * 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009074990A2 (en) * 2007-12-12 2009-06-18 Quark Pharmaceuticals, Inc. Rtp801l sirna compounds and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
JP5498954B2 (ja) 2007-12-21 2014-05-21 ジェン−プロウブ インコーポレイテッド 抗生剤耐性微生物の検出
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
WO2009100320A2 (en) * 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20090215050A1 (en) 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
CN102026670A (zh) * 2008-03-20 2011-04-20 夸克医药公司 用于抑制RTP801的新型siRNA化合物
US20090326049A1 (en) * 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
US20100113284A1 (en) * 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
US9290534B2 (en) * 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
EP2285385A4 (en) * 2008-04-15 2013-01-16 Quark Pharmaceuticals Inc COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
CA2723726C (en) 2008-05-13 2017-09-12 Michael M. Becker Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
CA2723917A1 (en) 2008-05-30 2009-12-30 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of salmonella
US8501805B2 (en) * 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
US8153606B2 (en) 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
CN107338251A (zh) 2008-12-04 2017-11-10 库尔纳公司 通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
CN102341498B (zh) 2008-12-04 2017-12-19 库尔纳公司 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病
US8748133B2 (en) 2008-12-30 2014-06-10 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of Listeria
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
US8921039B2 (en) 2009-02-26 2014-12-30 Gen-Probe Incorporated Assay for detection of human parvovirus nucleic acid
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US8481698B2 (en) * 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
WO2010126913A1 (en) 2009-04-27 2010-11-04 Gen-Probe Incorporated Methods and kits for use in the selective amplification of target sequences
KR101722541B1 (ko) 2009-05-06 2017-04-04 큐알엔에이, 인크. Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
CN106237345A (zh) 2009-05-06 2016-12-21 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
CA3185821A1 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
KR101801404B1 (ko) 2009-06-16 2017-12-20 큐알엔에이, 인크. 콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
WO2010151674A2 (en) 2009-06-26 2010-12-29 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
JP2011024434A (ja) 2009-07-22 2011-02-10 Galaxy Pharma Inc オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011012136A1 (en) 2009-07-28 2011-02-03 Exiqon A/S A method for classifying a human cell sample as cancerous
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
CA2770104C (en) 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
CA2771228C (en) 2009-08-21 2020-12-29 Opko Curna, Llc Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
US20110196141A1 (en) * 2009-09-07 2011-08-11 Council Of Scientific & Industrial Research Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides
EP2480669B1 (en) 2009-09-25 2017-11-08 CuRNA, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US20150025122A1 (en) 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
NO2513310T3 (ja) 2009-12-16 2018-03-31
WO2011087789A2 (en) 2009-12-22 2011-07-21 Becton, Dickinson And Company Methods for the detection of microorganisms
ES2661387T3 (es) 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
JP2011130725A (ja) * 2009-12-25 2011-07-07 Contig I:Kk Ｌｎａオリゴヌクレオチドとそれを含有する化粧品
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101853511B1 (ko) 2009-12-31 2018-06-20 큐알엔에이, 인크. 인슐린 수용체 기질 2 및 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의한 ｉｒｓ2 관련된 질환의 치료
CA2785832A1 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
EP2521785B1 (en) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011088148A1 (en) * 2010-01-12 2011-07-21 Isis Pharmaceuticals, Inc. Modulation of transforming growth factor-beta 1 expression
RU2611192C2 (ru) 2010-01-25 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
EP2539452B1 (en) 2010-02-22 2016-07-27 CuRNA, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
US20110213011A1 (en) * 2010-02-26 2011-09-01 Dean Nicholas M Modulation of smad3 expression
ES2743600T3 (es) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Métodos de tratamiento de los trastornos inflamatorios vasculares
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
KR101877065B1 (ko) 2010-04-02 2018-07-10 큐알엔에이, 인크. 집락 자극 인자 3 (ｃｓｆ3)에 대한 자연 안티센스 전사체의 저해에 의한 집락 자극 인자 3 (ｃｓｆ3) 관련된 질환의 치료
AU2011237630B2 (en) 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
TWI644675B (zh) 2010-04-09 2018-12-21 可娜公司 藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139710A1 (en) 2010-04-26 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds with conformationally restricted monomers and uses thereof
US8278049B2 (en) 2010-04-26 2012-10-02 Ann & Robert H. Lurie Children's Hospital of Chicago Selective enrichment of CpG islands
WO2011139843A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Multi-sirna compositions for reducing gene expression
RU2018110641A (ru) 2010-05-03 2019-02-27 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
RU2585229C2 (ru) 2010-05-26 2016-05-27 Курна, Инк. Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
JP6081910B2 (ja) 2010-06-02 2017-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 肝線維症治療用組成物および肝線維症の治療法
WO2011159836A2 (en) 2010-06-15 2011-12-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
CN109112126B (zh) 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
US9822397B2 (en) 2010-06-30 2017-11-21 Gen-Probe Incorporated Method and apparatus for identifying analyte-containing samples using single-read determination of analyte and process control signals
WO2012006551A2 (en) 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
EP2601611B1 (en) 2010-08-02 2020-12-09 Integrated Dna Technologies, Inc. Methods for predicting stability and melting temperatures of nucleic acid duplexes
RU2624048C2 (ru) 2010-10-06 2017-06-30 Курна, Инк. Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
US8648053B2 (en) 2010-10-20 2014-02-11 Rosalind Franklin University Of Medicine And Science Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012064758A2 (en) 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
US9127275B2 (en) 2010-12-10 2015-09-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
EP2652151A2 (en) 2010-12-15 2013-10-23 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
SG193923A1 (en) 2011-03-29 2013-11-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
CN105886506A (zh) 2011-04-13 2016-08-24 Isis制药公司 Ptp1b 表达的反义调节
WO2012151324A1 (en) 2011-05-02 2012-11-08 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
CN103620036B (zh) 2011-06-09 2016-12-21 库尔纳公司 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
BR112013033260B1 (pt) 2011-06-21 2022-06-21 Alnylam Pharmaceuticals Ácido ribonucleico de fita dupla (dsrna) para inibir a expressão de angptl3, composição farmacêutica e método in vitro para inibir a expressão de angptl3 em uma célula
EP4134433A1 (en) 2011-06-23 2023-02-15 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
EP2724156B1 (en) 2011-06-27 2017-08-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
EP2739735A2 (en) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US9976138B2 (en) 2011-08-29 2018-05-22 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
EP2751270B1 (en) 2011-08-29 2018-08-22 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
MX365525B (es) 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
EP2758547B1 (en) 2011-09-21 2015-09-16 Gen-Probe Incorporated Methods for amplifying nucleic acid using tag-mediated displacement
CN104011210B (zh) 2011-10-11 2018-05-01 布里格姆及妇女医院股份有限公司 神经退行性病症中的microRNA
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2773777B1 (en) 2011-10-31 2020-05-13 University of Utah Research Foundation Genetic alterations in glioblastoma
US9243291B1 (en) 2011-12-01 2016-01-26 Isis Pharmaceuticals, Inc. Methods of predicting toxicity
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN112386605A (zh) 2011-12-16 2021-02-23 国立大学法人东京医科齿科大学 嵌合的双链核酸
ES2842938T3 (es) 2012-01-11 2021-07-15 Ionis Pharmaceuticals Inc Composiciones y métodos para la modulación del empalme de IKBKAP
ES2694592T3 (es) 2012-03-15 2018-12-21 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
ES2779698T3 (es) 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9828602B2 (en) 2012-06-01 2017-11-28 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
AU2013202793B2 (en) 2012-07-31 2014-09-18 Gen-Probe Incorporated System, method and apparatus for automated incubation
US10253360B2 (en) 2012-09-28 2019-04-09 Bna Inc. BNA clamp method
EP3459549B1 (en) 2012-10-12 2022-04-06 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
JP2016509572A (ja) 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Ｂｃｌ２発現の調節による癌の処置のためにバイオマーカーを使用する方法
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
WO2014093537A1 (en) 2012-12-11 2014-06-19 Isis Pharmaceuticals, Inc. Competitive modulation of micrornas
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
ES2817050T3 (es) 2013-02-04 2021-04-06 Ionis Pharmaceuticals Inc Compuestos antisentido selectivos y usos de los mismos
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP2961841B1 (en) 2013-03-01 2020-01-22 National University Corporation Tokyo Medical and Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR102905197B1 (ko) 2013-03-14 2025-12-31 알닐람 파마슈티칼스 인코포레이티드 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
DK2970968T3 (en) 2013-03-15 2018-03-05 Miragen Therapeutics Inc CONNECTED BICYCLIC Nucleosides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2902623A1 (en) 2013-03-15 2014-09-25 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of mir-145 and uses thereof
EP2971160B1 (en) 2013-03-15 2018-05-30 Bio-Rad Laboratories, Inc. Digital assays for mutation detection
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
WO2014172698A1 (en) 2013-04-19 2014-10-23 Isis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
DK2999785T3 (en) 2013-05-22 2018-07-23 Alnylam Pharmaceuticals Inc SERPINA1-IRNA COMPOSITIONS AND PROCEDURES FOR USE THEREOF
KR102486617B1 (ko) 2013-05-22 2023-01-12 알닐람 파마슈티칼스 인코포레이티드 Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
US11028387B2 (en) 2013-05-30 2021-06-08 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides
WO2014197835A2 (en) 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer
US20160220640A1 (en) 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
CA2915443A1 (en) 2013-06-16 2014-12-24 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
EP3730619A1 (en) 2013-06-21 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
JP7019233B2 (ja) 2013-07-11 2022-02-15 モデルナティエックス インコーポレイテッド ＣＲＩＳＰＲ関連タンパク質をコードする合成ポリヌクレオチドおよび合成ｓｇＲＮＡを含む組成物ならびに使用方法
JP6617702B2 (ja) 2013-07-15 2019-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｆｔｙ７２０のアザサイクリック拘束アナログ
WO2015017675A2 (en) 2013-07-31 2015-02-05 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
EP3656781A1 (en) 2013-08-08 2020-05-27 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
KR20160106040A (ko) 2013-08-14 2016-09-09 퀴아젠 맨스필드, 인코퍼레이티드 ｃＭＥＴ 핵산의 멀티모달 분석을 위한 조성물 및 방법
JP2016527899A (ja) 2013-08-14 2016-09-15 キアゲン マンスフィールド インコーポレイテッド Ｎｒａｓ核酸およびｂｒａｆ核酸のマルチプレックス解析のための組成物および方法
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US10077444B2 (en) 2013-10-02 2018-09-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
KR102469850B1 (ko) 2013-10-04 2022-11-23 알닐람 파마슈티칼스 인코포레이티드 Ａｌａｓ1 유전자의 발현을 억제하기 위한 조성물 및 방법
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP3683321B1 (en) 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US9758546B2 (en) 2013-10-21 2017-09-12 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
CA2931829A1 (en) 2013-12-02 2015-06-11 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
IL314045A (en) 2013-12-12 2024-09-01 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
CN106456694B (zh) 2013-12-20 2020-06-30 通用医疗公司 与循环肿瘤细胞相关的方法和测定法
US9765332B2 (en) 2014-01-29 2017-09-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
KR20230152154A (ko) 2014-02-11 2023-11-02 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
DK3129493T3 (da) 2014-04-09 2021-09-27 Scripps Research Inst Import af unaturlige eller modificerede nukleosidtriphosphater ind i celler via nukleinsyre-triphosphat-transportører
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
WO2015168514A1 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
BR122020023687B1 (pt) 2014-05-22 2023-03-07 Alnylam Pharmaceuticals, Inc Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
CA2950589A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP4159741A1 (en) 2014-07-16 2023-04-05 ModernaTX, Inc. Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
KR20170070022A (ko) 2014-08-29 2017-06-21 칠드런'즈 메디컬 센터 코포레이션 암의 치료를 위한 방법 및 조성물
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
JP2017529082A (ja) 2014-09-18 2017-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ハンチントン病ハプロタイプのための対立遺伝子特異的な療法
WO2016054615A2 (en) 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US10364433B2 (en) 2014-11-14 2019-07-30 The Regents Of The University Of California Modulation of AGPAT5 expression
CA2964979A1 (en) 2014-11-14 2016-05-19 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
EP3221451A1 (en) 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
AU2015360794B2 (en) 2014-12-08 2021-07-08 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
JP2018503685A (ja) 2015-01-20 2018-02-08 ザ・チルドレンズ・メディカル・センター・コーポレーション 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物
SG10201906716QA (en) 2015-01-20 2019-08-27 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US10961532B2 (en) 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016172632A2 (en) 2015-04-24 2016-10-27 Atila Biosystems, Inc Amplification with primers of limited nucleotide composition
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
JP2018519811A (ja) 2015-06-29 2018-07-26 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ｃｒｉｓｐｒ ｒｎａ及び修飾単一ｃｒｉｓｐｒ ｒｎａならびにその使用
WO2017011276A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
CN114525280A (zh) 2015-09-02 2022-05-24 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1（PD-L1）的iRNA组合物及其使用方法
WO2017048789A1 (en) 2015-09-14 2017-03-23 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
CN108366990B (zh) 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
BR112018004620A2 (pt) 2015-09-24 2018-09-25 Ionis Pharmaceuticals, Inc. moduladores da expressão de kras
WO2017053781A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
RS65879B1 (sr) 2015-11-06 2024-09-30 Ionis Pharmaceuticals Inc Konjugovana antisensna jedinjenja za terapijsku upotrebu
JP7108307B2 (ja) 2015-11-30 2022-07-28 デューク ユニバーシティ 遺伝子編集によるヒトジストロフィン遺伝子の修正用の治療標的および使用方法
EP3389670A4 (en) 2015-12-04 2020-01-08 Ionis Pharmaceuticals, Inc. METHODS OF TREATING BREAST CANCER
EP3386518B1 (en) 2015-12-07 2025-06-25 Genzyme Corporation Methods and compositions for treating a serpinc1-associated disorder
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CA3005256A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
EP3400300A4 (en) 2016-01-05 2019-08-07 Ionis Pharmaceuticals, Inc. PROCESS FOR REDUCING LRRK2 EXPRESSION
US11384112B2 (en) 2016-02-17 2022-07-12 Tokyo Institute Of Technology Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide
EP4512904A3 (en) 2016-02-25 2025-04-09 The Brigham and Women's Hospital, Inc. Treatment methods for fibrosis targeting smoc2
US11136577B2 (en) 2016-03-09 2021-10-05 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
US10961271B2 (en) 2016-03-16 2021-03-30 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
WO2017180835A1 (en) 2016-04-13 2017-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
WO2017180915A2 (en) 2016-04-13 2017-10-19 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
MA45295A (fr) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
IL262728B2 (en) 2016-05-06 2023-10-01 Astrazeneca Ab Oligonucleotides conjugated to the GLP-1 receptor ligand complex and their uses
JP7080826B2 (ja) 2016-05-16 2022-06-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
US11236339B2 (en) 2016-06-17 2022-02-01 Ionis Pharmaceuticals, Inc. Modulation of GYS1 expression
HUE060123T2 (hu) 2016-06-24 2023-01-28 Scripps Research Inst Új nukleozid-trifoszfát-transzporter és alkalmazásai
JP7197463B2 (ja) 2016-07-15 2022-12-27 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｍｎ２の調節のための化合物及び方法
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
IL265359B2 (en) 2016-09-14 2025-02-01 Janssen Biopharma Llc Modified oligonucleotides and pharmaceutical preparations containing them
KR102468174B1 (ko) 2016-09-15 2022-11-17 에프. 호프만-라 로슈 아게 멀티플렉스 pcr 수행 방법
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
US11033570B2 (en) 2016-12-02 2021-06-15 Cold Spring Harbor Laboratory Modulation of Lnc05 expression
AU2017376950B2 (en) 2016-12-16 2024-02-22 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
CN110268060B (zh) 2017-01-10 2024-07-26 箭头药业股份有限公司 α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
EP3597197A4 (en) 2017-03-17 2021-01-06 National University Corporation Chiba University Novel technique for treating cancer using structurally-reinforced s-tud
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
WO2018191603A1 (en) 2017-04-14 2018-10-18 University Of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
MA50278A (fr) 2017-04-18 2020-02-26 Alnylam Pharmaceuticals Inc Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
NZ761103A (en) 2017-07-10 2026-01-30 Genzyme Corp Methods and compositions for treating a bleeding event in a subject having hemophilia
CA3069321A1 (en) 2017-07-11 2019-01-17 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof
US12497642B2 (en) 2017-07-11 2025-12-16 The Scripps Research Institute Incorporation of unnatural nucleotides and methods of use in vivo thereof
KR102708105B1 (ko) 2017-08-03 2024-09-24 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3668984A4 (en) 2017-08-18 2021-09-08 Ionis Pharmaceuticals, Inc. MODULATION OF THE NOTCH SIGNALING PATH FOR THE TREATMENT OF RESPIRATORY DISORDERS
EP3673080B1 (en) 2017-08-25 2023-10-18 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
CN111527207B (zh) 2017-09-14 2024-04-26 詹森生物制药有限公司 GalNAc衍生物
US11261445B2 (en) 2017-10-17 2022-03-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination treatment for cystic fibrosis
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
EP3710587A1 (en) 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
US11725208B2 (en) 2017-12-14 2023-08-15 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2019126097A1 (en) 2017-12-18 2019-06-27 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
WO2019133883A1 (en) 2017-12-29 2019-07-04 The Scripps Research Institute Unnatural base pair compositions and methods of use
EP3740575A1 (en) 2018-01-15 2020-11-25 Ionis Pharmaceuticals, Inc. Modulators of dnm2 expression
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
TW202442671A (zh) 2018-02-26 2024-11-01 美商欣爍克斯公司 Il-15結合物及其用途
BR112020018365A2 (pt) 2018-03-13 2020-12-29 Janssen Pharmaceutica Nv Oligonucleotídeos modificados e métodos para uso em tauopatias
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
MX2020011695A (es) 2018-05-04 2021-02-26 Stoke Therapeutics Inc Métodos y composiciones para el tratamiento de la enfermedad por almacenamiento de éster de colesterilo.
PE20212131A1 (es) 2018-05-09 2021-11-05 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir de la expresion de atxn3
EP3799604A4 (en) 2018-05-09 2022-09-07 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS TO REDUCE FXI EXPRESSION
EP3790893A4 (en) 2018-05-11 2022-03-16 University Of Massachusetts METHOD OF IMPROVING LEPTIN SENSITIVITY FOR TREATMENT OF OBESITY AND DIABETES
TWI851574B (zh) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
US11578325B2 (en) 2018-05-24 2023-02-14 David Berz Methods and formulations for the treatment of obesity and obesity-related metabolic diseases
EP3823725A4 (en) 2018-07-17 2023-05-10 Aronora, Inc. METHODS FOR SAFELY REDUCING THROMBOPOIETIN
BR112021000308A2 (pt) 2018-07-25 2021-04-13 Ionis Pharmaceuticals, Inc. Compostos e métodos para redução da expressão de atxn2
WO2020022499A1 (ja) 2018-07-27 2020-01-30 国立大学法人大阪大学 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
WO2020037125A1 (en) 2018-08-16 2020-02-20 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the lect2 gene
US11939582B2 (en) 2018-08-20 2024-03-26 Rogcon, Inc. Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
EP3620520A1 (en) 2018-09-10 2020-03-11 Universidad del Pais Vasco Novel target to treat a metabolic disease in an individual
JP2022500003A (ja) 2018-09-18 2022-01-04 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
TW202542311A (zh) 2018-09-19 2025-11-01 美商Ionis製藥公司 Pnpla3表現之調節劑
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
CA3117572A1 (en) 2018-11-08 2020-05-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
CN113646430A (zh) 2018-11-15 2021-11-12 Ionis制药公司 Irf5表达的调节剂
MX2021005886A (es) 2018-11-21 2021-06-23 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de priones.
EP3894559A4 (en) 2018-12-03 2023-04-05 Triplet Therapeutics, Inc. METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
JP7562424B2 (ja) 2018-12-17 2024-10-07 イルミナ ケンブリッジ リミテッド シーケンシング用プライマーオリゴヌクレオチド
JP2022515744A (ja) 2018-12-20 2022-02-22 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１関連障害の治療のための組成物及び方法
MY206794A (en) 2018-12-20 2025-01-08 Humabs Biomed Sa Combination hbv therapy
CN113195734B (zh) 2018-12-20 2024-12-24 豪夫迈·罗氏有限公司 通过固相分子成像检测靶核酸
CA3122432A1 (en) 2018-12-21 2020-06-25 Ionis Pharmaceuticals, Inc. Modulators of hsd17b13 expression
CA3126933A1 (en) 2019-01-16 2020-07-23 Genzyme Corporation Serpinc1 irna compositions and methods of use thereof
US11214803B2 (en) 2019-01-31 2022-01-04 Ionis Pharmaceuticals, Inc. Modulators of YAP1 expression
WO2020163532A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
US12492399B2 (en) 2019-03-14 2025-12-09 Rena Therapeutics Inc. Nucleic acid complex for regulating IHH expression
WO2020191177A1 (en) 2019-03-21 2020-09-24 Sudhir Agrawal Antisense oligonucleotides for allele specificity
EP3963072A1 (en) 2019-05-03 2022-03-09 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20220339256A1 (en) 2019-05-13 2022-10-27 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus (hbv) infection
FI3976791T3 (fi) 2019-05-28 2025-06-10 Ionis Pharmaceuticals Inc Yhdisteitä ja menetelmiä fus:n ilmentymisen vähentämiseksi
BR112021025130A2 (pt) 2019-06-14 2022-03-15 Scripps Research Inst Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
JPWO2020256084A1 (ja) * 2019-06-19 2020-12-24
WO2021005223A1 (en) 2019-07-10 2021-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of epilepsy
ES3048358T3 (en) 2019-07-26 2025-12-10 Ionis Pharmaceuticals Inc Compounds and methods for modulating gfap
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
EP4007812A1 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
EP4013870A1 (en) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
JP7803850B2 (ja) 2019-08-15 2026-01-21 アイオーニス ファーマシューティカルズ， インコーポレーテッド 結合修飾オリゴマー化合物及びその使用
US20210046160A1 (en) 2019-08-15 2021-02-18 Synthorx, Inc. Immuno Oncology Combination Therapies With IL-2 Conjugates
WO2021041206A1 (en) 2019-08-23 2021-03-04 Synthorx, Inc. Il-15 conjugates and uses thereof
WO2021046122A1 (en) 2019-09-03 2021-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CN114746122A (zh) 2019-09-10 2022-07-12 新索思股份有限公司 Il-2缀合物和治疗自身免疫性疾病的使用方法
US12503699B2 (en) 2019-10-04 2025-12-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing UGT1a1 gene expression
JP7757277B2 (ja) 2019-10-14 2025-10-21 アストラゼネカ・アクチエボラーグ Ｐｎｐｌａ３発現のモジュレーター
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
US12486512B2 (en) 2019-10-18 2025-12-02 Alnylam Pharmaceuticals, Inc. Solute carrier family member iRNA compositions and methods of use thereof
BR112022007540A2 (pt) 2019-10-22 2022-07-12 Alnylam Pharmaceuticals Inc Composições de irna de componente complementar c3 e métodos de uso das mesmas
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
TW202132567A (zh) 2019-11-01 2021-09-01 美商阿尼拉製藥公司 亨汀頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
EP4054644A1 (en) 2019-11-04 2022-09-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
CN114981431A (zh) 2019-11-13 2022-08-30 阿尔尼拉姆医药品有限公司 用于治疗血管紧张素原(agt)相关病症的方法和组合物
WO2021099394A1 (en) 2019-11-19 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antisense oligonucleotides and their use for the treatment of cancer
WO2021102373A1 (en) 2019-11-22 2021-05-27 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
EP3831843A1 (en) 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
BR112022011417A2 (pt) 2019-12-13 2022-08-30 Alnylam Pharmaceuticals Inc Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
JP7753106B2 (ja) 2020-01-31 2025-10-14 株式会社三和化学研究所 Ａｔｎ１のアンチセンスオリゴヌクレオチド
CA3170377A1 (en) 2020-02-10 2021-08-19 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing vegf-a expression
JP7735288B2 (ja) 2020-02-18 2025-09-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
PH12022552258A1 (en) 2020-02-28 2023-11-20 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2
JPWO2021177418A1 (ja) 2020-03-04 2021-09-10
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
EP4114948A1 (en) 2020-03-06 2023-01-11 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
EP4114949A1 (en) 2020-03-06 2023-01-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin (ttr)
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en) 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
WO2021202443A2 (en) 2020-03-30 2021-10-07 Alnylam Pharmaceucticals, Inc. Compositions and methods for silencing dnajc15 gene expression
US12534731B2 (en) 2020-04-01 2026-01-27 Alnylam Pharmaceuticals, Inc. Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
IL297121A (en) 2020-04-06 2022-12-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing myoc expression
KR20230008078A (ko) 2020-04-07 2023-01-13 알닐람 파마슈티칼스 인코포레이티드 Scn9a 발현을 사일런싱하기 위한 조성물 및 방법
EP4133077A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021206917A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3176196A1 (en) 2020-04-21 2021-10-28 Flagship Pioneering, Inc. Bifunctional molecules and methods of using thereof
CA3181400A1 (en) 2020-04-27 2021-11-04 Alnylam Pharmaceuticals, Inc. Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
EP4150078A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
EP4150088A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231691A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150090A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231680A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150086A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4153746A1 (en) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
US11408000B2 (en) 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
US20230203496A1 (en) 2020-06-09 2023-06-29 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
CA3184289A1 (en) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
IL299201A (en) 2020-06-24 2023-02-01 Vir Biotechnology Inc Transgenic hepatitis B virus neutralizing antibodies and their uses
EP4171648A1 (en) 2020-06-25 2023-05-03 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
CN116113697A (zh) 2020-07-10 2023-05-12 国家健康与医学研究院 用于治疗癫痫的方法和组合物
TW202227102A (zh) 2020-09-22 2022-07-16 瑞典商阿斯特捷利康公司 治療脂肪肝病之方法
EP4217489A1 (en) 2020-09-24 2023-08-02 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
TW202229552A (zh) 2020-10-05 2022-08-01 美商艾拉倫製藥股份有限公司 Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
WO2022076859A1 (en) 2020-10-09 2022-04-14 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
KR20230084203A (ko) 2020-10-09 2023-06-12 신톡스, 인크. Il-2 접합체 및 펨브롤리주맙을 사용한 면역 종양 병용 요법
CA3198823A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en) 2020-10-23 2022-04-28 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
AU2021364920A1 (en) 2020-10-23 2023-06-22 Synthorx, Inc. Reverse transcription of polynucleotides comprising unnatural nucleotides
MX2023005490A (es) 2020-11-13 2023-05-23 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) del factor de coagulacion v (f5) y sus metodos de uso.
WO2022106695A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
WO2022119873A1 (en) 2020-12-01 2022-06-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
KR20230118076A (ko) 2020-12-11 2023-08-10 야마사 쇼유 가부시키가이샤 시토신형 가교형 뉴클레오시드 아미다이트 결정 및 그 제조 방법
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
US12018261B2 (en) 2020-12-18 2024-06-25 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor XII
US20240035077A1 (en) 2020-12-22 2024-02-01 Roche Molecular Systems, Inc. Methods for performing multiplexed real-time pcr with the use of large stokes shift fluorescent dyes
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
KR20230146048A (ko) 2021-02-12 2023-10-18 알닐람 파마슈티칼스 인코포레이티드 슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
WO2022174101A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Skin cancer combination therapy with il-2 conjugates and cemiplimab
EP4298220A1 (en) 2021-02-25 2024-01-03 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods of use thereof
WO2022182574A1 (en) 2021-02-26 2022-09-01 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL305418A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
US20220290221A1 (en) 2021-03-15 2022-09-15 Roche Molecular Systems, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus 2 (sars-cov-2) variants having spike protein mutations
WO2022212231A2 (en) 2021-03-29 2022-10-06 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
WO2022212153A1 (en) 2021-04-01 2022-10-06 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
IL307926A (en) 2021-04-26 2023-12-01 Alnylam Pharmaceuticals Inc Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
WO2022232343A1 (en) 2021-04-29 2022-11-03 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022245583A1 (en) 2021-05-18 2022-11-24 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
US20240263177A1 (en) 2021-05-20 2024-08-08 Korro Bio, Inc. Methods and Compositions for Adar-Mediated Editing
AU2022285344A1 (en) 2021-05-31 2023-12-14 Rena Therapeutics Inc. Ligand-bound nucleic acid complex
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
JP2024522996A (ja) 2021-06-02 2024-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
WO2022256538A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
JP2024521907A (ja) 2021-06-04 2024-06-04 アルナイラム ファーマシューティカルズ， インコーポレイテッド ヒト９番染色体オープンリーディングフレーム７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ剤組成物及びその使用方法
AR126070A1 (es) 2021-06-08 2023-09-06 Alnylam Pharmaceuticals Inc Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
WO2022271836A2 (en) 2021-06-22 2022-12-29 AcuraStem, Inc. Pikfyve antisense oligonucleotides
EP4363574A1 (en) 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
CA3225469A1 (en) 2021-06-30 2023-01-05 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
TW202333748A (zh) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
AU2022316149A1 (en) 2021-07-21 2024-02-08 AcuraStem Incorporated Unc13a antisense oligonucleotides
CA3226878A1 (en) 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
EP4377458A1 (en) 2021-07-29 2024-06-05 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
WO2023014677A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
PE20241132A1 (es) 2021-08-04 2024-05-24 Alnylam Pharmaceuticals Inc Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
CA3228733A1 (en) 2021-08-13 2023-02-16 Alnylam Pharmaceuticals, Inc. Factor xii (f12) irna compositions and methods of use thereof
IL311030A (en) 2021-08-31 2024-04-01 Alnylam Pharmaceuticals Inc DFFA-like Cell Death Inducer B (CIDEB) IRNA compositions and methods of using them
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
EP4401742A2 (en) 2021-09-17 2024-07-24 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
CA3232420A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
CA3233101A1 (en) 2021-09-24 2023-03-30 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
WO2023056440A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
US20250352667A1 (en) 2021-10-22 2025-11-20 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
JP2024541989A (ja) 2021-10-29 2024-11-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
EP4423272A2 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
EP4430187A2 (en) 2021-11-10 2024-09-18 University of Rochester Antisense oligonucleotides for modifying protein expression
US20250019702A1 (en) 2021-11-10 2025-01-16 University Of Rochester Gata4-targeted therapeutics for treatment of cardiac hypertrophy
CA3241316A1 (en) 2021-12-03 2023-06-08 Quralis Corporation Gapmer antisense oligonucleotides with modified backbone chemistries
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
KR102731759B1 (ko) 2021-12-10 2024-11-21 니토 보세키 가부시기가이샤 핵산의 대상 염기 서열 중에 있어서의 변이를 검출하기 위한 방법, 핵산의 증폭을 선택적으로 저해하는 방법, 및 이것들을 실시하기 위한 키트
JP7428951B2 (ja) 2021-12-10 2024-02-07 日東紡績株式会社 核酸の対象塩基配列中における変異を検出するための方法、核酸の増幅を選択的に阻害する方法、およびこれらを実施するためのキット
US20250302950A1 (en) 2021-12-20 2025-10-02 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
EP4469575A2 (en) 2022-01-24 2024-12-04 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
CN119213127A (zh) 2022-04-28 2024-12-27 阿库拉斯特姆公司 Syf2反义寡核苷酸
WO2024010841A2 (en) 2022-07-06 2024-01-11 Molecular Axiom, Llc Compositions and methods for treating pancreatic cancer
EP4558149A1 (en) 2022-07-21 2025-05-28 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
US20260049309A1 (en) 2022-08-15 2026-02-19 Novo Nordisk A/S Regulation of activity of rnai molecules
WO2024050261A1 (en) 2022-08-29 2024-03-07 University Of Rochester Antisense oligonucleotide-based anti-fibrotic therapeutics
MA71735A (fr) 2022-09-15 2025-05-30 Regeneron Pharmaceuticals, Inc. Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
CN120752339A (zh) 2023-01-06 2025-10-03 国家医疗保健研究所 静脉内施用用于治疗疼痛的反义寡核苷酸
WO2024155986A2 (en) 2023-01-20 2024-07-25 AcuraStem Incorporated Unc13a antisense oligonucleotides
CN120603947A (zh) 2023-01-31 2025-09-05 阿库拉斯特姆公司 Syf2反义寡核苷酸
CN120659879A (zh) 2023-02-06 2025-09-16 爱可施丹股份有限公司 Pikfyve反义寡核苷酸
CN121263208A (zh) 2023-03-20 2026-01-02 新索思股份有限公司 使用il-2 peg缀合物的癌症疗法
TW202448484A (zh) 2023-04-20 2024-12-16 美商雅迪克斯製藥公司 Ｍａｐｔ調節組合物及其使用方法
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
GB202306715D0 (en) 2023-05-05 2023-06-21 Univ Dublin Microfluidic nucleic acid extraction
WO2024233864A2 (en) 2023-05-10 2024-11-14 Dicerna Pharmaceuticals, Inc. Galnac-conjugated rnai oligonucleotides
TW202502385A (zh) 2023-05-12 2025-01-16 美商雅迪克斯製藥公司 Ｎｍｄａ配位體結合之化合物及其用途
CN121335980A (zh) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法
AU2024313301A1 (en) 2023-06-20 2025-12-11 Adarx Pharmaceuticals, Inc. Lrrk2-modulating compositions and methods of use thereof
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
US20250092375A1 (en) 2023-07-25 2025-03-20 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
US20250092426A1 (en) 2023-07-25 2025-03-20 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025034422A1 (en) 2023-08-04 2025-02-13 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating ctnnb1-associated disorders
WO2025054459A1 (en) 2023-09-08 2025-03-13 Dicerna Pharmaceuticals, Inc. Rnai oligonucleotide conjugates
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025076031A2 (en) 2023-10-03 2025-04-10 Alnylam Pharmaceuticals, Inc. Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025080939A1 (en) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025128853A2 (en) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression
GB202400711D0 (en) 2024-01-18 2024-03-06 Univ Dublin A method for determining the risk of, or prognosis of, lung, pancreatic, and ovarian cancer, and cutaneous and uveal melanoma.
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
TW202543656A (zh) 2024-02-19 2025-11-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 靶向ＣＩＤＥＢ之ＲＮＡｉ藥劑及相關方法
WO2025199231A2 (en) 2024-03-20 2025-09-25 Vertex Pharmaceuticals Incorporated Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en) 2024-03-25 2025-10-02 Synthorx, Inc. Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en) 2024-03-26 2024-05-08 Senisca Ltd Novel oligoncleotides
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025259743A1 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006436A1 (en) 2024-06-25 2026-01-02 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
JPH0953409A (ja) † 1995-08-15 1997-02-25 Mitsubishi Heavy Ind Ltd ガスタービン用セラミック静翼
GB9612600D0 (en) * 1996-06-13 1996-08-21 Ciba Geigy Ag Chemical compounds
JP3756313B2 (ja) † 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTMANN K.-H., KESSELRING R., PIELES U.: "6'-CARBON-SUBSTITUTED CARBOCYCLIC ANALOGS OF 2'-DEOXYRIBONUCLEOSIDES - SYNTHESIS AND EFFECT ON DNA/RNA DUPLEX STABILITY.", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 52., no. 39., 1 January 1996 (1996-01-01), AMSTERDAM, NL, pages 12699 - 12722., XP002916465, ISSN: 0040-4020, DOI: 10.1016/0040-4020(96)00755-7 *
OBIKA ET AL.: "Properties of Novel oligonucleotide Analogues Containing an Acyclic Nucleoside and a Carbamate Linkage", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 12, 1996, pages 1357 - 1360
OBIKA S., ET AL.: "PROPERTIES OF NOVEL OLIGONUCLEOTIDE ANALOGUES CONTAINING AN ACYCLIC NUCLEOSIDE AND A CARBAMATE LINKAGE.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 06., no. 12., 1 January 1996 (1996-01-01), AMSTERDAM, NL, pages 1357 - 1360., XP002916466, ISSN: 0960-894X, DOI: 10.1016/0960-894X(96)00223-5 *
OBIKA S., ET AL.: "SYNTHESIS OF 2'-O,4'-C-METHYLENEURIDINE AND -CYTIDINE. NOVEL BICYCLIC NUCLEOSIDES HAVING A FIXED C3,-ENDO SUGAR PUCKERING.", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 38., no. 50., 15 December 1997 (1997-12-15), AMSTERDAM, NL, pages 8735 - 8738., XP002916464, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(97)10322-7 *

Cited By (963)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695902B2 (en) 1996-06-06 2010-04-13 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US6670461B1 (en) 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US8034909B2 (en) 1997-09-12 2011-10-11 Exiqon A/S Oligonucleotide analogues
US8080644B2 (en) 1997-09-12 2011-12-20 Exiqon A/S Oligonucleotide analogues
US8153365B2 (en) 1997-09-12 2012-04-10 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7034133B2 (en) 1997-09-12 2006-04-25 Exiqon A/S Oligonucleotide analogues
RU2243231C2 (ru) * 1997-09-12 2004-12-27 Эксикон А/С Бициклические аналоги нуклеозидов, нуклеотидов и олигонуклеотидов
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
RU2211223C2 (ru) * 1998-05-26 2003-08-27 Ай-Си-Эн Фармасьютикалз, Инк. Новые нуклеозиды, имеющие бициклическую сахарную группировку, и содержащие их олигонуклеотиды
US7816333B2 (en) 1999-02-12 2010-10-19 Daiichi Sankyo Company, Limited Oligonucleotide analogues and methods utilizing the same
WO2000047599A1 (en) * 1999-02-12 2000-08-17 Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
US7314923B2 (en) 1999-02-12 2008-01-01 Daiichi Sankyo Company, Limited Nucleoside and oligonucleotide analogues
US8957201B2 (en) 1999-02-12 2015-02-17 Daiichi Sankyo Company, Limited Oligonucleotide analogues and methods utilizing the same
AU758956B2 (en) * 1999-02-12 2003-04-03 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
US7335765B2 (en) 1999-02-12 2008-02-26 Daiichi Sankyo Company, Limited Nucleoside and oligonucleotide analogues
WO2000056748A1 (en) * 1999-03-18 2000-09-28 Exiqon A/S Xylo-lna analogues
US6303315B1 (en) 1999-03-18 2001-10-16 Exiqon A/S One step sample preparation and detection of nucleic acids in complex biological samples
AU777049B2 (en) * 1999-03-18 2004-09-30 Qiagen Gmbh Xylo-LNA analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US6316198B1 (en) 1999-03-18 2001-11-13 Exiqon A/S Detection of mutations in genes by specific LNA primers
US6639059B1 (en) 1999-03-24 2003-10-28 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6734291B2 (en) 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
WO2000066604A3 (en) * 1999-05-04 2001-01-11 Exiqon As L-ribo-lna analogues
WO2001007455A1 (en) * 1999-07-22 2001-02-01 Sankyo Company, Limited Novel bicyclonucleoside analogues
US7994145B2 (en) 1999-07-22 2011-08-09 Takeshi Imanishi Bicyclonucleoside analogues
AU766656B2 (en) * 1999-07-22 2003-10-23 Takeshi Imanishi Novel bicyclonucleoside analogues
US7217805B2 (en) 1999-07-22 2007-05-15 Sankyo Company, Limited Bicyclonucleoside analogues
WO2001048190A3 (en) * 1999-12-23 2002-05-10 Exiqon As Therapeutic uses of lna-modified oligonucleotides
EP2316975A1 (en) 2000-06-06 2011-05-04 Applied Biosystems, LLC Asynchronous primed PCR
EP2256213A1 (en) 2000-06-06 2010-12-01 Applied Biosystems, LLC Asynchronous primed PCR
WO2002018388A1 (fr) * 2000-08-29 2002-03-07 Takeshi Imanishi Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues
EP2179996A1 (en) 2000-11-28 2010-04-28 Applera Corporation Sulfonated diarylrhodamine dyes
EP2221347A1 (en) 2000-11-28 2010-08-25 Applera Corporation Sulfonated diarylrhodamine dyes
US7229767B2 (en) 2001-03-27 2007-06-12 University Of Delaware Genomics applications for modified OLIGO nucleotides
EP2000148A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of prostate cancer
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000545A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2221376A2 (en) 2001-06-21 2010-08-25 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
EP2270024A1 (en) 2001-06-21 2011-01-05 ISIS Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US6822088B2 (en) 2001-07-17 2004-11-23 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides on solid support
US7829275B2 (en) 2001-07-20 2010-11-09 North Carolina State University Light addressable electrochemical detection of duplex structures
EP2280019A1 (en) 2001-07-25 2011-02-02 ISIS Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
EP2332955A2 (en) 2001-07-30 2011-06-15 ISIS Pharmaceuticals, Inc. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
EP2174945A1 (en) 2001-08-01 2010-04-14 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2336145A1 (en) 2001-08-01 2011-06-22 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2316968A1 (en) 2001-08-07 2011-05-04 ISIS Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (A) expression
EP2272985A1 (en) 2001-08-07 2011-01-12 ISIS Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (A) expression
EP2153843A1 (en) 2001-09-18 2010-02-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2143437A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2151244A1 (en) 2001-09-18 2010-02-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2270230A2 (en) 2001-10-09 2011-01-05 ISIS Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A2 (en) 2001-10-09 2011-01-05 ISIS Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003033696A1 (en) * 2001-10-18 2003-04-24 Sankyo Company, Limited Vegf antisense compound
EP2196544A1 (en) 2001-11-21 2010-06-16 Applied Biosystems, LLC Kit for ligation detection assays using codeable labels
EP2388318A1 (en) 2001-12-10 2011-11-23 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US8492390B2 (en) 2002-05-08 2013-07-23 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US7005265B1 (en) 2002-06-20 2006-02-28 Wenhong Fan Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
US7358068B2 (en) 2002-09-13 2008-04-15 Replicor, Inc. Antiviral oligonucleotides
EP2330194A2 (en) 2002-09-13 2011-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US8008269B2 (en) 2002-09-13 2011-08-30 Replicor Inc. Antiviral oligonucleotides
US8008270B2 (en) 2002-09-13 2011-08-30 Replicor Inc. Antiviral oligonucleotides targeting viral families
US8067385B2 (en) 2002-09-13 2011-11-29 Replicor, Inc. Antiviral oligonucleotides targeting HBV
EP2272958A1 (en) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
US9464106B2 (en) 2002-10-21 2016-10-11 Exiqon A/S Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US7696345B2 (en) 2002-11-05 2010-04-13 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2336319A1 (en) 2002-11-13 2011-06-22 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2336318A1 (en) 2002-11-13 2011-06-22 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US9994850B2 (en) 2002-11-18 2018-06-12 Roche Innovation Center Copenhagen A/S Antisense design
US9951333B2 (en) 2002-11-18 2018-04-24 Roche Innovation Center Copenhagen A/S Antisense design
US7687617B2 (en) 2002-11-18 2010-03-30 Santaris Pharma A/S Oligonucleotides with alternating segments of locked and non-locked nucleotides
EP2284269A2 (en) 2002-11-18 2011-02-16 Santaris Pharma A/S Antisense design
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
US9428534B2 (en) 2002-11-18 2016-08-30 Roche Innovation Center Copenhagen A/S Antisense design
EP3222722A1 (en) 2002-11-18 2017-09-27 Roche Innovation Center Copenhagen A/S Antisense design
EP2752488A2 (en) 2002-11-18 2014-07-09 Santaris Pharma A/S Antisense design
US9890383B2 (en) 2002-11-18 2018-02-13 Roche Innovation Center Copenhagen A/S Antisense design
US9708614B2 (en) 2002-11-18 2017-07-18 Roche Innovation Center Copenhagen A/S Antisense design
EP2363503A1 (en) 2002-11-23 2011-09-07 ISIS Pharmaceuticals, Inc. Modulation of HIF1A and HIF2A expression
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
WO2004078922A2 (en) 2003-02-28 2004-09-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
EP2492282A1 (en) 2003-02-28 2012-08-29 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
EP2281869A2 (en) 2003-03-21 2011-02-09 ISIS Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 1 expression
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP3002007A1 (en) 2003-04-16 2016-04-06 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii expression
EP2441449A1 (en) 2003-04-16 2012-04-18 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein C-III expression
EP3412284A1 (en) 2003-04-16 2018-12-12 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii expression
EP2272857A1 (en) 2003-04-28 2011-01-12 ISIS Pharmaceuticals, Inc. Modulation of glucagon receptor expression
EP2327709A2 (en) 2003-04-28 2011-06-01 ISIS Pharmaceuticals, Inc. Modulation of glucagon receptor expression
EP2218727A1 (en) 2003-06-02 2010-08-18 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
EP2266997A1 (en) 2003-06-02 2010-12-29 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
EP2241572A2 (en) 2003-06-03 2010-10-20 Eli Lilly And Company Modulation of survivin expression
US11111535B2 (en) 2003-06-20 2021-09-07 Qiagen Gmbh Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
EP2530157A2 (en) 2003-07-31 2012-12-05 Regulus Therapeutics, Inc Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP2284267A2 (en) 2003-08-18 2011-02-16 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
WO2005019418A2 (en) 2003-08-18 2005-03-03 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP2256200A2 (en) 2003-09-18 2010-12-01 ISIS Pharmaceuticals, Inc. Modulation of eIF4E expression
EP2256201A2 (en) 2003-09-18 2010-12-01 ISIS Pharmaceuticals, Inc. Modulation of eIF4E expression
EP2444482A1 (en) 2003-11-03 2012-04-25 Isis Pharmaceuticals, Inc. Modulation of SGLT2 expression
EP2253706A2 (en) 2003-11-17 2010-11-24 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
WO2005049630A2 (en) 2003-11-17 2005-06-02 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
EP2295073A1 (en) 2003-11-17 2011-03-16 Genentech, Inc. Antibody against CD22 for the treatment of tumour of hematopoietic origin
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP2301568A1 (en) 2003-11-17 2011-03-30 Genentech, Inc. Antibody against IRTA2 for the treatment of tumour of hematopoietic origin
US7504495B2 (en) 2003-11-20 2009-03-17 Exiqon A/S Quencher compositions comprising anthraquinone moieties
EP2363480A2 (en) 2004-01-20 2011-09-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
EP2468865A1 (en) 2004-02-06 2012-06-27 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of stat3 expression
EP2527444A2 (en) 2004-02-06 2012-11-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of stat3 expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A2 (en) 2004-03-15 2014-02-26 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNASE H
US8383344B2 (en) 2004-04-07 2013-02-26 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1959012A2 (en) 2004-12-29 2008-08-20 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US9267130B2 (en) 2005-01-06 2016-02-23 Applied Biosystems, Llc Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
EP2208796A2 (en) 2005-01-06 2010-07-21 Applied Biosystems, LLC Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
EP2813581A1 (en) 2005-01-06 2014-12-17 Applied Biosystems, LLC Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
EP2050763A2 (en) 2005-03-10 2009-04-22 Genentech, Inc. Methods and compositions for modulating vascular integrity
US10370661B2 (en) 2005-06-14 2019-08-06 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US8999947B2 (en) 2005-06-14 2015-04-07 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US9719089B2 (en) 2005-06-14 2017-08-01 Northwestern University Nucleic acid functionalized nonoparticles for therapeutic applications
US8962254B2 (en) 2005-07-15 2015-02-24 Applied Biosystems, Llc Analyzing messenger RNA and micro RNA in the same reaction mixture
EP2405024A1 (en) 2005-07-15 2012-01-11 Life Technologies Corporation Hot start reverse transcription by primer design
US9422603B2 (en) 2005-07-15 2016-08-23 Applied Biosystems, Llc Analyzing messenger RNA and micro RNA in the same reaction mixture
US7745122B2 (en) 2005-07-15 2010-06-29 Applied Biosystems, Llc Analyzing messenger RNA and micro RNA in the same reaction mixture
EP2308990A1 (en) 2005-07-15 2011-04-13 Life Technologies Corporation Analyzing messenger RNA and micro RNA in the same reaction mixture
US9593374B2 (en) 2005-08-17 2017-03-14 Lianidou Evriklia Composition and method for determination of CK19 expression
EP2338992A2 (en) 2005-08-29 2011-06-29 Regulus Therapeutics, Inc Antisense compounds having enhanced anti-microRNA activity
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
EP2338991A2 (en) 2005-08-29 2011-06-29 Regulus Therapeutics, Inc Methods for use in modulating MIR-122a
US9580743B2 (en) 2005-09-09 2017-02-28 Life Technologies Corporation SSB-polymerase fusion proteins
EP2458011A1 (en) 2005-10-03 2012-05-30 Life Technologies Corporation Compositions, methods, and kits for amplifying nucleic acids
EP2333115A1 (en) 2005-12-22 2011-06-15 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
US9598693B2 (en) 2006-01-27 2017-03-21 Ionis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP2388327A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
US9127272B2 (en) 2006-01-27 2015-09-08 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of target nucleic acids
WO2007106690A2 (en) 2006-03-15 2007-09-20 Siemens Healthcare Diagnostics Inc. Degenerate nucleobase analogs
EP2360277A1 (en) 2006-05-03 2011-08-24 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
US8969316B2 (en) 2006-05-05 2015-03-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2
EP2505647A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2
EP2505650A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
EP2363482A1 (en) 2006-05-05 2011-09-07 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
EP2505649A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCGR
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
EP2458006A1 (en) 2006-05-05 2012-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression APOB
US8143230B2 (en) 2006-05-05 2012-03-27 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
EP2363481A1 (en) 2006-05-05 2011-09-07 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
EP2505648A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PTP1B
EP2397551A1 (en) 2006-05-05 2011-12-21 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
US9045754B2 (en) 2006-05-05 2015-06-02 Isis Pharmaceuticals, Inc. Short antisense compounds with gapmer configuration
US10370656B2 (en) 2006-06-08 2019-08-06 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP2484781A2 (en) 2006-08-01 2012-08-08 Applied Biosystems, LLC Detection of analytes and nucleic acids
EP3305915A1 (en) 2006-08-01 2018-04-11 Applied Biosystems, LLC Detection of analytes and nucleic acids
US9310361B2 (en) 2006-10-05 2016-04-12 Massachusetts Institute Of Technology Multifunctional encoded particles for high-throughput analysis
EP2410054A1 (en) 2006-10-18 2012-01-25 Isis Pharmaceuticals, Inc. Antisense compounds
EP2410053A1 (en) 2006-10-18 2012-01-25 Isis Pharmaceuticals, Inc. Antisense compounds
US9550988B2 (en) 2006-10-18 2017-01-24 Ionis Pharmaceuticals, Inc. Antisense compounds
EP3202905A1 (en) 2006-10-18 2017-08-09 Ionis Pharmaceuticals, Inc. Antisense compounds
EP3916095A1 (en) 2006-10-18 2021-12-01 Ionis Pharmaceuticals, Inc. Antisense compounds
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
US8664190B2 (en) 2006-11-27 2014-03-04 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US11530410B2 (en) 2006-11-27 2022-12-20 Ionis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8912160B2 (en) 2006-11-27 2014-12-16 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8084437B2 (en) 2006-11-27 2011-12-27 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US9650636B2 (en) 2006-11-27 2017-05-16 Ionis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8293684B2 (en) 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
US9890427B2 (en) 2007-02-09 2018-02-13 Northwestern University Particles for detecting intracellular targets
US11155877B2 (en) 2007-04-27 2021-10-26 Quest Diagnostics Investments Llc Nucleic acid detection combining amplification with fragmentation
US10106857B2 (en) 2007-04-27 2018-10-23 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
US11965212B2 (en) 2007-04-27 2024-04-23 Quest Diagnostics Investments Llc Nucleic acid detection combining amplification with fragmentation
US8999634B2 (en) 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
US9783854B2 (en) 2007-04-27 2017-10-10 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
EP2826863A1 (en) 2007-05-30 2015-01-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US7807372B2 (en) 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
WO2009045469A2 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
WO2009044392A2 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US8715938B2 (en) 2007-11-20 2014-05-06 Life Technologies Corporation Reversible di-nucleotide terminator sequencing
US8017338B2 (en) 2007-11-20 2011-09-13 Life Technologies Corporation Reversible di-nucleotide terminator sequencing
US10365224B2 (en) 2007-12-06 2019-07-30 Genalyte, Inc. Label-free optical sensors
JPWO2009093384A1 (ja) * 2008-01-24 2011-05-26 独立行政法人産業技術総合研究所 ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法
WO2009093384A1 (ja) * 2008-01-24 2009-07-30 National Institute Of Advanced Industrial Science And Technology ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
EP2982753A1 (en) 2008-04-18 2016-02-10 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
WO2010027831A1 (en) 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
EP3375451A1 (en) 2008-08-25 2018-09-19 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
WO2010042281A2 (en) 2008-08-25 2010-04-15 Excaliard Pharmaceuticals Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2010024231A1 (ja) * 2008-08-26 2010-03-04 株式会社日立ハイテクノロジーズ 高発現遺伝子由来のcDNAクローンの含有率を低減させたcDNAライブラリーの作製方法
US10612086B2 (en) 2008-09-16 2020-04-07 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP2447274A2 (en) 2008-10-24 2012-05-02 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US11041811B2 (en) 2008-10-27 2021-06-22 Genalyte, Inc. Biosensors based on optical probing and sensing
US9846126B2 (en) 2008-10-27 2017-12-19 Genalyte, Inc. Biosensors based on optical probing and sensing
US9844562B2 (en) 2008-11-24 2017-12-19 Northwestern University Polyvalent RNA-nanoparticle compositions
US9139827B2 (en) 2008-11-24 2015-09-22 Northwestern University Polyvalent RNA-nanoparticle compositions
EP3335705A1 (en) 2008-11-24 2018-06-20 Northwestern University Polyvalent rna-nanoparticle compositions
US10391116B2 (en) 2008-11-24 2019-08-27 Northwestern University Polyvalent RNA-nanoparticle compositions
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
WO2010074562A1 (en) 2008-12-22 2010-07-01 Keygene N.V. Use of double stranded rna to increase the efficiency of targeted gene alteration in plant protoplasts
US11633503B2 (en) 2009-01-08 2023-04-25 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
US10098958B2 (en) 2009-01-08 2018-10-16 Northwestern University Delivery of oligonucleotide functionalized nanoparticles
US8680254B2 (en) 2009-01-14 2014-03-25 Philadelphia Health & Education Corporation Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
US10041075B2 (en) 2009-01-14 2018-08-07 Drexel University Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
US9885049B2 (en) 2009-01-14 2018-02-06 Drexel University Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
US10337015B2 (en) 2009-01-14 2019-07-02 Drexel University Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
US9359603B2 (en) 2009-01-14 2016-06-07 Drexel University Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
US9096895B2 (en) 2009-02-02 2015-08-04 Exiqon A/S Method for quantification of small RNA species
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010120420A1 (en) 2009-04-15 2010-10-21 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
EP3524275A1 (en) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Innate immune supression enables repeated delivery of long rna molecules
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010135384A2 (en) 2009-05-21 2010-11-25 Siemens Healthcare Diagnostics Inc. Universal tags with non-natural nucleobases
EP3597657A1 (en) 2009-05-21 2020-01-22 Siemens Healthcare Diagnostics Inc. Universal tags with non-natural nucleobases
EP3150619A1 (en) 2009-05-21 2017-04-05 Siemens Healthcare Diagnostics Inc. Universal tags with non-natural nucleobases
EP3276004A2 (en) 2009-06-08 2018-01-31 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
WO2011047307A1 (en) 2009-10-15 2011-04-21 Ibis Biosciences, Inc. Multiple displacement amplification
EP2957641A1 (en) 2009-10-15 2015-12-23 Ibis Biosciences, Inc. Multiple displacement amplification
EP3225695A1 (en) 2009-10-15 2017-10-04 Ibis Biosciences, Inc. Multiple displacement amplification
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056687A2 (en) 2009-10-27 2011-05-12 Swift Biosciences, Inc. Polynucleotide primers and probes
US10480030B2 (en) 2009-10-27 2019-11-19 Swift Biosciences, Inc. Polynucleotide primers and probes
US8541562B2 (en) 2009-10-29 2013-09-24 Osaka University Bridged artificial nucleoside and nucleotide
WO2011052436A1 (ja) 2009-10-29 2011-05-05 国立大学法人大阪大学 架橋型人工ヌクレオシドおよびヌクレオチド
US9376690B2 (en) 2009-10-30 2016-06-28 Northwestern University Templated nanoconjugates
US9757475B2 (en) 2009-10-30 2017-09-12 Northwestern University Templated nanoconjugates
WO2011053994A1 (en) 2009-11-02 2011-05-05 Alnylam Pharmaceuticals, Inc. Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
WO2011056215A1 (en) 2009-11-03 2011-05-12 Landers James P Versatile, visible method for detecting polymeric analytes
WO2011063403A1 (en) 2009-11-23 2011-05-26 Swift Biosciences, Inc. Devices to extend single stranded target molecules
EP3002297A2 (en) 2009-11-30 2016-04-06 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8710209B2 (en) 2009-12-09 2014-04-29 Nitto Denko Corporation Modulation of HSP47 expression
EP3434773A2 (en) 2009-12-09 2019-01-30 Nitto Denko Corporation Modulation of hsp47 expression
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US10093923B2 (en) 2009-12-09 2018-10-09 Nitto Denko Corporation Modulation of HSP47 expression
EP3012324A2 (en) 2009-12-09 2016-04-27 Nitto Denko Corporation Modulation of hsp47 expression
EP2862929A1 (en) 2009-12-09 2015-04-22 Quark Pharmaceuticals, Inc. Compositions and methods for treating diseases, disorders or injury of the CNS
US9206424B2 (en) 2009-12-09 2015-12-08 Nitto Denko Corporation Modulation of HSP47 expression
US11180799B2 (en) 2009-12-22 2021-11-23 Sequenom, Inc. Processes and kits for identifying aneuploidy
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2011085056A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
EP3421040A1 (en) 2010-01-08 2019-01-02 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
EP3628750A1 (en) 2010-02-08 2020-04-01 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP3208347A1 (en) 2010-02-08 2017-08-23 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP3561060A1 (en) 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP3321361A1 (en) 2010-02-08 2018-05-16 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP3214174A1 (en) 2010-03-04 2017-09-06 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
US8889350B2 (en) 2010-03-26 2014-11-18 Swift Biosciences, Inc. Methods and compositions for isolating polynucleotides
WO2011133695A2 (en) 2010-04-20 2011-10-27 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
EP3091027A1 (en) 2010-04-28 2016-11-09 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
US9061044B2 (en) 2010-04-29 2015-06-23 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
US11535849B2 (en) 2010-04-29 2022-12-27 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
US9399774B2 (en) 2010-04-29 2016-07-26 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
WO2011134474A1 (en) 2010-04-30 2011-11-03 Exiqon A/S In situ hybridization method and buffer
US10023912B2 (en) 2010-04-30 2018-07-17 Exiqon A/S In situ hybridization method and buffer
US9212390B2 (en) 2010-04-30 2015-12-15 Exiqon A/S In situ hybridization method and buffer
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
US9290816B2 (en) 2010-06-07 2016-03-22 Firefly Bioworks Inc. Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
WO2011156278A1 (en) 2010-06-07 2011-12-15 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US9476101B2 (en) 2010-06-07 2016-10-25 Firefly Bioworks, Inc. Scanning multifunctional particles
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3369817A1 (en) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway
WO2012005572A1 (en) 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2913402A1 (en) 2010-07-16 2015-09-02 Tocagen Inc. Retrovirus detection
EP3489360A2 (en) 2010-07-19 2019-05-29 Ionis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
EP3031920A1 (en) 2010-07-19 2016-06-15 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (dmpk) expression
EP3633038A2 (en) 2010-07-19 2020-04-08 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (dmpk) expression
WO2012013784A1 (en) 2010-07-29 2012-02-02 Centre National De La Recherche Scientifique (C.N.R.S) Regulation of glypican 4 activity to modulate the fate of stem cells and uses thereof
EP2412724A1 (en) 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
US9416360B2 (en) 2010-11-05 2016-08-16 MiRagen Therapeutics, Inc. Base modified oligonucleotides
EP3266881A1 (en) 2010-11-05 2018-01-10 Genalyte, Inc. Optical analyte detection systems and methods of use
US9921165B2 (en) 2010-11-05 2018-03-20 Genalyte, Inc. Optical analyte detection systems and methods of use
EP3733866A1 (en) 2010-11-05 2020-11-04 Genalyte, Inc. Optical analyte detection systems and methods of use
WO2012061778A2 (en) 2010-11-05 2012-05-10 Genalyte, Inc. Optical analyte detection systems and methods of use
EP3521451A1 (en) 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US9518258B2 (en) 2010-12-02 2016-12-13 Keygene N.V. Targeted alteration of DNA with oligonucleotides
US9150854B2 (en) 2010-12-02 2015-10-06 Keygene N.V. Targeted alteration of DNA
WO2012074386A1 (en) 2010-12-02 2012-06-07 Keygene N.V. Targeted alteration of dna with oligonucleotides
WO2012074385A1 (en) 2010-12-02 2012-06-07 Keygene N.V. Targeted alteration of dna
EP2857512A1 (en) 2010-12-02 2015-04-08 Keygene N.V. Targeted alteration of DNA
EP2826868A1 (en) 2011-01-11 2015-01-21 Seegene, Inc. Detection of target nucleic acid sequences by pto cleavage and extension assay
EP3543352A1 (en) 2011-01-11 2019-09-25 Seegene, Inc. Detection of target nucleic acid sequences by pto cleavage and extension assay
EP2708608A1 (en) 2011-01-11 2014-03-19 Seegene, Inc. Detection of target nucleic acid sequences by pto cleavage and extension assay
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
WO2012096523A2 (en) 2011-01-11 2012-07-19 Seegene, Inc. Detection of target nucleic acid sequences by pto cleavage and extension assay
WO2012096573A1 (en) 2011-01-11 2012-07-19 Interna Technologies B.V. Mirna for treating diseases and conditions associated with neo-angiogenesis
WO2012106509A1 (en) 2011-02-02 2012-08-09 The Trustees Of Princeton University Sirtuin modulators as virus production modulators
US10813934B2 (en) 2011-02-02 2020-10-27 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
WO2012106508A1 (en) 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012118910A2 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US9487778B2 (en) 2011-03-03 2016-11-08 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2012118911A1 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2012134195A2 (en) 2011-03-29 2012-10-04 Seegene, Inc. Detection of target nucleic acid sequence by pto cleavage and extension-dependent cleavage
EP3466960A2 (en) 2011-04-01 2019-04-10 Ionis Pharmaceuticals, Inc. Modulation of signal transducer and activator of transcription 3 (stat3) expression
WO2012136859A1 (en) 2011-04-07 2012-10-11 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US10188682B2 (en) 2011-04-07 2019-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US11975032B2 (en) 2011-04-07 2024-05-07 Medizinische Hochschule Hannover Medicament for liver regeneration and for treatment of liver failure
EP3192870A1 (en) 2011-04-07 2017-07-19 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US9186381B2 (en) 2011-04-07 2015-11-17 Helmholtz Zentrum Fuer Infektionsforschung Gmbh Medicament for liver regeneration and for treatment of liver failure
EP3312189A1 (en) 2011-04-21 2018-04-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
EP3505528A1 (en) 2011-04-21 2019-07-03 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
EP3816288A2 (en) 2011-04-21 2021-05-05 Glaxo Group Limited Modulation of hepatitis b virus (hbv) expression
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
EP3357497A1 (en) 2011-04-27 2018-08-08 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein ciii (apociii) expression
WO2012149495A1 (en) 2011-04-27 2012-11-01 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein ciii (apociii) expression
WO2012149339A2 (en) 2011-04-29 2012-11-01 Sequenom, Inc. Quantification of a minority nucleic acid species
EP3378954A1 (en) 2011-04-29 2018-09-26 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
WO2012150835A2 (en) 2011-05-04 2012-11-08 Seegene, Inc. Detection of target nucleic acid sequences by po cleavage and hybridization
US10195145B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier
US8741867B2 (en) 2011-06-08 2014-06-03 Nitto Denko Corporation Retinoid-liposomes for treating fibrosis
US8664376B2 (en) 2011-06-08 2014-03-04 Nitto Denko Corporation Retinoid-liposomes for enhancing modulation of HSP47 expression
WO2012170957A2 (en) 2011-06-08 2012-12-13 Nitto Denko Corporation Retinoid-liposomes for enhancing modulation of hsp47 expression
US9456984B2 (en) 2011-06-08 2016-10-04 Nitto Denko Corporation Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier
EP3075855A1 (en) 2011-06-08 2016-10-05 Nitto Denko Corporation Retinoid-liposomes for enhancing modulation of hsp47 expression
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3320922A1 (en) 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9315811B2 (en) 2011-06-10 2016-04-19 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
WO2012174476A2 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US9322021B2 (en) 2011-06-29 2016-04-26 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
WO2013003808A1 (en) 2011-06-29 2013-01-03 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US11732261B2 (en) 2011-08-11 2023-08-22 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9650421B2 (en) 2011-09-02 2017-05-16 Northwestern University Self-assembled nanostructures
WO2013040499A1 (en) 2011-09-14 2013-03-21 Northwestern University Nanoconjugates able to cross the blood-brain barrier
US9889209B2 (en) 2011-09-14 2018-02-13 Northwestern University Nanoconjugates able to cross the blood-brain barrier
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
US10398784B2 (en) 2011-09-14 2019-09-03 Northwestern Univerity Nanoconjugates able to cross the blood-brain barrier
WO2013043817A1 (en) 2011-09-20 2013-03-28 Isis Phamaceuticals, Inc. Antisense modulation of gcgr expression
EP3401401A1 (en) 2011-09-20 2018-11-14 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
WO2013067076A2 (en) 2011-11-03 2013-05-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2013070786A1 (en) 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
EP3650544A1 (en) 2011-11-07 2020-05-13 Ionis Pharmaceuticals, Inc. Modulation of tmprss6 expression
US9725722B2 (en) 2011-11-07 2017-08-08 Ionis Pharmaceuticals, Inc. Modulation of TMPRSS6 expression
WO2013090457A2 (en) 2011-12-12 2013-06-20 Oncoimmunin Inc. In vivo delivery of oligonucleotides
US9546368B2 (en) 2011-12-22 2017-01-17 Ionis Pharmaceuticals, Inc. Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression
WO2013096837A1 (en) 2011-12-22 2013-06-27 Isis Pharmaceuticals, Inc. Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
WO2013095132A1 (en) 2011-12-22 2013-06-27 Interna Technologies B.V. Mirna for treating head and neck cancer
EP3330278A1 (en) 2012-02-08 2018-06-06 Ionis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US10738359B2 (en) 2012-03-02 2020-08-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11312997B2 (en) 2012-03-02 2022-04-26 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2013133561A1 (en) 2012-03-05 2013-09-12 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay
WO2013138251A1 (en) 2012-03-12 2013-09-19 The Board Of Trustes Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
EP3907506A1 (en) 2012-03-12 2021-11-10 The Board of Trustees of the University of Illinois Optical analyte detection systems with magnetic enhancement and methods of their use
US9896709B2 (en) 2012-03-13 2018-02-20 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
WO2013138536A1 (en) 2012-03-13 2013-09-19 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US10238753B2 (en) 2012-03-16 2019-03-26 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
US10273474B2 (en) 2012-03-30 2019-04-30 Washington University Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
US11781135B2 (en) 2012-03-30 2023-10-10 Washington University Methods for treating Alzheimer's disease
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US11566245B2 (en) 2012-04-20 2023-01-31 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9914922B2 (en) 2012-04-20 2018-03-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US11634711B2 (en) 2012-05-17 2023-04-25 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US11859180B2 (en) 2012-05-17 2024-01-02 Ionis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US11306354B2 (en) 2012-05-21 2022-04-19 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
WO2013177248A2 (en) 2012-05-22 2013-11-28 Isis Pharmaceuticals, Inc. Modulation of enhancer rna mediated gene expression
US9518261B2 (en) 2012-05-22 2016-12-13 Ionis Pharmaceuticals, Inc. Modulation of enhancer RNA mediated gene expression
EP3822352A2 (en) 2012-05-24 2021-05-19 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
WO2013177468A2 (en) 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
EP3825403A2 (en) 2012-05-24 2021-05-26 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
DE202013012240U1 (de) 2012-05-25 2016-02-02 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
EP4570908A2 (en) 2012-05-25 2025-06-18 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
DE202013012241U1 (de) 2012-05-25 2016-01-18 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
EP3597749A1 (en) 2012-05-25 2020-01-22 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
DE202013012242U1 (de) 2012-05-25 2016-02-02 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
EP3401400A1 (en) 2012-05-25 2018-11-14 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3241902A1 (en) 2012-05-25 2017-11-08 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP4289948A2 (en) 2012-05-25 2023-12-13 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP4458361A2 (en) 2012-06-25 2024-11-06 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US9617539B2 (en) 2012-06-25 2017-04-11 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
WO2014004572A2 (en) 2012-06-25 2014-01-03 Isis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
EP3461895A1 (en) 2012-06-25 2019-04-03 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
EP3770258A1 (en) 2012-06-25 2021-01-27 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP3354750A1 (en) 2012-07-18 2018-08-01 Siemens Healthcare Diagnostics Inc. Kit of normalizing biological samples
WO2014018930A1 (en) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
EP3693460A1 (en) 2012-07-27 2020-08-12 Ionis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
WO2014028739A1 (en) 2012-08-15 2014-02-20 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
US9403865B2 (en) 2012-08-15 2016-08-02 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
EP3421602A1 (en) 2012-09-06 2019-01-02 The University of Chicago Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
US9777271B2 (en) 2012-09-06 2017-10-03 The University Of Chicago Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
US9499817B2 (en) 2012-09-06 2016-11-22 The University Of Chicago Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2014039916A1 (en) 2012-09-06 2014-03-13 The University Of Chicago Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
KR20150056647A (ko) 2012-09-21 2015-05-26 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드
WO2014046212A1 (ja) 2012-09-21 2014-03-27 国立大学法人大阪大学 グアニジン架橋を有する人工ヌクレオシドおよびオリゴヌクレオチド
WO2014059238A2 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals Inc Modulation of androgen receptor expression
EP4052709A1 (en) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
US9523094B2 (en) 2012-10-11 2016-12-20 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9963699B2 (en) 2012-10-15 2018-05-08 Ionis Pharmaceuticals, Inc. Methods for modulating C9ORF72 expression
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
WO2014062686A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for modulating c9orf72 expression
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3483273A1 (en) 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
WO2014070868A1 (en) 2012-10-31 2014-05-08 Isis Pharmaceuticals Inc Cancer treatment
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EP3800256A1 (en) 2012-11-06 2021-04-07 InteRNA Technologies B.V. Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
WO2014076196A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Anti apob antisense conjugate compounds
US11155816B2 (en) 2012-11-15 2021-10-26 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
EP3406718A1 (en) 2012-11-15 2018-11-28 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
WO2014076195A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Oligonucleotide conjugates
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
US12176067B2 (en) 2012-12-20 2024-12-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
WO2014118267A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Lna oligonucleotide carbohydrate conjugates
US9701708B2 (en) 2013-01-31 2017-07-11 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
EP3400947A1 (en) 2013-02-14 2018-11-14 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
US9315535B2 (en) 2013-02-18 2016-04-19 Shionogi & Co., Ltd. Nucleoside and nucleotide having nitrogen-containing heterocycle structure
WO2014126229A1 (ja) 2013-02-18 2014-08-21 塩野義製薬株式会社 含窒素複素環構造を有するヌクレオシド及びヌクレオチド
EP2770065A1 (en) 2013-02-25 2014-08-27 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence
WO2014134179A1 (en) 2013-02-28 2014-09-04 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014134144A1 (en) 2013-02-28 2014-09-04 The General Hospital Corporation Mirna profiling compositions and methods of use
WO2014142575A1 (en) 2013-03-13 2014-09-18 Seegene, Inc. Quantification of target nucleic acid using melting peak analysis
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
US9644207B2 (en) 2013-03-14 2017-05-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
EP3495505A1 (en) 2013-03-14 2019-06-12 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger rna
US11155815B2 (en) 2013-03-14 2021-10-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
WO2014152659A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
WO2014152673A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
US9983206B2 (en) 2013-03-15 2018-05-29 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
US10739340B2 (en) 2013-03-15 2020-08-11 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
EP4398254A2 (en) 2013-04-29 2024-07-10 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US9932581B2 (en) 2013-05-01 2018-04-03 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein C-III expression
US12509684B2 (en) 2013-05-01 2025-12-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein C-III expression
US12291709B2 (en) 2013-05-01 2025-05-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US11851655B2 (en) 2013-05-01 2023-12-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9957504B2 (en) 2013-05-01 2018-05-01 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US10883104B2 (en) 2013-05-01 2021-01-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
WO2014197938A1 (en) 2013-06-13 2014-12-18 Antisense Therapeutics Ltd Combination therapy
US9909124B2 (en) 2013-06-21 2018-03-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
WO2014205449A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
EP3656386A1 (en) 2013-06-21 2020-05-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
EP3730614A2 (en) 2013-07-02 2020-10-28 Ionis Pharmaceuticals, Inc. Modulators of growth hormone receptor
WO2015002971A2 (en) 2013-07-02 2015-01-08 Isis Pharmaceuticals, Inc. Modulators of growth hormone receptor
WO2015008985A1 (en) 2013-07-15 2015-01-22 Seegene, Inc. Detection of target nucleic acid sequence by pto cleavage and extension-dependent immobilized oligonucleotide hybridization
US12091662B2 (en) 2013-07-19 2024-09-17 Biogen Ma Inc. Compositions for modulating tau expression
US11591595B2 (en) 2013-07-19 2023-02-28 Biogen Ma Inc. Compositions for modulating Tau expression
EP3910060A1 (en) 2013-07-19 2021-11-17 Biogen MA Inc. Compositions for modulating tau expression
US9683235B2 (en) 2013-07-19 2017-06-20 Ionis Pharmaceuticals, Inc. Compositions for modulating Tau expression
US10793856B2 (en) 2013-07-19 2020-10-06 Biogen Ma Inc. Compositions for modulating Tau expression
WO2015010135A2 (en) 2013-07-19 2015-01-22 Isis Pharmaceuticals, Inc. Compositions for modulating tau expression
WO2015021457A2 (en) 2013-08-09 2015-02-12 Isis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression
EP3995580A2 (en) 2013-08-09 2022-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression
US11840686B2 (en) 2013-08-28 2023-12-12 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
US11053500B2 (en) 2013-08-28 2021-07-06 lonis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
WO2015031679A2 (en) 2013-08-28 2015-03-05 Isis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
US9670492B2 (en) 2013-08-28 2017-06-06 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
EP3715457A2 (en) 2013-08-28 2020-09-30 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
EP3603677A1 (en) 2013-09-13 2020-02-05 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
EP4166667A2 (en) 2013-10-11 2023-04-19 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US11339393B2 (en) 2013-10-11 2022-05-24 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2015057998A1 (en) 2013-10-16 2015-04-23 The University Of British Columbia Device for formulating particles at small volumes
WO2015057008A2 (en) 2013-10-18 2015-04-23 Seegene, Inc. Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
EP3375877A1 (en) 2013-11-18 2018-09-19 Crispr Therapeutics AG Crispr-cas system materials and methods
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
US11883535B2 (en) 2013-12-03 2024-01-30 Northwestern University Liposomal particles, methods of making same and uses thereof
WO2015126502A2 (en) 2013-12-03 2015-08-27 Northwestern University Liposomal particles, methods of making same and uses thereof
US10792251B2 (en) 2013-12-03 2020-10-06 Northwestern University Liposomal particles, methods of making same and uses thereof
US9205102B2 (en) 2013-12-06 2015-12-08 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
EP3770259A1 (en) 2013-12-24 2021-01-27 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US11118183B2 (en) 2013-12-24 2021-09-14 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2015100394A1 (en) 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015125783A1 (ja) * 2014-02-18 2015-08-27 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
JPWO2015125783A1 (ja) * 2014-02-18 2017-03-30 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US12410475B2 (en) 2014-03-13 2025-09-09 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143246A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
EP3978610A2 (en) 2014-03-19 2022-04-06 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
EP4137573A2 (en) 2014-04-01 2023-02-22 Biogen MA Inc. Compositions for modulating sod-1 expression
WO2015153800A2 (en) 2014-04-01 2015-10-08 Isis Pharmaceuticals, Inc. Compositions for modulating sod-1 expression
EP3757214A1 (en) 2014-04-01 2020-12-30 Biogen MA Inc. Compositions for modulating sod-1 expression
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP4219718A2 (en) 2014-05-01 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
US10793862B2 (en) 2014-05-01 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US11312964B2 (en) 2014-05-01 2022-04-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
EP3862362A2 (en) 2014-05-01 2021-08-11 Ionis Pharmaceuticals, Inc. Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
US9994855B2 (en) 2014-05-01 2018-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US11613752B2 (en) 2014-05-01 2023-03-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating PKK expression
EP4534092A2 (en) 2014-05-01 2025-04-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating pkk expression
EP3608406A1 (en) 2014-05-01 2020-02-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
US10294477B2 (en) 2014-05-01 2019-05-21 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating PKK expression
EP3845547A1 (en) 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression
EP3757215A2 (en) 2014-05-01 2020-12-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10875884B2 (en) 2014-05-01 2020-12-29 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
EP3974534A1 (en) 2014-05-01 2022-03-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US11957788B2 (en) 2014-06-04 2024-04-16 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2015190922A1 (en) 2014-06-10 2015-12-17 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease
EP4039807A1 (en) 2014-06-10 2022-08-10 Erasmus University Rotterdam Medical Center Antisense oligonucleotides useful in treatment of pompe disease
JPWO2016006697A1 (ja) * 2014-07-10 2017-04-27 賢二 中野 アンチセンス抗悪性腫瘍剤
WO2016006697A1 (ja) * 2014-07-10 2016-01-14 賢二 中野 アンチセンス抗悪性腫瘍剤
WO2016017422A1 (ja) * 2014-07-31 2016-02-04 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
JPWO2016017422A1 (ja) * 2014-07-31 2017-05-25 国立大学法人大阪大学 架橋型ヌクレオシドおよびヌクレオチド
US12264344B2 (en) 2014-08-19 2025-04-01 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016027168A2 (en) 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
US11229688B2 (en) 2014-08-21 2022-01-25 Omrix Biopharmaceuticals Ltd. Stabilized thrombin
WO2016027263A2 (en) 2014-08-21 2016-02-25 Omrix Biopharmaceuticals Ltd. Stabilized thrombin
EP3754017A2 (en) 2014-08-21 2020-12-23 Omrix Biopharmaceuticals Ltd. Stabilized thrombin
US10159719B2 (en) 2014-08-21 2018-12-25 Omrix Biopharmaceuticals Ltd. Kit with stabilized thrombin
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016034611A1 (en) 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
WO2016054032A1 (en) 2014-09-29 2016-04-07 The Jackson Laboratory High efficiency, high throughput generation of genetically modified mammals by electroporation
US11098309B2 (en) 2014-10-14 2021-08-24 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions and methods for reactivating latent immunodeficiency virus
US11807852B2 (en) 2014-10-14 2023-11-07 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
US10351853B2 (en) 2014-10-14 2019-07-16 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
WO2016075583A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intelle Ctual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
WO2016075584A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Combination long acting compositions and methods for hepatitis c
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016126972A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
EP4481401A2 (en) 2015-02-24 2024-12-25 The University of British Columbia Continuous flow microfluidic system and method
WO2016138353A1 (en) 2015-02-26 2016-09-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of p23h rhodopsin
EP4056703A1 (en) 2015-03-03 2022-09-14 Ionis Pharmaceuticals, Inc. Methods for modulating mecp2 expression
EP4636085A2 (en) 2015-03-03 2025-10-22 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
WO2016141236A1 (en) 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
US10415038B2 (en) 2015-04-03 2019-09-17 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating TMPRSS6 expression
WO2016161429A1 (en) 2015-04-03 2016-10-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating tmprss6 expression
WO2016164602A1 (en) 2015-04-08 2016-10-13 The University Of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
US10801029B2 (en) 2015-04-08 2020-10-13 The University Of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
US10273483B2 (en) 2015-04-08 2019-04-30 The University Of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
EP3722424A1 (en) 2015-04-16 2020-10-14 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US9605263B2 (en) 2015-04-16 2017-03-28 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2016168592A2 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
WO2017015109A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
EP3919619A1 (en) 2015-07-17 2021-12-08 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
WO2017018360A1 (ja) * 2015-07-24 2017-02-02 日産化学工業株式会社 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
WO2017023861A1 (en) 2015-08-03 2017-02-09 The Regents Of The University Of California Compositions and methods for modulating abhd2 activity
US11591594B2 (en) 2015-08-24 2023-02-28 Roche Innovation Center Copenhagen A/S LNA-G process
WO2017032726A1 (en) 2015-08-24 2017-03-02 Roche Innovation Center Copenhagen A/S Lna-g process
JP2022033869A (ja) * 2015-09-18 2022-03-02 田辺三菱製薬株式会社 架橋型核酸ＧｕＮＡ、その製造方法および中間体化合物
JPWO2017047816A1 (ja) * 2015-09-18 2018-07-05 田辺三菱製薬株式会社 架橋型核酸ＧｕＮＡ、その製造方法および中間体化合物
WO2017047816A1 (ja) * 2015-09-18 2017-03-23 田辺三菱製薬株式会社 架橋型核酸ＧｕＮＡ、その製造方法および中間体化合物
US10961269B2 (en) 2015-09-18 2021-03-30 Mitsubishi Tanabe Pharma Corporation Bridged nucleic acid GuNA, method for producing same, and intermediate compound
EP3974436A1 (en) 2015-09-18 2022-03-30 Mitsubishi Tanabe Pharma Corporation Crosslinked nucleic acid guna method for producing same, and intermediate compound
WO2017064546A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
US10912792B2 (en) 2015-10-08 2021-02-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
EP4474389A2 (en) 2015-10-08 2024-12-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
WO2017075421A1 (en) 2015-10-29 2017-05-04 Temple University-Of The Commonwealth System Of Higher Education Modification of 3' terminal ends of nucleic acids by dna polymerase theta
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
WO2017079442A1 (en) 2015-11-04 2017-05-11 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
US10557137B2 (en) 2015-11-06 2020-02-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
US11319536B2 (en) 2015-11-06 2022-05-03 Ionis Pharmacueticals, Inc. Modulating apolipoprotein (a) expression
US12410430B2 (en) 2015-11-06 2025-09-09 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (A) expression
US12259380B2 (en) 2015-11-12 2025-03-25 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
EP4220360A2 (en) 2015-11-12 2023-08-02 F. Hoffmann-La Roche AG Oligonucleotides for inducing paternal ube3a expression
EP3798307A1 (en) 2015-11-12 2021-03-31 F. Hoffmann-La Roche AG Oligonucleotides for inducing paternal ube3a expression
US10494633B2 (en) 2015-11-12 2019-12-03 Roche Innovation Center Copenhagen A/S Oligonucleotides for inducing paternal UBE3A expression
US10739332B2 (en) 2015-11-12 2020-08-11 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US11852627B2 (en) 2015-11-12 2023-12-26 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US11320421B2 (en) 2015-11-12 2022-05-03 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US10718753B2 (en) 2015-11-12 2020-07-21 Hoffman-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US11667903B2 (en) 2015-11-23 2023-06-06 The Regents Of The University Of California Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
WO2017098468A1 (en) 2015-12-09 2017-06-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
EP3656872A1 (en) 2015-12-09 2020-05-27 Novartis AG Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
EP4406541A2 (en) 2015-12-21 2024-07-31 Novartis AG Compositions and methods for decreasing tau expression
WO2017109679A1 (en) 2015-12-21 2017-06-29 Novartis Ag Compositions and methods for decreasing tau expression
EP4678748A2 (en) 2015-12-21 2026-01-14 Novartis AG Compositions and methods for decreasing tau expression
EP3797860A1 (en) 2016-01-06 2021-03-31 The University of British Columbia Bifurcating mixers and methods of their use and manufacture
WO2017124086A1 (en) 2016-01-15 2017-07-20 The Jackson Laboratory Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
US11530409B2 (en) 2016-01-26 2022-12-20 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
EP4015647A1 (en) 2016-02-26 2022-06-22 The Board of Trustees of the Leland Stanford Junior University Multiplexed single molecule rna visualization with a two-probe proximity ligation system
EP4354140A2 (en) 2016-02-26 2024-04-17 The Board of Trustees of the Leland Stanford Junior University Multiplexed single molecule rna visualization with a two-probe proximity ligation system
WO2017147483A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed single molecule rna visualization with a two-probe proximity ligation system
US11466081B2 (en) 2016-03-14 2022-10-11 Hoffmann-La Roche Inc. Oligonucleotides for reduction of PD-L1 expression
US10745480B2 (en) 2016-03-14 2020-08-18 Hoffmann-La Roche, Inc. Oligonucleotides for reduction of PD-L1 expression
US10829555B2 (en) 2016-03-14 2020-11-10 Hoffman-La Roche Inc. Oligonucleotides for reduction of PD-L1 expression
WO2017157899A1 (en) 2016-03-14 2017-09-21 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
EP3786297A1 (en) 2016-03-14 2021-03-03 F. Hoffmann-La Roche AG Oligonucleotides for reduction of pd-l1 expression
US12552862B2 (en) 2016-03-14 2026-02-17 Hoffmann-La Roche Inc. Oligonucleotides for reduction of PD-L1 expression
US11248019B2 (en) 2016-04-14 2022-02-15 Hoffmann-La Roche Inc. Trityl-mono-GalNAc compounds and their use
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
US11708614B2 (en) 2016-06-15 2023-07-25 Streck Llc Assays and methods for determining microbial resistance
US12385102B2 (en) 2016-06-15 2025-08-12 Streck, Llc Assays and methods for determining microbial resistance
WO2017218573A1 (en) 2016-06-16 2017-12-21 The Regents Of The University Of California Methods and compositions for detecting a target rna
DE212017000062U1 (de) 2016-06-16 2018-11-29 The Regents Of The University Of California Verwendung zum Nachweis einer einzelsträngigen Target-RNA
DE212017000061U1 (de) 2016-06-16 2018-12-04 The Regents Of The University Of California Zusammensetzung zum Nachweis einer einzelsträngigen Target-RNA
DE212017000056U1 (de) 2016-06-16 2018-11-21 The Regents Of The University Of California Kits zum Nachweisen einer Target-RNA in einer Probe
EP4036249A1 (en) 2016-06-16 2022-08-03 The Regents of the University of California Methods and compositions for detecting a target rna
US11191775B2 (en) 2016-06-17 2021-12-07 Hoffmann-La Roche Inc. PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection
WO2017216390A1 (en) 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
US11534452B2 (en) 2016-06-17 2022-12-27 Hoffmann-La Roche Inc. Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
US10519450B2 (en) 2016-07-01 2019-12-31 Hoffmann-La Roche Inc. Antisense oligonucleotides for modulating HTRA1 expression
WO2018002105A1 (en) 2016-07-01 2018-01-04 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
WO2018026282A1 (en) 2016-08-05 2018-02-08 Erasmus University Medical Center Rotterdam (Erasmus Mc) Antisense oligomeric compound for pompe disease
WO2018026284A1 (en) 2016-08-05 2018-02-08 Erasmus University Medical Center Rotterdam (Erasmus Mc) Natural cryptic exon removal by pairs of antisense oligonucleotides
WO2018231060A1 (en) 2016-08-05 2018-12-20 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018044239A1 (en) 2016-09-01 2018-03-08 Agency For Science, Technology And Research Method of treating cancer by antisense oligonucleotides targeting prdm15
US11053498B2 (en) 2016-09-29 2021-07-06 Biogen Ma Inc. Compounds and methods for reducing Tau expression
US10407680B2 (en) 2016-09-29 2019-09-10 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing Tau expression
WO2018080393A1 (en) 2016-10-28 2018-05-03 Agency For Science, Technology And Research Antisense oligonucleotides
WO2018087200A1 (en) 2016-11-11 2018-05-17 Roche Innovation Center Copenhagen A/S Therapeutic oligonucleotides capture and detection
WO2018130584A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
WO2018130585A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
WO2018130582A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rel expression
WO2018130581A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rela expression
WO2018130583A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
US11572558B2 (en) 2017-02-06 2023-02-07 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2018143475A1 (ja) 2017-02-06 2018-08-09 日産化学工業株式会社 一本鎖オリゴヌクレオチド
WO2018181428A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
US12163148B2 (en) 2017-05-10 2024-12-10 The Regents Of The University Of California Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
US11453891B2 (en) 2017-05-10 2022-09-27 The Regents Of The University Of California Directed editing of cellular RNA via nuclear delivery of CRISPR/CAS9
WO2018220034A1 (en) 2017-06-01 2018-12-06 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
US11690920B2 (en) 2017-07-13 2023-07-04 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
WO2019022196A1 (ja) 2017-07-26 2019-01-31 日産化学株式会社 一本鎖オリゴヌクレオチド
US11555188B2 (en) 2017-07-26 2023-01-17 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2019030313A2 (en) 2017-08-11 2019-02-14 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019038228A1 (en) 2017-08-22 2019-02-28 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
US11591645B2 (en) 2017-08-31 2023-02-28 Seegene, Inc. Evaluation of performance of components using a pair of dimer-forming primers
WO2019045532A2 (en) 2017-08-31 2019-03-07 Seegene, Inc. EVALUATION OF COMPONENT PERFORMANCE USING A PAIR OF DIMER FORMER PRIMERS
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
WO2019066461A2 (en) 2017-09-29 2019-04-04 Seegene, Inc. DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY CLEAVAGE ANALYSIS AND EXTENSION OF PTO
WO2019073018A1 (en) 2017-10-13 2019-04-18 Roche Innovation Center Copenhagen A/S METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
US11484546B2 (en) 2017-10-16 2022-11-01 Hoffman-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
US12303525B2 (en) 2017-10-16 2025-05-20 Hoffman-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
WO2019076842A1 (en) 2017-10-16 2019-04-25 F. Hoffmann-La Roche Ag NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 MRNA FOR THE TREATMENT OF HEPATITIS B INFECTION
US10953034B2 (en) 2017-10-16 2021-03-23 Hoffmann-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
WO2019086603A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019115416A2 (en) 2017-12-11 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en) 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
WO2019118935A1 (en) 2017-12-14 2019-06-20 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and their use in genome editing and other applications
WO2019116346A1 (en) 2017-12-15 2019-06-20 Novartis Ag Polya tail length analysis of rna by mass spectrometry
WO2019121838A1 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Companion diagnostic for htra1 rna antagonists
WO2019122277A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
EP4092117A1 (en) 2017-12-22 2022-11-23 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
US11597926B2 (en) 2017-12-22 2023-03-07 Roche Innovation Center Copenhagen A/S Thiophosphoramidites
WO2019122282A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019122279A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019137883A1 (en) 2018-01-10 2019-07-18 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating pias4 expression
US11359197B2 (en) 2018-01-12 2022-06-14 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019137974A1 (en) 2018-01-12 2019-07-18 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating gsk3b expression
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US11447775B2 (en) 2018-01-12 2022-09-20 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US12180478B2 (en) 2018-01-12 2024-12-31 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019138057A1 (en) 2018-01-12 2019-07-18 Roche Innovation Center Copenhagen A/S Alpha-synuclein antisense oligonucleotides and uses thereof
US12241065B2 (en) 2018-01-12 2025-03-04 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019141656A1 (en) 2018-01-17 2019-07-25 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating erc1 expression
WO2019141723A1 (en) 2018-01-18 2019-07-25 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019154979A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Oligonucleotides for modulating tmem106b expression
WO2019155094A1 (en) 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
US11058767B2 (en) 2018-02-21 2021-07-13 Bristol-Myers Squibb Company CAMK2D antisense oligonucleotides and uses thereof
WO2019165067A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
US12203110B2 (en) 2018-03-19 2025-01-21 Crispr Therapeutics Ag RNA-programmable endonuclease systems and uses thereof
WO2019183150A1 (en) 2018-03-19 2019-09-26 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and uses thereof
WO2019182037A1 (ja) 2018-03-20 2019-09-26 国立大学法人東京工業大学 毒性が低減されたアンチセンスオリゴヌクレオチド
US11732262B2 (en) 2018-04-05 2023-08-22 Hoffmann—La Roche, Inc. Use of FUBP1 inhibitors for treating hepatitis B virus infection
WO2019193165A1 (en) 2018-04-05 2019-10-10 F. Hoffmann-La Roche Ag Use of fubp1 inhibitors for treating hepatitis b virus infection
WO2019215067A1 (en) 2018-05-07 2019-11-14 Roche Innovation Center Copenhagen A/S Massively parallel discovery methods for oligonucleotide therapeutics
WO2019215065A1 (en) 2018-05-07 2019-11-14 Roche Innovation Center Copenhagen A/S Massively parallel discovery methods for oligonucleotide therapeutics
WO2019217459A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2019215066A1 (en) 2018-05-07 2019-11-14 Roche Innovation Center Copenhagen A/S Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
WO2019215175A1 (en) 2018-05-08 2019-11-14 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating myh7 expression
WO2019219723A1 (en) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treatment of microrna related diseases
WO2019224172A1 (en) 2018-05-25 2019-11-28 Roche Innovation Center Copenhagen A/S Novel process for making allofuranose from glucofuranose
WO2019233921A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
US11066669B2 (en) 2018-06-05 2021-07-20 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
WO2019233922A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
WO2019246112A1 (en) 2018-06-18 2019-12-26 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
WO2019246450A1 (en) 2018-06-20 2019-12-26 Yale University Rig-i agonists and treatments using same
WO2019243391A1 (en) 2018-06-21 2019-12-26 F. Hoffmann-La Roche Ag Hybridizing all-lna oligonucleotides
WO2019246262A2 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
WO2020007700A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting spi1
WO2020007702A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
WO2020007772A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
US12163131B2 (en) 2018-07-03 2024-12-10 Hoffmann-La Roche Inc. Oligonucleotides for modulating Tau expression
US11279929B2 (en) 2018-07-03 2022-03-22 Hoffmann-La Roche, Inc. Oligonucleotides for modulating Tau expression
US11753640B2 (en) 2018-07-03 2023-09-12 Hoffmann-La Roche Inc. Oligonucleotides for modulating Tau expression
WO2020007892A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
WO2020007826A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mbtps1
WO2020007889A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting stat1
WO2020011743A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mafb
WO2020011653A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011745A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
WO2020011744A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
WO2020011902A1 (en) 2018-07-13 2020-01-16 F. Hoffmann-La Roche Ag Oligonucleotides for modulating rtel1 expression
EP4512407A2 (en) 2018-07-13 2025-02-26 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
US12497621B2 (en) 2018-07-13 2025-12-16 Hoffmann-La Roche Inc. Oligonucleotides for modulating RTEL1 expression
WO2020025527A1 (en) 2018-07-31 2020-02-06 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
WO2020025563A1 (en) 2018-07-31 2020-02-06 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
US11273442B1 (en) 2018-08-01 2022-03-15 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
US11761029B2 (en) 2018-08-01 2023-09-19 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
WO2020041456A1 (en) 2018-08-22 2020-02-27 The Regents Of The University Of California Variant type v crispr/cas effector polypeptides and methods of use thereof
WO2020038971A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting vcan
US12421552B2 (en) 2018-08-23 2025-09-23 Roche Innovation Center Copenhagen A/S MicroRNA-134 biomarker
WO2020038968A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
WO2020038973A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting sptlc1
WO2020038976A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting usp8
EP3844303A1 (en) 2018-08-27 2021-07-07 The Regents of The University of California Reporter nucleic acids for type v crispr-mediated detection
WO2020043750A1 (en) 2018-08-28 2020-03-05 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
WO2020068398A2 (en) 2018-09-07 2020-04-02 The General Hospital Corporation Compositions and methods for immune checkpoint inhibition
WO2020056341A2 (en) 2018-09-14 2020-03-19 Northwestern University Programming protein polymerization with dna
US12258620B2 (en) 2018-09-25 2025-03-25 Co-Diagnostics, Inc. Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
WO2020069055A1 (en) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2020086701A1 (en) 2018-10-24 2020-04-30 Codiak Biosciences, Inc. Methods to improve potency of electroporation
WO2020089260A1 (en) 2018-11-01 2020-05-07 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting tia1
EP3877517A1 (en) 2018-11-09 2021-09-15 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
WO2020099533A1 (en) 2018-11-16 2020-05-22 F. Hoffmann-La Roche Ag Streptavidin-coated solid phases with a member of a binding pair
WO2020104492A1 (en) 2018-11-22 2020-05-28 Roche Innovation Center Copenhagen A/S Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
US12263227B2 (en) 2018-11-28 2025-04-01 Crispr Therapeutics Ag Optimized mRNA encoding CAS9 for use in LNPs
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020109344A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides
WO2020118259A1 (en) 2018-12-06 2020-06-11 Northwestern University Protein crystal engineering through dna hybridization interactions
WO2020123663A1 (en) 2018-12-11 2020-06-18 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
WO2020136125A2 (en) 2018-12-21 2020-07-02 Boehringer Ingelheim International Gmbh Antisense oligonucleotides targeting card9
US11174470B2 (en) 2019-01-04 2021-11-16 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
WO2020152303A1 (en) 2019-01-25 2020-07-30 F. Hoffmann-La Roche Ag Lipid vesicle for oral drug delivery
WO2020167822A2 (en) 2019-02-13 2020-08-20 University Of Rochester Gene networks that mediate remyelination of the human brain
WO2020169695A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Phosphonoacetate gapmer oligonucleotides
WO2020169696A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Novel phosphoramidites
WO2020173845A1 (en) 2019-02-26 2020-09-03 Roche Innovation Center Copenhagen A/S Oligonucleotide formulation method
US12157890B2 (en) 2019-02-27 2024-12-03 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
WO2020178258A1 (en) 2019-03-05 2020-09-10 F. Hoffmann-La Roche Ag Intracellular targeting of molecules
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
DE212020000516U1 (de) 2019-03-07 2022-01-17 The Regents of the University of California CRISPR-CAS-Effektorpolypeptide
WO2020186059A2 (en) 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP4613867A2 (en) 2019-03-12 2025-09-10 CRISPR Therapeutics AG Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020191377A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
US11261446B2 (en) 2019-03-29 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating UBE3A-ATS
WO2020203880A1 (ja) 2019-03-29 2020-10-08 田辺三菱製薬株式会社 Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物
US12129466B2 (en) 2019-03-29 2024-10-29 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating UBE3A-ATS
WO2020206115A2 (en) 2019-04-03 2020-10-08 Bristol-Myers Squibb Company Angptl2 antisense oligonucleotides and uses thereof
WO2020201339A1 (en) 2019-04-04 2020-10-08 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
US12421268B2 (en) 2019-04-16 2025-09-23 Roche Innovation Center Copenhagen A/S Process for preparing nucleotide P(V) monomers
WO2020212301A1 (en) 2019-04-16 2020-10-22 Roche Innovation Center Copenhagen A/S Novel process for preparing nucleotide p(v) monomers
US12344625B2 (en) 2019-04-30 2025-07-01 Roche Innovation Center Copenhagen A/S Process for preparing rhenium chelated MAG3 oligonucleotides
WO2020221705A1 (en) 2019-04-30 2020-11-05 Roche Innovation Center Copenhagen A/S Novel process for preparing rhenium chelated mag3 oligonucleotides
WO2020236600A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2020243644A1 (en) 2019-05-31 2020-12-03 Streck, Inc. Detection of antibiotic resistance genes
WO2020245233A1 (en) 2019-06-06 2020-12-10 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
WO2020245377A1 (en) 2019-06-07 2020-12-10 F. Hoffmann-La Roche Ag Hybridizing all-lna oligonucleotides
EP4560315A2 (en) 2019-06-07 2025-05-28 F. Hoffmann-La Roche AG Hybridizing all-lna oligonucleotides
WO2021011936A2 (en) 2019-07-18 2021-01-21 University Of Rochester Cell-type selective immunoprotection of cells
WO2021020412A1 (ja) 2019-07-30 2021-02-04 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
WO2021030769A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
WO2021030776A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2021030768A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with stat3-antisense oligonucleotides
WO2021030777A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle linked to molecules and uses thereof
WO2021030780A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
WO2021030773A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
EP4470619A2 (en) 2019-08-14 2024-12-04 Lonza Sales AG Extracellular vesicle-aso constructs targeting stat6
WO2021030781A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
WO2021062058A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021075538A1 (ja) 2019-10-18 2021-04-22 第一三共株式会社 二環性ホスホロアミダイトの製造方法
KR20220083707A (ko) 2019-10-18 2022-06-20 다이이찌 산쿄 가부시키가이샤 2 고리성 포스포르아미다이트의 제조 방법
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
WO2021092371A2 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021108647A1 (en) 2019-11-27 2021-06-03 Crispr Therapeutics Ag Methods of synthesizing rna molecules
WO2021119275A1 (en) 2019-12-11 2021-06-17 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
WO2021123074A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Methods of sequencing by synthesis using a consecutive labeling scheme
WO2021122993A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of saraf inhibitors for treating hepatitis b virus infection
WO2021122869A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of scamp3 inhibitors for treating hepatitis b virus infection
WO2021122910A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sbds inhibitors for treating hepatitis b virus infection
WO2021122921A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of cops3 inhibitors for treating hepatitis b virus infection
WO2021122735A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sept9 inhibitors for treating hepatitis b virus infection
WO2021123086A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for inhibiting scn9a expression
WO2021130270A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2021130266A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
WO2021158810A1 (en) 2020-02-05 2021-08-12 Bristol-Myers Squibb Company Oligonucleotides for splice modulation of camk2d
WO2021170697A1 (en) 2020-02-28 2021-09-02 F. Hoffmann-La Roche Ag Oligonucleotides for modulating cd73 exon 7 splicing
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021198883A1 (en) 2020-03-31 2021-10-07 Janssen Biopharma, Inc. Synthesis of oligonucleotides and related compounds
WO2021231210A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2021231211A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2021231204A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
WO2021230286A1 (ja) 2020-05-12 2021-11-18 田辺三菱製薬株式会社 Ａｔａｘｉｎ ３発現を調節するための化合物、方法及び医薬組成物
US12203071B2 (en) 2020-05-13 2025-01-21 Hoffmann-La Roche Inc. Oligonucleotide agonists targeting progranulin
WO2021229036A1 (en) 2020-05-13 2021-11-18 F. Hoffmann-La Roche Ag Oligonucleotide agonists targeting progranulin
WO2021233551A1 (en) 2020-05-22 2021-11-25 F.Hoffmann-La Roche Ag Oligonucleotides for splice modulation of card9
WO2021249993A1 (en) 2020-06-09 2021-12-16 Roche Innovation Center Copenhagen A/S Guanosine analogues for use in therapeutic polynucleotides
WO2021260197A1 (en) 2020-06-26 2021-12-30 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for modulating fubp1 expression
WO2022008935A1 (en) 2020-07-10 2022-01-13 Horizon Discovery Limited Method for producing genetically modified cells
WO2022011214A1 (en) 2020-07-10 2022-01-13 Alnylam Pharmaceuticals, Inc. Circular sirnas
WO2022018155A1 (en) 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Lna oligonucleotides for splice modulation of stmn2
WO2022018187A1 (en) 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Oligonucleotides targeting rna binding protein sites
US12084657B2 (en) 2020-07-23 2024-09-10 Hoffmann-La Roche Inc. Oligonucleotides targeting RNA binding protein sites
WO2022038211A2 (en) 2020-08-21 2022-02-24 F. Hoffmann-La Roche Ag Use of a1cf inhibitors for treating hepatitis b virus infection
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
US11447521B2 (en) 2020-11-18 2022-09-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
WO2022107025A1 (en) 2020-11-18 2022-05-27 Lemba Bv Umlilo antisense transcription inhibitors
WO2022117747A2 (en) 2020-12-03 2022-06-09 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
WO2022117745A1 (en) 2020-12-03 2022-06-09 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
WO2022122613A1 (en) 2020-12-08 2022-06-16 F. Hoffmann-La Roche Ag Novel synthesis of phosphorodithioate oligonucleotides
US12104153B2 (en) 2020-12-18 2024-10-01 Hoffmann-La Roche Inc. Antisense oligonucleotide for targeting progranulin
WO2022129320A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Antisense oligonucleotides for targeting progranulin
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
WO2022147214A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
US11898145B2 (en) 2021-02-02 2024-02-13 Hoffmann-La Roche Inc. Enhanced oligonucleotides for inhibiting RTEL1 expression
WO2022167456A1 (en) 2021-02-02 2022-08-11 F. Hoffmann-La Roche Ag Enhanced oligonucleotides for inhibiting rtel1 expression
WO2022178180A1 (en) 2021-02-17 2022-08-25 Codiak Biosciences, Inc. Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
WO2022178149A2 (en) 2021-02-17 2022-08-25 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
WO2022192038A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
WO2022213118A1 (en) 2021-03-31 2022-10-06 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
WO2022212884A1 (en) 2021-04-01 2022-10-06 Codiak Biosciences, Inc. Extracellular vesicle compositions
WO2022241408A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
WO2022240721A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
WO2022240760A2 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
WO2022256597A1 (en) 2021-06-04 2022-12-08 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
WO2022258555A1 (en) 2021-06-08 2022-12-15 F. Hoffmann-La Roche Ag Oligonucleotide progranulin agonists
WO2022261292A1 (en) 2021-06-10 2022-12-15 Intellia Therapeutics, Inc. Modified guide rnas comprising an internal linker for gene editing
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
WO2022258753A1 (en) 2021-06-11 2022-12-15 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
WO2022271818A1 (en) 2021-06-23 2022-12-29 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
WO2023003922A1 (en) 2021-07-21 2023-01-26 Alnylam Pharmaceuticals, Inc. Metabolic disorder-associated target gene irna compositions and methods of use thereof
WO2023021046A1 (en) 2021-08-16 2023-02-23 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2023034817A1 (en) 2021-09-01 2023-03-09 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023036669A1 (en) 2021-09-07 2023-03-16 Bayer Aktiengesellschaft Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023043280A1 (ko) 2021-09-17 2023-03-23 주식회사 씨젠 합성 비자연 염기를 포함하는 태그 올리고뉴클레오타이드를 이용한 타겟 핵산 서열의 검출
WO2023052317A1 (en) 2021-09-29 2023-04-06 F. Hoffmann-La Roche Ag Rna editing
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023078883A1 (en) 2021-11-03 2023-05-11 F. Hoffmann-La Roche Ag Oligonucleotides for modulating apolipoprotein e4 expression
WO2023083906A2 (en) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
WO2023104693A1 (en) 2021-12-07 2023-06-15 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting actl6b
WO2023111210A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Combination of oligonucleotides for modulating rtel1 and fubp1
WO2023111336A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Oligonucleotide gba agonists
WO2023117738A1 (en) 2021-12-20 2023-06-29 F. Hoffmann-La Roche Ag Threose nucleic acid antisense oligonucleotides and methods thereof
WO2023122762A1 (en) 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
US12319916B2 (en) 2021-12-22 2025-06-03 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023141507A1 (en) 2022-01-20 2023-07-27 Genentech, Inc. Antisense oligonucleotides for modulating tmem106b expression
WO2023150553A1 (en) 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
WO2023156652A1 (en) 2022-02-21 2023-08-24 F. Hoffmann-La Roche Ag Antisense oligonucleotide
WO2023217890A1 (en) 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2023222858A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Improved oligonucleotides targeting rna binding protein sites
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023240277A2 (en) 2022-06-10 2023-12-14 Camp4 Therapeutics Corporation Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
WO2023242324A1 (en) 2022-06-17 2023-12-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for targeting progranulin
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
EP4332221A1 (en) 2022-08-29 2024-03-06 Roche Innovation Center Copenhagen A/S Threose nucleic acid antisense oligonucleotides and methods thereof
WO2024046937A1 (en) 2022-08-29 2024-03-07 F. Hoffmann-La Roche Ag Threose nucleic acid antisense oligonucleotides and methods thereof
WO2024052403A1 (en) 2022-09-06 2024-03-14 F. Hoffmann-La Roche Ag Double-stranded rna molecule for administration to the eye
WO2024073042A1 (en) 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2024098061A2 (en) 2022-11-04 2024-05-10 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
KR20250108634A (ko) 2022-11-10 2025-07-15 룩스나 바이오테크 가부시키가이샤 가교부에 구아니디노 구조를 갖는 수식 뉴클레오시드 및 그것을 이용한 올리고뉴클레오티드의 제조 방법
EP4617279A1 (en) 2022-11-10 2025-09-17 Luxna Biotech Co., Ltd. Modified nucleoside having guanidino structure in bridged part and method for producing oligonucleotide using same
WO2024101446A1 (ja) 2022-11-10 2024-05-16 ルクサナバイオテク株式会社 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法
WO2024104914A1 (en) 2022-11-14 2024-05-23 BioNTech SE Rna capping efficiency assay
WO2024119145A1 (en) 2022-12-01 2024-06-06 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2024126654A1 (en) 2022-12-14 2024-06-20 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting actl6b
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
WO2024161314A1 (en) 2023-01-31 2024-08-08 Seqirus Inc. Capping assay
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2024175707A1 (en) 2023-02-22 2024-08-29 Helmholtz-Zentrum für Infektionsforschung GmbH A synthetic oligonucleotide for treating nidovirales infections
WO2024216155A1 (en) 2023-04-12 2024-10-17 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery of double-stranded rna agents
WO2024227047A2 (en) 2023-04-28 2024-10-31 Beam Therapeutics Inc. Modified guide rna
WO2024227765A2 (en) 2023-05-04 2024-11-07 F. Hoffmann-La Roche Ag Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2024231285A1 (en) 2023-05-05 2024-11-14 BioNTech SE Method of analysing contaminants in rna products by ion-pair chromatography
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024243062A1 (en) 2023-05-19 2024-11-28 Streck Llc Detection of antibiotic resistance genes
WO2024256674A1 (en) 2023-06-14 2024-12-19 Sanofi Methods of simultaneously identifying or quantifying capping and tailing modifications of messenger rna
WO2024256707A1 (en) 2023-06-16 2024-12-19 F. Hoffmann-La Roche Ag Double stranded oligonucleotide for modulating jak1 expression
WO2025005265A1 (ja) * 2023-06-30 2025-01-02 日産化学株式会社 毒性が低減されたアンチセンスオリゴヌクレオチド
WO2025038902A2 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2025038901A1 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2025061842A1 (en) 2023-09-19 2025-03-27 Charité - Universitätsmedizin Berlin Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci)
WO2025064660A2 (en) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
WO2025072246A1 (en) 2023-09-26 2025-04-03 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 50 in duchenne muscular dystrophy
WO2025074330A1 (en) 2023-10-04 2025-04-10 Lemba Bv Compounds for inhibition of il-1beta expression
WO2025074331A1 (en) 2023-10-04 2025-04-10 Lemba Bv Compounds for inhibiting amanzi
WO2025101994A2 (en) 2023-11-10 2025-05-15 Intellia Therapeutics, Inc. Compositions, methods, and systems for genomic editing
WO2025132962A2 (en) 2023-12-21 2025-06-26 F. Hoffmann-La Roche Ag Antisense oligonucleotide
WO2025252669A1 (en) 2024-06-03 2025-12-11 Evotec International Gmbh Modified oligonucleotides for reducing atxn3 expression
WO2025255388A1 (en) 2024-06-05 2025-12-11 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2026006390A2 (en) 2024-06-26 2026-01-02 Intellia Therapeutics, Inc. Modified guide rnas for genome editing

Also Published As

Publication number Publication date
AU6120998A (en) 1998-09-22
EP2295441A3 (en) 2011-10-26
EP2295441A2 (en) 2011-03-16
JP3756313B2 (ja) 2006-03-15
ATE541576T2 (de) 2012-02-15
HK1154590A1 (en) 2012-04-27
EP1013661B2 (en) 2018-10-24
DK1013661T4 (en) 2019-01-21
CA2283509A1 (en) 1998-09-11
EP2295441B1 (en) 2014-05-07
AU720472B2 (en) 2000-06-01
JPH10304889A (ja) 1998-11-17
ES2380354T3 (es) 2012-05-10
EP2361921A3 (en) 2012-06-27
ES2485716T3 (es) 2014-08-14
PT2295441E (pt) 2014-07-25
DK1013661T3 (da) 2012-03-19
EP2361921B1 (en) 2015-06-03
DE98905804T1 (de) 2010-08-26
EP1013661A1 (en) 2000-06-28
DK2295441T3 (da) 2014-07-21
PT1013661E (pt) 2012-03-28
CA2283509C (en) 2005-01-04
EP2361921A2 (en) 2011-08-31
DK2361921T3 (en) 2015-09-14
EP1013661B1 (en) 2012-01-18
ES2545211T3 (es) 2015-09-09
ES2380354T5 (es) 2019-04-02
EP1013661A4 (en) 2000-11-22
US6268490B1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
JP3756313B2 (ja) 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
USRE44779E1 (en) Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) Bicyclonucleoside and oligonucleotide analogue
US6043060A (en) Nucleotide analogues
KR100211552B1 (ko) 유전자 발현 억제용 화합물 및 방법
US6166198A (en) Methods for oligonucleotide synthesis
JP3781879B2 (ja) 新規ヌクレオチド類縁体
JP3119871B2 (ja) オリゴデオキシリボヌクレオチド類
US5807837A (en) Composition and method for the treatment or prophylaxis of viral infections using modified oligodeoxyribonucleotides
JPWO1992001704A1 (ja) オリゴデオキシリボヌクレオチド類
AU742476B2 (en) Novel bicyclonucleoside and oligonucleotide analogue
JP7776154B2 (ja) ホスホロチオエート及びボラノホスフェートを含むキメラ型核酸オリゴマー、及びその製造方法
WO1995031470A2 (en) Antisense inhibitors of gene expression
JPH069682A (ja) レトロウイルス感染用治療薬としてのポリヌクレオチドホスホロジチオエート
HK1160473A (en) Novel bicyclonucleoside and oligonnucleotide analogue
HK1154590B (en) Bicyclonucleoside oligonucleotide analogue
JPH08245665A (ja) 新規フォスファイト化合物及びそれを用いたキラルフォスファイト化合物の立体選択的製造方法
JPH08119945A (ja) 新規ヌクレオチド類縁体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GM GW HU ID IL IS KE KG KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 61209/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2283509

Country of ref document: CA

Ref country code: CA

Ref document number: 2283509

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 13533781

Country of ref document: US

Ref document number: 09380638

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998905804

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998905804

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 61209/98

Country of ref document: AU